Tuesday, November 16, 2021
Print Entire 2020 Program:
|
|
SESSION 1 SCHEDULE | |
Tuesday
SESSION 1:
PROGRESS IN CORONARY ARTERY STENTING, TRANSCATHETER VALVE REPLACEMENT, AND TREATMENT OF ASCENDING AORTIC DISEASE
Moderators:Hazim J. Safi, MD / Juan F. Granada, MD
|
|
x | |
6:45 AM - 6:50 AM | Opening Remarks |
Presenter(s):Frank J. Veith, MD | |
CORONARY STENTS | |
6:50 AM - 6:55 AM | What Is New In Coronary Artery Stenting: How Good Are New Drug Eluting Stents: Is There A Role For Bare Metal Stents |
Presenter(s):Martin B. Leon, MD | |
6:56 AM - 7:01 AM | The EXCEL Trial At 5 Years: Take Home Messages |
Presenter(s):Gregg W. Stone, MD | |
TRANSCATHETER HEART VALVES | |
7:02 AM - 7:07 AM | Update On Status Of Transcatheter Mitral Valve Repair (TMVR) |
Presenter(s):Juan F. Granada, MD | |
7:08 AM - 7:13 AM | DEBATE: Update On Transcatheter Aortic Valve Replacement (TAVR): A Cardiologist’s View |
Presenter(s):Martin B. Leon, MD | |
7:14 AM - 7:19 AM | DEBATE: Update On Current State Of TAVR: A Cardiac Surgeon’s View: What Is The Role Of Surgery In Aortic Valve Disease Treatment |
Presenter(s):Ali Khoynezhad, MD, PhD | |
THE ASCENDING AORTA | |
7:20 AM - 7:25 AM | Progress In Endovascular Graft Treatment Of Ascending Aortic Lesions |
Presenter(s):Rodney A. White, MD | |
7:26 AM - 7:31 AM | Progress In Endovascular Combined Devices For Repairing Lesions Of The Ascending Aorta And The Aortic Valve: The Endo-Bentall Concept |
Presenter(s):Ali Khoynezhad, MD, PhD | |
7:32 AM - 7:37 AM | Update On Endovascular Treatment Of Ascending Aortic Lesions: What Is Here And What Is On The Horizon |
Presenter(s):Christoph A. Nienaber, MD, PhD | |
7:38 AM - 7:43 AM | Endovascular Treatment Of Type A Aortic Dissections (TAADs): What Is Here And What Is Coming |
Presenter(s):Ali Azizzadeh, MD | |
7:44 AM - 7:50 AM | Panel Discussion |
END OF SESSION 1 | |
SESSION 2 SCHEDULE | |
Tuesday
SESSION 2:
PROGRESS IN THE TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS
Moderators:Alan B. Lumsden, MD, FACS / Anthony L. Estrera, MD
|
|
x | |
7:50 AM - 7:55 AM | Hybrid Repair Of Aortic Arch And Thoracic Aortic Aneurysms Using ThoraFlex (Hybrid) And Relay Devices For Frozen Elephant Trunk (FET) And TEVAR: Indications And Results |
Presenter(s):Joseph S. Coselli, MD / Ourania Preventza, MD | |
7:56 AM - 8:01 AM | Complete Aortic Arch Replacement With Elephant Trunk Or FET Is Rarely The End Of The Story With Aortic Dissections: What To Do About It |
Presenter(s):Götz M. Richter, MD, PhD | |
8:02 AM - 8:07 AM | Endovascular Arch Repair With Cook 2- Or 3-Branched Device For Lesions Involving The Entire Aortic Arch: Indications, Contraindications And Results |
Presenter(s):Stephan Haulon, MD | |
8:08 AM - 8:13 AM | Comparison Of Early And Midterm Results With 2-Branched Endograft (Relay – Terumo Aortic) And Single Branched Device (Nexus – Endospan) For Treatment Of Zone 0 Arch Lesions |
Presenter(s):Toru Kuratani, MD, PhD | |
8:14 AM - 8:19 AM | Update On RelayBranch Double Branched Device (Terumo Aortic) For Arch Lesion Endograft Repairs: Advantages, Limitations And Results |
Presenter(s):Vicente Riambau, MD, PhD / Ciro Ferrer, MD, PhD / Martin Czerny, MD | |
8:20 AM - 8:25 AM | Direction-Turnover Technique For Endovascular Repair Of Aortic Arch Lesions With Branched Or In Vitro Fenestrated Endografts |
Presenter(s):Qingsheng Lu, MD / Zaiping Jing, MD | |
8:26 AM - 8:31 AM | Total And Partial Aortic Arch Lesion Repairs With the Gore TAG Single Branch Endograft: An Off-The-Shelf (OTS) Device For Revascularizing Arch Branches: Experience To Date, Advantages And Limitations |
Presenter(s):Michael D. Dake, MD | |
8:32 AM - 8:37 AM | How Best To Treat TBADs Extending Into The Arch Or Ascending Aorta; When Open, When Endo, When Hybrid |
Presenter(s):I-Hui Wu, MD, PhD | |
8:38 AM - 8:43 AM | How To Prevent Complications During Partial Or Total Endovascular Aortic Arch Repairs |
Presenter(s):Chang Shu, MD | |
8:44 AM - 8:49 AM | How Best To Treat Aortic Arch Lesions: Customized Versus Chimney Versus Physician Modified Endografts: When Open: Role Of Each |
Presenter(s):Nicola Mangialardi, MD | |
8:50 AM - 8:55 AM | Value Of Ascending Aortic Banding As Primary Or Adjunctive Treatment For Aortic Arch Lesions |
Presenter(s):Chun Che Shih, MD, PhD | |
8:56 AM - 9:02 AM | Panel Discussion |
END OF SESSION 2 | |
SESSION 3 SCHEDULE | |
Tuesday
SESSION 3:
PROGRESS IN THE ENDOVASCULAR TREATMENT OF AORTIC DISSECTIONS: REPORTING STANDARDS, CLASSIFICATION SYSTEMS, STABILIZE, AND MORE
Moderators:Joseph S. Coselli, MD / Michael D. Dake, MD
|
|
x | |
9:02 AM - 9:07 AM | New SVS-STS Aortic Dissection Reporting Standards And Classification System: How Are They Different And Better |
Presenter(s):Joseph V. Lombardi, MD | |
9:08 AM - 9:13 AM | The TEM Aortic Dissection Classification System: What Is It And How Does It Improve Clinical Practice |
Presenter(s):Martin Czerny, MD | |
9:14 AM - 9:19 AM | Current Advances And Trends In TEVAR Treatment For Type B Aortic Dissection In China: More Or Less Liberal Use; More Or Less Aortic Coverage; What Adjunctive Procedures Are Used More |
Presenter(s):Weiguo Fu, MD | |
9:20 AM - 9:25 AM | Update On The STABILISE Concept For Treating Acute And Chronic TBADs By Disrupting The Intimal Flap By Overdilating The Distal Bare Stent: How It Works, Precautions And Results |
Presenter(s):Jean-Marc Alsac, MD, PhD | |
9:26 AM - 9:31 AM | Experience With The STABILISE Technique For Acute And Subacute TBADs: Indications, Technical Tips, Precautions And Results |
Presenter(s):Andrea Kahlberg, MD / Germano Melissano, MD / Roberto Chiesa, MD | |
9:32 AM - 9:37 AM | Duel Lumen Interventions To Promote False Lumen Thrombosis In Chronic Aortic Dissections: The FLIRT Procedure: Indications, Technique And Results |
Presenter(s):Christoph A. Nienaber, MD, PhD | |
9:38 AM - 9:43 AM | DEBATE: Fenestrated And Branched Endovascular Grafts (F/B/EVAR) Are Usually The Best Treatment For Post-Dissection Thoraco-Abdominal Aneurysms (TAAAs) |
Presenter(s):Gustavo S. Oderich, MD, FACS | |
9:44 AM - 9:49 AM | DEBATE: There Will Always Be A Need For Open Repair For Post-Dissection TAAAs: In What Circumstances |
Presenter(s):Hazim J. Safi, MD / Anthony L. Estrera, MD | |
9:50 AM - 9:55 AM | Distal Stent-Graft Induced New Re-Entry Tears (SINEs) With TEVAR Treatment Of TBADs: Prevention By Avoiding Oversizing And Ballooning And Using Tapered Endografts |
Presenter(s):Ludovic Canaud, MD, PhD | |
9:56 AM - 10:01 AM | The Impact Of Distal Stent-Graft Induced New Entry Tears On Aortic Remodeling Of Chronic TBADs: How To Prevent And Treat Them |
Presenter(s):Chun Che Shih, MD, PhD | |
10:02 AM - 10:07 AM | When Is TEVAR The Best Treatment For Marfan Syndrome And Its Complications |
Presenter(s):James H. Black, III, MD | |
10:08 AM - 10:14 AM | Panel Discussion |
10:14 AM - 10:24 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 3 | |
SESSION 4 SCHEDULE | |
Tuesday
SESSION 4:
MORE NEW DEVELOPMENTS IN THE TREATMENT OF TBADs, THORACIC AORTIC DISEASE AND THORACOABDOMINAL ANEURYSMS (TAAAs)
Moderators:Hazim J. Safi, MD / Ali Khoynezhad, MD, PhD
|
|
x | |
10:24 AM - 10:29 AM | Long-Term Durability Of Open Repair Of Type I-IV TAAAs Remains Excellent: When Should It Be The First Line Treatment And When Should A Hybrid (Endo + Open) Down-Staging Approach Be Used To Improve Outcomes: How To Do The Latter |
Presenter(s):Mark Conrad, MD, MMSc / Richard P. Cambria, MD | |
10:30 AM - 10:35 AM | New Strategies And Indications For Open TAAA Repair Including Failed EVAR And F/B/EVAR: Technical Tips And Results |
Presenter(s):Roberto Chiesa, MD / Germano Melissano, MD | |
10:36 AM - 10:41 AM | Aortic Arch Repairs With Frozen Elephant Trunk (FET) Followed By Open Or Endo Extensions For TAAA Repairs: Techniques And Outcomes; Importance Of Staging |
Presenter(s):Michael J. Jacobs, MD | |
10:42 AM - 10:47 AM | Lessons Learned From The STABLE I And II Trials: What Are The Advantages And Limitations Of A Distal Bare Stent Combined With A Proximal Covered Stent |
Presenter(s):Joseph V. Lombardi, MD | |
10:48 AM - 10:53 AM | Changing Current Trends In Management And Outcomes With Acute TBADs: Based On 3000 Patients In The IRAD Registry: What Is Helping And What Is Not |
Presenter(s):Santi Trimarchi, MD, PhD | |
10:54 AM - 10:59 AM | Why Is F/B/EVAR The Best Treatment For Post TBAD TAAAs: Challenges And Results |
Presenter(s):Eric L.G. Verhoeven, MD, PhD | |
11:00 AM - 11:05 AM | Roles Of Inner And Outer Branched Endografts And The t-Branched OTS Device (Cook) To Treat TAAAs After TBADs: Technical Tips And Results |
Presenter(s):Marcelo Ferreira, MD | |
11:06 AM - 11:12 AM | Panel Discussion |
11:12 AM - 11:17 AM | Gore TAMBE Endovascular Graft Device For TAAA Repair: How Does It Work: Results To Date, Advantages And Limitations |
Presenter(s):Mark A. Farber, MD | |
11:18 AM - 11:23 AM | How To Predict TAAA Patients Who Should Not Have An Endovascular Repair And How To Minimize Mortality: Age And Mural Thrombus Matter |
Presenter(s):Patrick W. Kelly, MD | |
11:24 AM - 11:29 AM | How To Treat Dynamic Branch Occlusion And Malperfusion With TBADs If Blood Pressure Control And TEVAR Coverage Of The Primary Tear Does Not Work: A Step Wise Plan |
Presenter(s):Firas F. Mussa, MD | |
11:30 AM - 11:35 AM | Improved Aortic Remodeling With TEVAR And A Distal Bare Metal Stent In Acute Complicated TBAD |
Presenter(s):Christoph A. Nienaber, MD, PhD | |
11:36 AM - 11:41 AM | Embolization Strategies To Achieve False Lumen Thrombosis With False Lumen TAAAs After TEVAR For TBADs |
Presenter(s):Carlos H. Timaran, MD | |
11:41 AM - 11:47 AM | Varying Solutions To Treat Type 1 Endoleaks After TEVAR And EVAR |
Presenter(s):Nicola Mangialardi, MD | |
11:48 AM - 11:53 AM | High Failure Rate Of Best Medical Treatment For Intramural Hematoma Mandates Increased Use Of TEVAR: Does This Help Outcomes |
Presenter(s):Jean M. Panneton, MD | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 4 | |
SESSION 5 SCHEDULE | |
Tuesday
SESSION 5:
NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY AND TREATMENT, EVAR AND EVAS (ENDOVASCULAR ANEURYSM SEALING) (5 AND 4 3/4-MINUTE [SS] TALKS)
Moderators:Juan C. Parodi, MD / Kenneth Ouriel, MD, MBA
|
|
x | |
1:00 PM - 1:05 PM | Current Pros And Cons Of The Nellix EVAS Endograft For AAA Repair: First Update Of The EVAS2 IDE Trial Of The Modified Improved Nellix Endograft |
Presenter(s):Jeffrey P. Carpenter, MD | |
1:06 PM - 1:11 PM | Update On The Nellix EVAS Endograft For AAA Repair: Indications, Advantages And Limitations |
Presenter(s):Matt M. Thompson, MD | |
1:12 PM - 1:17 PM | Failing EVARs Are An Emerging Epidemic: Etiology And How Best To Avoid And Treat The Problem |
Presenter(s):Murray L. Shames, MD | |
1:18 PM - 1:23 PM | Diabetes And AAAs: Facts, Clues And Potential Treatment Opportunities |
Presenter(s):Ronald L. Dalman, MD | |
1:24 PM - 1:28 PM | [SS] How Does Metformin Work To Slow AAA Growth At The Cellular Level: Could It Be Effective Treatment For Small AAAs: Is It The Reason For Decreased AAA Incidence In Diabetes |
Presenter(s):Kak Khee Yeung, MD, PhD | |
1:28 PM - 1:33 PM | Further Thoughts About The Odd Relationship Between Diabetes And AAA Disease: How Should It Influence Treatment |
Presenter(s):Christos D. Liapis, MD | |
1:34 PM - 1:39 PM | Should Saccular AAAs Be Fixed At A Smaller Diameter Than Fusiform AAAs: How Should Saccular AAA Diameter Be Measured: To Include The Normal Aorta Or Not |
Presenter(s):Frans L. Moll, MD, PhD | |
1:40 PM - 1:46 PM | Panel Discussion |
Moderator(s): Mark A. Adelman, MD / Michel Makaroun, MD | |
1:46 PM - 1:51 PM | How Should AAA Sac Behavior After EVAR Be Used To Assess Treatment Success And Patient Prognosis |
Presenter(s):Jean-Pierre Becquemin, MD, FRCS | |
1:52 PM - 1:56 PM | [SS] Impact Of AAA Sac Size On EVAR Outcomes Short And Long-Term: Large Size Is Associated With Failure: What To Do About It |
Presenter(s):Carlos H. Timaran, MD | |
1:56 PM - 2:00 PM | [SS] Decreased AAA Sac Diameter After EVAR Is Associated With Good Outcomes While Sac Stability Is Not |
Presenter(s):Andres Schanzer, MD | |
2:00 PM - 2:05 PM | In Patients Suitable for EVAR Or Open Repair, Adverse Neck Anatomy (Short, Wide, Angulated) Is Associated With Increased Reintervention And Mortality Rates Equally After Open and Endo Repairs: From The DREAM RCT: How Should This Influence Treatment |
Presenter(s):Jan D. Blankensteijn, MD | |
2:06 PM - 2:10 PM | [SS] Why AAA Diameter Is Often Not Enough To Make A Decision Regarding Threshold For Repair Or Re-Treatment After EVAR: What Other Parameters Should Enter Into The Decision |
Presenter(s):S. Rao Vallabhaneni, MD, FRCS | |
2:10 PM - 2:15 PM | Improved AAA Sac Diameter Surveillance After EVAR Using A Home Smart Phone Ultrasound System: Device Description And Why It Will Improve Outcomes |
Presenter(s):Roger M. Greenhalgh, MD / Ian Loftus, MD | |
2:16 PM - 2:21 PM | Key New Developments In Long-Term Evaluation Of EVAR For AAA Treatment |
Presenter(s):Jason T. Lee, MD | |
2:22 PM - 2:27 PM | Long-Term EVAR Outcomes Have Improved Over Time Whereas Open Repair Outcomes Have Remained Stable: A VQI Propensity Study Explains Differing Results Of RCTs And Shows Late Survival Advantage Of EVAR |
Presenter(s):Marc L. Schermerhorn, MD | |
2:28 PM - 2:40 PM | Panel Discussion And BreakVisit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 5 | |
SESSION 6 SCHEDULE | |
Tuesday
SESSION 6:
MORE ABOUT AAAs, EVAR AND THE PUBLISHED UK NICE AAA GUIDELINES AND THEIR IMPACT ON AAA TREATMENT IN THE UK AND ELSEWHERE (5 AND 4-MINUTE TALKS)
|
|
x | |
2:40 PM - 2:45 PM | Key Points In The Recently Published NICE Guidelines For Treatment Of AAAs And What Data Justifies Them: A View From The Writing Committee Chairman |
Presenter(s):Andrew W. Bradbury, MD, FRCSEd | |
2:46 PM - 2:51 PM | The Scientific Rationale Underlying The AAA NICE Guidelines: A View From A Writing Committee Member |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FACPh, F | |
2:52 PM - 2:57 PM | Long-Term Results Of The OVER RCT: Pertinence To NICE AAA Guidelines: How Operator Training And Experience Influence EVAR Outcomes |
Presenter(s):Jon S. Matsumura, MD | |
2:58 PM - 3:03 PM | Why EVAR Is The Best Treatment For AAAs – Especially In Young Patients With A Long Life Expectancy |
Presenter(s):Fabio Verzini, MD, PhD | |
3:04 PM - 3:09 PM | Impact Of NICE Guidelines On AAA Practice In The UK: Decreased Use Of EVAR Is NOT Justified By Recent Data Showing That EVAR Has Better 10-Year Survival Than Open Repair |
Presenter(s):Ian Loftus, MD | |
3:10 PM - 3:15 PM | What Is Happening Due To The NICE AAA Guidelines In The UK And Why It Is Harmful |
Presenter(s):Nicholas J.W. Cheshire, MD | |
3:16 PM - 3:20 PM | [SS] Are The NICE AAA Guidelines The End Of EVAR In The UK: Why The Guidelines Are Wrong And Can They Be Fixed |
Presenter(s):Michael P. Jenkins, MBBS, BSc, MS, FRCS, FEBVS | |
3:20 PM - 3:24 PM | What Is Wrong With The NICE AAA Guidelines: Do They Still Limit The Use Of EVAR As In The Draft Guidelines |
Presenter(s):Bijan Modarai, PhD, FRCS | |
3:24 PM - 3:28 PM | [SS] Impact Of NICE AAA Draft And Final Guidelines On Complex AAA Endovascular Repair: Will They Be Good For Patients |
Presenter(s):Tara M. Mastracci, MD | |
3:28 PM - 3:32 PM | [SS] What Are The Flaws In The Final Version Of The NICE AAA Guidelines |
Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC | |
3:32 PM - 3:37 PM | Impact Of UK NICE AAA Guidelines On Other Countries Served By The European ESVS Guidelines |
Presenter(s):Anders Wanhainen, MD, PhD | |
3:38 PM - 3:42 PM | [SS] Will The UK NICE AAA Guidelines Have An Impact Outside The UK And EU: What Will It Be |
Presenter(s):Andrew Holden, MBChB | |
3:42 PM - 3:46 PM | [SS] Why Are The NICE AAA Guidelines So Flawed: Has Bias Played A Role |
Presenter(s):Frans L. Moll, MD, PhD | |
3:46 PM - 3:50 PM | [SS] The UK NICE AAA Guidelines Are Based On Outdated Data And Are Therefore Misleading |
Presenter(s):Hans-Henning Eckstein, MD, PhD | |
3:50 PM - 3:56 PM | Panel Discussion |
END OF SESSION 6 | |
SESSION 7 SCHEDULE | |
Tuesday
SESSION 7:
MORE NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC DISSECTIONS AND THORACIC PATHOLOGY; STROKE PREVENTION WITH TEVAR
Moderators:Mark A. Farber, MD / Thomas C. Bower, MD
|
|
x | |
3:56 PM - 4:01 PM | Update On Stroke Reduction Strategies With TEVAR (Including For Arch Repairs): How To Decrease Particulate And Gas Emboli: What Is The STEP 2 Study Telling Us |
Presenter(s):Tilo Koelbel, MD, PhD / Stephan Haulon, MD | |
4:02 PM - 4:07 PM | Advances In Stroke Prevention From TEVAR: How To Decrease Gas And Particulate Emboli: When Should These Methods Be Used |
Presenter(s):Richard G.J. Gibbs, FRCS | |
4:08 PM - 4:13 PM | Update On Value Of Embolic Brain Protection Devices For Proximal TEVAR And TAVR Procedures: When Are They Mandatory |
Presenter(s):Jeffrey P. Carpenter, MD | |
4:14 PM - 4:19 PM | What Is Best Medical Treatment For TBAD Patients: How Best To Control Blood Pressure And To Get Patients To Comply: They Don’t |
Presenter(s):Colin D. Bicknell, MD, FRCS | |
4:20 PM - 4:25 PM | Material Properties Of The Aortic Arch Can Predict Bird Beaking And Type 1A Endoleaks With TEVAR: Will Conformable Endografts With Proximal Adjustable Angle Control Eliminate The Problem |
Presenter(s):Thomas L. Forbes, MD | |
4:26 PM - 4:31 PM | Natural History Of Aortic Intramural Hematomas (IMHs) And Predictors Of Need For TEVAR Treatment: Which IMH Patients Do Not Need TEVAR |
Presenter(s):I-Hui Wu, MD, PhD | |
4:32 PM - 4:37 PM | How To Deal With An Uncontrolled And Enlarging False Lumen After TEVAR For TBADs |
Presenter(s):Cherrie Z. Abraham, MD | |
4:38 PM - 4:43 PM | Long-Term (>5 Years) Good Results Of Valiant Captiva Endografts For TEVAR In TBAD Patients: What Are The Differences Between The Captiva And Navion Systems |
Presenter(s):Joseph E. Bavaria, MD | |
4:44 PM - 4:49 PM | How To Treat Aortic Dissections With An Entry Tear In The Aortic Arch |
Presenter(s):Santi Trimarchi, MD, PhD | |
4:50 PM - 4:56 PM | Panel Discussion |
END OF SESSION 7 | |
SESSION 8 SCHEDULE | |
Tuesday
SESSION 8:
MORE NEW DEVELOPMENTS REGARDING TBADs AND TEVAR: NATURAL HISTORY; NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TBADs
Moderators:Joseph E. Bavaria, MD / Thomas L. Forbes, MD
|
|
x | |
4:56 PM - 5:01 PM | Long-Term Outcomes Of Medically Managed Acute TBADs: How Were Patients Selected For This Treatment |
Presenter(s):Thomas C. Bower, MD | |
MEGA DEBATE ON TREATMENT OF ACUTE UNCOMPLICATED TBADs | |
5:02 PM - 5:07 PM | DEBATE: Many Uncomplicated Acute TBADs Never Need Invasive Interventions And Are Better Treated Medically; How To Select Such Patients |
Presenter(s):Rachel E. Clough, MD, PhD, FRCS | |
5:08 PM - 5:13 PM | DEBATE: With Uncomplicated Acute TBADs, The Case For Waiting 2-6 Weeks From Onset And Then Limiting Aortic Coverage With TEVAR |
Presenter(s):Mark A. Farber, MD | |
5:14 PM - 5:19 PM | DEBATE: With Uncomplicated TBADs, The Case For Early TEVAR With Extensive Aortic Coverage In Most Patients |
Presenter(s):William D. Jordan Jr., MD | |
5:20 PM - 5:25 PM | DEBATE: Early Intervention For Acute TBADs (7-30 Days After Onset) With TEVAR For Acute TBADs Prevents Abdominal Extension Of False Lumen And TAAA Formation |
Presenter(s):Rodney A. White, MD | |
5:26 PM - 5:31 PM | Ideal Timing And Patient Selection Of TEVAR In Acute Uncomplicated TBAD Patients: When Is Medical Treatment Indicated |
Presenter(s):Ali Azizzadeh, MD | |
5:32 PM - 5:36 PM | [SS] Varying Solutions To Treat Type 1A Endoleaks After TEVAR And EVAR |
Presenter(s):Nicola Mangialardi, MD | |
5:36 PM - 5:40 PM | [SS] Impact Of Cocaine Abuse On The Course Of Acute TBADs And Their Treatment: What Is The Mechanism |
Presenter(s):Frank R. Arko, MD | |
5:40 PM - 5:45 PM | Techniques For And Advantages Of Rerouting A Misplaced TEVAR Which Is Leading To A Growing False Lumen And Malperfusion In Acute TBAD Patients |
Presenter(s):David M. Williams, MD | |
5:46 PM - 5:51 PM | Re-Entry Specific Endovascular Therapy (RESET), i.e. TEVAR Plus Dealing With Re-Entry Tears Improves Outcomes: How To Do It |
Presenter(s):Jean M. Panneton, MD | |
5:52 PM - 5:58 PM | Panel Discussion End Of Program A |
END OF SESSION 8 | |
SESSION 9 SCHEDULE | |
Tuesday
SESSION 9:
PROGRESS IN VASCULAR ROBOTICS, GUIDANCE SYSTEMS, LAPAROSCOPY AND SIMULATION
Moderators:Willem Wisselink, MD / Sean P. Lyden, MD
|
|
x | |
6:44 AM - 6:49 AM | Opening Remarks |
Presenter(s):Enrico Ascher, MD | |
6:50 AM - 6:55 AM | Update On Endovascular Robotics: They Have A Promising Future |
Presenter(s):Joseph J. Ricotta II, MD, MS, DFSVS,FACS | |
6:56 AM - 7:01 AM | Robotic Decompression Of The Median Arcuate Ligament (Video Presentation) |
Presenter(s):Michael J. Singh, MD | |
7:02 AM - 7:07 AM | Laparoscopic Assisted Aortofemoral Bypasses For Juxtarenal Aortic Occlusions: Why It Is The Best Treatment Method |
Presenter(s):Joseph S. Giglia, MD | |
7:08 AM - 7:13 AM | Laparoscopic Robotic Assisted Aortic Surgery: Is It Worthwhile And Cost Effective In The Endovascular Era: Based On A 7-Year Experience In 87 Patients |
Presenter(s):Pierre-Olivier Thiney, MD | |
7:14 AM - 7:19 AM | Present Status And Future Potential Of Radiation Free Guidewire And Catheter Guidance: The Fiber Optic RealShape (FORS) From Philips: What Are Microbots And How Do They Work |
Presenter(s):Barry T. Katzen, MD | |
7:20 AM - 7:25 AM | Updated Experience With Radiation Free Fiberoptic 3D Endovascular Guidance With The FORS System (Philips): Advantages And Limitations |
Presenter(s):Joost A. van Herwaarden, MD, PhD | |
7:26 AM - 7:31 AM | Update On The 3D Radiation Free Intraoperative Positioning System (IOPS) From Centerline For Endovascular Guidance: How Does It Work, Advantages And Limitations |
Presenter(s):Matthew J. Eagleton, MD | |
7:32 AM - 7:37 AM | The MAZE BOX: A Simple Table Top Endovascular Simulator For Training In Endovascular Tasks And Procedures |
Presenter(s):Barend M.E. Mees, MD, PhD | |
7:38 AM - 7:44 AM | Panel Discussion |
END OF SESSION 9 | |
SESSION 10 SCHEDULE | |
Tuesday
SESSION 10:
NEW DEVELOPMENTS IN CAROTID DISEASE AND ITS TREATMENT; DIFFERING VIEWS ON TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS) AND CAROTID SCREENING
|
|
x | |
7:44 AM - 7:49 AM | Variations In Carotid Treatment Within Countries And Between Countries In Europe, The US And Australia Is Great Despite All The RCTs: What Are The Implications |
Presenter(s):Maarit Venermo, MD, PhD | |
7:50 AM - 7:55 AM | Current Optimal Treatment For Carotid Artery Dissection: When Best Medical Therapy (BMT), When Open Surgery, When Carotid Stenting (CAS) With Proximal Embolic Protection |
Presenter(s):Felice Pecoraro, MD | |
7:56 AM - 8:01 AM | What Vascular Surgeons And Vascular Specialists Need To Know About What Can Be Learned From MRI And MRA Studies Of The Head And Neck |
Presenter(s):Emmanuel M. Houdart, MD | |
8:02 AM - 8:07 AM | Near Total Occlusions And String Signs Of The Internal Carotid Artery (ICA): How Are They Best Treated: Do We Have Updated Evidence |
Presenter(s):Christos D. Liapis, MD | |
8:08 AM - 8:13 AM | Radiation And Carotid Stenosis: What Is The Relationship And How Is Radiation Stenosis Best Treated When Asymptomatic And When Symptomatic |
Presenter(s):Cynthia K. Shortell, MD | |
8:14 AM - 8:20 AM | Panel Discussion |
DIFFERING VIEWS ON TREATMENT OF ACS | |
8:20 AM - 8:25 AM | DEBATE: Almost ALL Asymptomatic Carotid Stenosis (ACS) Patients Are Best Treated Medically: Invasive Treatment Causes More Harm Than Good |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
8:26 AM - 8:31 AM | DEBATE: Not So: About 25% Of ACS Patients Can Benefit From CEA Or CAS And Should Be So Treated |
Presenter(s):Bruce A. Perler, MD, MBA | |
8:32 AM - 8:37 AM | DEBATE: Both Views Are Wrong: About 5-10% Of ACS Patients Should Be Treated Invasively And Benefit From Such Treatment: Why Are Too Many ACS Patients Getting CEA Or CAS |
Presenter(s):Kosmas I. Paraskevas, MD | |
8:38 AM - 8:43 AM | DEBATE: ACS: When Not To Treat Invasively And When To Treat Invasively: A Balanced Logical View – But No One Knows Which View Is Right Or Best |
Presenter(s):Martin Storck, MD, PhD | |
DIFFERING VIEWS ON CAROTID SCREENING | |
8:44 AM - 8:49 AM | DEBATE: The Case For Widespread Carotid Screening |
Presenter(s):George S. Lavenson, MD | |
8:50 AM - 8:55 AM | DEBATE: The Case Against Carotid Screening: It Leads To Unneeded And Possibly Harmful Treatment |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
8:56 AM - 9:01 AM | DEBATE: Lifeline Proprietary Carotid Screening: Who Profits: Is It A Good Thing Or A Hoax And A Scam: What Can It Tell Us About The Prevalence Of ACS |
Presenter(s):Thomas G. Brott, MD | |
9:02 AM - 9:07 AM | Screening For ACS And Common Femoral Artery Disease: How Can It Guide Lipid Treatment: How Low Should LDL-Cholesterol (LDL-C) Be Pushed And What Will It Do To Carotid Plaques |
Presenter(s):Andrew N. Nicolaides, MS, FRCS | |
9:08 AM - 9:15 AM | Panel Discussion |
9:15 AM - 9:30 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 10 | |
SESSION 11 SCHEDULE | |
Tuesday
SESSION 11:
MORE ABOUT CAROTID AND VERTEBRAL DISEASE: UPDATE ON INVASIVE TREATMENT FOR ACUTE STROKES
Moderators:Allan L. Brook, MD / Klaus D. Mathias, MD
|
|
x | |
9:30 AM - 9:35 AM | Carotid Webs Can Cause Strokes In Young Patients – How Are They Best Diagnosed And Treated: Should They Be Treated In Asymptomatic Patients |
Presenter(s):Emmanuel M. Houdart, MD | |
9:36 AM - 9:41 AM | When After Thrombolysis Treatment From A Stroke Should Carotid Endarterectomy (CEA) Be Performed And What Is The Best Timing For Those CEAs: Delay Has Consequences |
Presenter(s):Maarit Venermo, MD, PhD | |
9:42 AM - 9:47 AM | Why Vascular Surgeons Should Become Involved In Intracranial Endovascular Treatments For Acute Strokes: How To Learn These Procedures And Benefit Patients |
Presenter(s):Laura Capoccia, MD | |
9:48 AM - 9:43 AM | What Is New With Endovascular Intracranial Techniques For Arterial Clot Removal For Acute Strokes: New Methods; When And How Can The Time Window For Success Be Increased |
Presenter(s):Colin P. Derdeyn, MD | |
9:54 AM - 9:59 AM | Update And New Developments In Intracranial Endovascular Treatment For Acute Strokes: Should Other Specialists Learn How To Do It And the Ways To Learn |
Presenter(s):L. Nelson Hopkins, MD | |
10:00 AM - 10:05 AM | Acute Stroke Interventions: What Is New: Who Should Do Them And Lessons Learned |
Presenter(s):Horst Sievert, MD | |
10:06 AM - 10:11 AM | How Best To Treat An ICA Occlusion With Distal Embolization: Sequence Of Treatment: Team Composition: Technical Tips |
Presenter(s):Timothy M. Sullivan, MD | |
10:12 AM - 10:17 AM | Improvements In The Treatment Of Acute Strokes: Why A Dedicated Stroke Center Matters: What And Who Must Be Involved: Yes, It Does Matter In Better Patient Outcomes |
Presenter(s):Hernan A. Bazan, MD, DFSVS, FACS | |
10:18 AM - 10:23 AM | Endovascular Interventions In The Vertebro-Basilar System For Acute Strokes: A New Horizon, What Is Involved And Results |
Presenter(s):Ivo Petrov, MD, PhD | |
10:24 AM - 10:30 AM | Panel Discussion |
END OF SESSION 11 | |
SESSION 12 SCHEDULE | |
Tuesday
SESSION 12:
PROGRESS IN THE TREATMENT OF AORTIC AND AORTO-ILIAC OCCLUSIVE DISEASE
|
|
x | |
10:30 AM - 10:35 AM | Current Concepts And Techniques For Treating External Iliac Artery Endofibrosis In Committed Athletes: What Works And Doesn’t Work: Is There A role For Endovascular Treatment |
Presenter(s):Kenneth J. Cherry, MD | |
10:36 AM - 10:41 AM | Iliac Stenosis In Professional Cyclists: How To Diagnose And Treat: ABIs Don’t Help |
Presenter(s):Gabriel Szendro, MD | |
10:42 AM - 10:47 AM | Value Of VBX Balloon Expandable Covered Stents In Treating Complex Aorto-Iliac Occlusive Disease: Advantages And Limitations |
Presenter(s):Ehrin Armstrong, MD | |
COVERED ENDOVASCULAR RECONSTRUCTION OF THE AORTIC BIFURCATION (CERAB) PROCEDURE | |
10:48 AM - 10:53 AM | Midterm Outcomes Of The CERAB And Chimney CERAB Procedure With Covered Stents For Complex Aorto-Iliac Occlusive Disease: Why It’s Better Than Kissing Stents And Which Covered Stent Works Best |
Presenter(s):Michel M.P. Reijnen, MD, PhD / Peter C.J. Goverde, MD | |
10:54 AM - 10:59 AM | CERAB Procedure Versus Kissing Stents For Complex Aorto-Iliac Occlusive Diseases: Advantages And Disadvantages Of Each: CERAB Requires More Time And Radiation |
Presenter(s):Maria A. Ruffino, MD, EBIR | |
11:00 AM - 11:05 AM | Covered Endovascular Reconstruction Of The Aortic Bifurcation (CERAB) Procedure: Indications, Challenges And Technical Tips |
Presenter(s):Hany Zayed, MD | |
11:06 AM - 11:11 AM | Value Of Shockwave Intravascular Lithotripsy For Calcified Aorto-Iliac Occlusive Disease Treatment |
Presenter(s):Andrew Holden, MBChB | |
11:12 AM - 11:18 AM | Panel Discussion |
11:18 AM - 11:23 AM | Treatment Of Isolated Aortic Stenosis Without Iliac Disease: When Stents; When Stent-Grafts; When Open Bypass |
Presenter(s):Sigrid Nikol, MD | |
11:24 AM - 11:29 AM | Endovascular Treatment Of Difficult Aorto-Iliac Occlusions: Technical Tips: Is Open Repair Ever Needed |
Presenter(s):Sonia Ronchey, MD,PhD | |
11:30 AM - 11:35 AM | DEBATE: How To Treat Chronic Flush Juxtarenal Aortic Occlusions Endovascularly With Safety: Endo Is The Way To Go |
Presenter(s):David J. Minion, MD | |
11:36 AM - 11:41 AM | DEBATE: Not So: Open Surgery Is the Best Way To Treat Flush Juxtarenal Aortic Occlusions Safely: Technical Tips On How To Do It |
Presenter(s):Thomas C. Bower, MD | |
11:42 AM - 11:47 AM | DEBATE: Both Wrong: Hybrid Repairs Are Best For Complex Aorto-Iliac Occlusive Disease: Technical Tips On How To Do It |
Presenter(s):Yamume Tshomba, MD | |
11:48 AM - 11:53 AM | Impact Of Female Gender On Outcomes Of Endovascular Treatment Of Aorto-Iliac Occlusive Disease: When Is Open Repair Indicated |
Presenter(s):Franco Grego, Vascular Surgery | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break –2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 12 | |
SESSION 13 SCHEDULE | |
Tuesday
SESSION 13:
NEW CONCEPTS, MACHINE LEARNING AND ARTIFICIAL INTELLIGENCE (AI)
Moderators:Barry T. Katzen, MD / Lindsay Machan, MD
|
|
x | |
1:00 PM - 1:05 PM | What Is Big Data In Vascular Surgery: How Can It Be Used With Artificial Intelligence (AI) In Evidence Based Medicine: Could It Replace Randomized Controlled Trials (RCTs) |
Presenter(s):Jean-Baptiste Ricco, MD, PhD | |
1:06 PM - 1:11 PM | What Is The Bright Future Of AI And Robotic Technology In Vascular Surgery |
Presenter(s):Willem Wisselink, MD | |
1:12 PM - 1:17 PM | How AI Will Change The Way We Practice Medicine |
Presenter(s):Lindsay Machan, MD | |
1:18 PM - 1:23 PM | How Vascular Treatment Will Intersect With Other New Technologies: Wearable Trackers, AI, And Tissue Engineering |
Presenter(s):David H. Deaton, MD, FACS | |
1:24 PM - 1:29 PM | How 3D And 4D Machine Learning Is Changing Vascular Surgery |
Presenter(s):Matthew T. Menard, MD | |
1:30 PM - 1:35 PM | How Can AI Be Used To Predict Endoleaks And AAA Growth: Will It Have Clinical Value |
Presenter(s):Kak Khee Yeung, MD, PhD | |
1:36 PM - 1:41 PM | How Can AI Facilitate AAA Monitoring Before And After EVAR |
Presenter(s):Stephan Haulon, MD | |
1:42 PM - 1:47 PM | Value Of Computational Fluid Dynamic Studies To Evaluate Closure Techniques With CEA, Predict Restenosis And Help In AAA Treatment |
Presenter(s):Santi Trimarchi, MD, PhD | |
1:48 PM - 1:53 PM | Siemens I-Flow: A New Intelligent Technology To Improve The Endo Treatment Of Lower Extremity Occlusive Disease |
Presenter(s):Ravi K. Veeraswamy, MD | |
1:54 PM - 1:59 PM | Totally Radiation Free Deployment Of A Complex AAA Endograft Using An Intraoperative Positioning System (IOPS From Centerline) And Positional Markers On Graft Components As Well As Catheters And Wires To Enable Accurate 3D Guidance: It Is Analogous To Precise GPS Targeting |
Presenter(s):Gustavo S. Oderich, MD, FACS | |
2:00 PM - 2:05 PM | Is Image Fusion Guidance For Complex And Simple Aortic Procedures Really Worthwhile And Cost Effective: Why Is It A Question |
Presenter(s):Rachel E. Clough, MD, PhD, FRCS | |
2:06 PM - 2:12 PM | Panel Discussion |
END OF SESSION 13 | |
SESSION 14 SCHEDULE | |
Tuesday
SESSION 14:
VASCULAR SURGERY’S NUMBERS, IDENTITY, RECOGNITION, INDEPENDENT SPECIALTY STATUS; HOW TO INCREASE OUR NUMBERS TO MEET FUTURE NEEDS FOR OUR SERVICES
Moderators:Kim J. Hodgson, MD / Ronald L. Dalman, MD
|
|
x | |
2:12 PM - 2:17 PM | Updated Workforce Model Predicts A Shortage Of Vascular Surgeons For The Next 20 Years: What Should Vascular Surgery And The American Board of Surgery (ABS) Do About It |
Presenter(s):K. Craig Kent, MD / Bhagwan Satiani, MD, MBA | |
2:18 PM - 2:23 PM | What Makes Vascular Surgery Different, Why Are There Insufficient Numbers Of Vascular Surgeons: How Can We Expand Our Numbers |
Presenter(s):Evan C. Lipsitz, MD, MBA | |
2:24 PM - 2:29 PM | The Clouded Identity Of Vascular Surgery Amongst Other Doctors And The Public: Why Is It So And What Can Be Done About It |
Presenter(s):James C. Stanley, MD / Frank J. Veith, MD | |
2:30 PM - 2:35 PM | Why US News & World Report Cannot And Does Not Rank Vascular Surgery Programs: Vascular Surgery Needs To Be An Independent ABMS Approved Specialty: Why Isn’t It |
Presenter(s):James H. Black, III, MD | |
2:36 PM - 2:41 PM | The American Board Of Vascular Surgery Or ABVS: Its Time Is Now |
Presenter(s):Alan M. Dietzek, MD, RPVI, FACS | |
2:42 PM - 2:47 PM | The SVS Executive Committee: What Is Its Function And How Has It Not Promoted Vascular Surgery And Thereby Failed To Serve Its Membership’s Interests |
Presenter(s):Benjamin W. Starnes, MD | |
2:48 PM - 2:53 PM | What Will Happen If Vascular Surgery Does Not Become A Separate Specialty: How Have Our Vascular Societies Failed Vascular Surgeons |
Presenter(s):David H. Deaton, MD, FACS | |
2:54 PM - 2:59 PM | Why Vascular Surgery Must Be An Independent Specialty: It Needs Independent Departments So As To Not Be Exploited By Other Department Chairs |
Presenter(s):Patrick J. Geraghty, MD | |
3:00 PM - 3:05 PM | The Key To More Vascular Surgeons Is Better Exposure To Medical Students: We Are A Hidden Specialty Because Of Our Subordinate Specialty Status Which Also Limits Our Training Programs |
Presenter(s):Jerry Goldstone, MD, FACS, FRCSEd | |
3:06 PM - 3:11 PM | Vascular Surgery Training Program’s Update For 0+5 And 5+2 Programs: Do We Need More Applicants Or More Programs Or Both: How Can We Get There |
Presenter(s):Murray L. Shames, MD | |
3:12 PM - 3:17 PM | Is Getting A Vascular Surgery Training Position Becoming Less Competitive For 0+5 Residencies; For 5+2 Fellowships |
Presenter(s):Peter L. Faries, MD, FACS | |
3:18 PM - 3:23 PM | Leadership Roles Vascular Surgeons And Vascular Specialists Should Seek: Why They Are Important And How To Get There Without Abandoning Your Original Specialty |
Presenter(s):Christopher J. Kwolek, MD, MBA | |
3:24 PM - 3:36 PM | Panel Discussion And Break Visit Pavilions And Exhibits (2nd and 3rd Floors) |
END OF SESSION 14 | |
SESSION 15 SCHEDULE | |
Tuesday
SESSION 15:
PROGRESS IN THE TREATMENT OF VISCERAL AND RENAL ARTERY DISEASE
Moderators:James C. Stanley, MD / Alan M. Dietzek, MD, RPVI, FACS
|
|
x | |
3:36 PM - 3:41 PM | DEBATE: All Visceral And Renal Artery Aneurysms Can Be Treated Endovascularly |
Presenter(s):Robert A. Lookstein, MD, MHCDL, FSIR, FAHA | |
3:42 PM - 3:47 PM | DEBATE: Open Treatment Of Visceral And Renal Artery Aneurysms Is Sometimes Best: When Is This |
Presenter(s):Timur P. Sarac, MD | |
3:48 PM - 3:53 PM | Technical Tips For Percutaneous Endovascular Treatment Of Visceral And Renal Artery Aneurysms |
Presenter(s):Jacob Cynamon, MD, FACR, FSIR | |
3:54 PM - 3:59 PM | Update On New SVS Practice Guidelines For Treating Visceral Artery Aneurysms; When Endo; When Open |
Presenter(s):Rabih A. Chaer, MD | |
4:00 PM - 4:05 PM | Technical Tips For Recanalizing Long Complex Visceral Artery (SMA) Occlusions |
Presenter(s):Armando Mansilha, MD, PhD, FEBVS | |
4:06 PM - 4:11 PM | Current Optimal Treatment Of Pancreatico-Duodenal Aneurysms With And Without Celiac Axis Occlusion: When Endo; When Open: Why They Are Both Challenging |
Presenter(s):Benjamin M. Jackson, MD / Ronald M. Fairman, MD | |
4:12 PM - 4:17 PM | With Acute Mesenteric Ischemia With Peritoneal Signs, Laparotomy And Retrograde SMA Stenting Is The Best Treatment: Technical Tips To Do it Safely And Quickly |
Presenter(s):Markus K. Furrer, MD | |
4:18 PM - 4:23 PM | At What Size Do Renal Artery Aneurysms Need to Be Treated Invasively: A New Vascular Consortium Study Shows They Are Only Dangerous When >3 cm In Diameter |
Presenter(s):Peter F. Lawrence, MD | |
4:24 PM - 4:39 PM | Optimal Current Treatment Of Renal Artery Aneurysms: When Endo; When Open; Technical Tips |
Presenter(s):Fred A. Weaver, MD, MMM | |
4:30 PM - 4:36 PM | Panel Discussion |
END OF SESSION 15 | |
SESSION 16 SCHEDULE | |
Tuesday
SESSION 16:
UPDATE ON OPEN VASCULAR SURGICAL AND HYBRID PROCEDURES; PROGRESS IN THE TREATMENT OF AORTIC COARCTATIONS (5-MINUTE AND SOME 4 3/4-MINUTE SHORT SUMMARY [SS] TALKS)
Moderators:Enrico Ascher, MD / Jerry Goldstone, MD, FACS, FRCSEd
|
|
x | |
OPEN AND HYBRID VASCULAR SURGERY | |
4:36 PM - 4:41 PM | New Techniques To Improve The Open Repair Of TAAAs |
Presenter(s):Laurent Chiche, MD, FEBVS | |
4:42 PM - 4:47 PM | Technical Tips For Performing Retroperitoneal Aorto-Bifemoral Bypass (Video Presentation) |
Presenter(s):William J. Quinones-Baldrich, MD | |
4:48 PM - 4:53 PM | Tips And Tricks For Open Retroperitoneal Exposure Of The Aorta And All Its Abdominal Branches |
Presenter(s):Kamphol Laohapensang, MD | |
4:54 PM - 4:59 PM | Minimal Incision For Retroperitoneal Aorto-Bifemoral Bypass: Technical Tips And Limitations |
Presenter(s):Robert M. Proczka, MD, PhD | |
5:00 PM - 5:05 PM | [SS] Duplex Surveillance Should Be Used After All Aorto-Bifemoral Bypasses: It Improves Outcomes |
Presenter(s):Keith D. Calligaro, MD | |
5:05 PM - 5:10 PM | [SS] Thoraco-Bifemoral Bypass: A Good Option After All Endo And Open Standard Approaches Have Failed: Technical Tips |
Presenter(s):Manju Kalra, MBBS | |
5:10 PM - 5:15 PM | [SS] Axillo-Unifemoral And Axillo-Bifemoral Bypasses Have Equal Patency For More Than A Year: Why The Bilateral Procedure Should Only Be Used When Bilateral Ischemia Exists |
Presenter(s):Jeffrey J. Siracuse, MD | |
5:15 PM - 5:20 PM | Panel Discussion |
5:20 PM - 5:25 PM | Technical Tips For Aortic And Inferior Vena Cava Resections During Cancer Operations |
Presenter(s):Benjamin M. Jackson, MD | |
5:26 PM - 5:31 PM | Update On Renal Consequences Of Left Renal Vein Division During Open AAA Repair: It Is Not Always Benign |
Presenter(s):Kimihiro Komori, MD, PhD | |
UPDATE ON COARCTATION TREATMENT | |
5:32 PM - 5:37 PM | DEBATE: Endovascular Techniques Are The Best Treatment For Aortic Coarctations: When Bare Stents; When Covered Stents; Precautions |
Presenter(s):Zvonimir Krajcer, MD, FACC | |
5:38 PM - 5:43 PM | DEBATE: Not So: Open Surgery Is Sometimes Needed: What Are The Indications |
Presenter(s):Michael J. Jacobs, MD | |
5:44 PM - 5:49 PM | Value Of BeGraft (From Bentley), A Balloon Expandable Covered Stent In Treating Aortic Coarctations: Can It Treat All Cases |
Presenter(s):Elchanan Bruckheimer, MBBS | |
5:50 PM - 5:55 PM | Long-Term Outcomes Of Stent-Graft Treatment Of Aortic Coarctations |
Presenter(s):Frank R. Arko, MD | |
5:56 PM - 6:02 PM | Panel Discussion End of Program B |
END OF SESSION 16 | |
SESSION 17 SCHEDULE | |
Tuesday
SESSION 17:
MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE TEAM APPROACH - PART 1
Moderators:Michael R. Jaff, DO
|
|
x | |
7:00 AM - 7:05 AM | Introduction To The Symposium |
Presenter(s):Frank J. Veith, MD | |
7:05 AM - 7:15 AM | Welcome And Introduction |
Presenter(s):Michael R. Jaff, DO | |
7:15 AM - 7:25 AM | The Basics Of Pulmonary Embolism: What Is The Role Of The History, Exam, Biomarkers |
Presenter(s):Raghu Kolluri, MD | |
7:25 AM - 7:35 AM | Do We Need An Echo To Manage Acute Submassive PE |
Presenter(s):David M. Dudzinski, MD | |
7:35 AM - 7:45 AM | Advanced Imaging For PE: What Is The Optimal Strategy For The Diagnosis Of Acute And Chronic PE |
Presenter(s):Brian B. Ghoshhajra, MD, MBA | |
7:45 AM - 8:00 AM | Medical Treatment Of PE: When, Why, For How Long, And How Can I Remember |
Presenter(s):Geno J. Merli, MD, MACP, FHM, FSVM | |
8:00 AM - 8:10 AM | Testing For Cancer And Other Hypercoagulable States In PE |
Presenter(s):Rachel Rosovsky, MD, MPH | |
8:10 AM - 8:20 AM | The First Opportunity – The Emergency Physician Algorithm For Acute PE Management |
Presenter(s):D. Mark Courtney, MD | |
8:20 AM - 8:35 AM | Intravenous Thrombolytic Therapy For PE: No Need For Catheter-Based Intervention |
Presenter(s):Jay Giri, MD, MPH | |
8:35 AM - 8:45 AM | Ultrasound-Assisted Pharmacomechanical Thrombectomy: Does This Really Work |
Presenter(s):Charles B. Ross, MD | |
8:45 AM - 8:55 AM | Ultrasound-Assisted Pharmacomechanical Thrombectomy: The Indigo System |
Presenter(s):Robert A. Lookstein, MD, MHCDL, FSIR, FAHA | |
8:55 AM - 9:05 AM | What Strategy Is Best For Acute PE Intervention |
Presenter(s):Patrick Troy, MD | |
9:05 AM - 9:15 AM | Step-By-Step Technical Tips For Pharmacomechanical Intervention For PE |
Presenter(s):Gary M. Ansel, MD | |
9:15 AM - 9:25 AM | Percutaneous Mechanical Thrombectomy Without Lytics: Where Does This Fit |
Presenter(s):Mitchell D. Weinberg, MD | |
Moderator(s): Michael R. Jaff, DO | |
9:25 AM - 9:40 AM | Panel Discussion |
Panelist(s): Gary M. Ansel, MD / D. Mark Courtney, MD / Brian B. Ghoshhajra, MD, MBA / Jay Giri, MD, MPH / Raghu Kolluri, MD / Robert A. Lookstein, MD, MHCDL, FSIR, FAHA / Geno J. Merli, MD, MACP, FHM, FSVM / Rachel Rosovsky, MD, MPH / Charles B. Ross, MD / Patrick Troy, MD / Mitchell D. Weinberg, MD | |
9:40 AM - 10:10 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 17 | |
SESSION 18 SCHEDULE | |
Tuesday
SESSION 18:
MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH - PART 2
Moderators:Michael R. Jaff, DO
|
|
x | |
10:10 AM - 10:20 AM | Low-Does Systemic Lytics: Is This An Effective Strategy For Acute PE Treatment |
Presenter(s):Mohsen Sharifi, MD | |
10:20 AM - 10:30 AM | Vortex Strategy For Massive PE |
Presenter(s):Christopher J. Kwolek, MD, MBA | |
10:30 AM - 10:40 AM | ECMO And Surgical Thromboembolectomy For Massive PE: When, How, And Why |
Presenter(s):Mark G. Davies, MD | |
10:40 AM - 10:55 AM | Putting It All Together: What Is The Modern Algorithm For Management Of Massive And Submassive PE |
Presenter(s):Ido Weinberg, MD, MSc | |
10:55 AM - 11:10 AM | Vena Cava Filters In PE Treatment: Do We Need To Do This, And If So, When |
Presenter(s):Ziv J. Haskal, MD, FACR, FAHA, FSIR | |
11:10 AM - 11:25 AM | Balloon Angioplasty For Chronic Thromboembolic Pulmonary Hypertension: Has This Become Mainstream |
Presenter(s):Kenneth Rosenfield, MD | |
11:25 AM - 11:35 AM | The Team Approach To PE Management: The National PERT Consortium |
Presenter(s):Victor F. Tapson, MD | |
Moderator(s): Michael R. Jaff, DO | |
11:35 AM - 12:00 PM | Challenging Cases And “PERT” Decisions |
Panelist(s): Mark G. Davies, MD / Ziv J. Haskal, MD, FACR, FAHA, FSIR / Christopher J. Kwolek, MD, MBA / Kenneth Rosenfield, MD / Mohsen Sharifi, MD / Victor F. Tapson, MD / Mitchell D. Weinberg, MD | |
12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) End of Program C-1 |
END OF SESSION 18 | |
SESSION 19 SCHEDULE | |
Tuesday
SESSION 19:
INTRODUCTION TO VASCULAR MALFORMATIONS
Moderators:Wayne F. Yakes, MD / Robert L. Vogelzang, MD
|
|
x | |
1:00 PM - 1:02 PM | Welcome And Introduction |
Presenter(s):Krassi Ivancev, MD, PhD | |
1:02 PM - 1:10 PM | International Society for the Study of Vascular Anomalies (ISSVA) Classification Of Vascular Malformations |
Presenter(s):Laurence M. Boon, MD, PhD | |
1:11 PM - 1:19 PM | Genetic Diagnosis And Molecular Therapies Of Vascular Anomalies |
Presenter(s):Miikka Vikkula, MD, PhD | |
1:20 PM - 1:28 PM | The Yakes AVM Classification System: A Guide To Curative AVM Treatment |
Presenter(s):Fiona Rohlffs, MD, PhD | |
1:29 PM - 1:34 PM | Case Examples Utilizing The Yakes AVM Classification System For Curative Treatment Of Complex AVMs |
Presenter(s):Robert L. Vogelzang, MD | |
1:35 PM - 1:40 PM | Case Examples Utilizing The Yakes AVM Classification System For Curative Treatment Of Complex AVMs |
Presenter(s):Fiona Rohlffs, MD, PhD | |
1:41 PM - 1:46 PM | Case Examples Utilizing The Yakes AVM Classification System For Curative Treatment Of Complex AVMs |
Presenter(s):Krassi Ivancev, MD, PhD | |
1:47 PM - 2:04 PM | The Yakes AVM Classification System: Treatment Outcomes In 100 Consecutive Patients |
Presenter(s):Krassi Ivancev, MD, PhD | |
END OF SESSION 19 | |
SESSION 20 SCHEDULE | |
Tuesday
SESSION 20:
SURGICAL AND ENDOVASCULAR MANAGEMENT OF VASCULAR MALFORMATIONS
Moderators:Krassi Ivancev, MD, PhD / Fiona Rohlffs, MD, PhD
|
|
x | |
2:05 PM - 2:13 PM | Combined Endovascular And Surgical Management Of Head & Neck Vascular Malformations |
Presenter(s):Laurence M. Boon, MD, PhD | |
2:14 PM - 2:22 PM | Curative Ethanol Endovascular Treatment Of Complex Head & Neck AVMs |
Presenter(s):Wayne F. Yakes, MD | |
2:23 PM - 2:31 PM | The Best Laid Plans: Complications And Difficult Outcomes In Challenging Vascular Malformations |
Presenter(s):Robert L. Vogelzang, MD | |
2:32 PM - 2:40 PM | Endovascular Ethanol Treatment Of Complex Venous Malformations |
Presenter(s):Wayne F. Yakes, MD | |
2:41 PM - 2:49 PM | The Kerber Potpourri: The World’s First Microcatheter System And Polymerizing Embolic Agents To First Enter Brain Arteries, The World’s First Carotid Angioplasty, Supradose Cisplatin Head & Neck Carcinoma Therapy, And Modern Uses Of Cyanoacrylates |
Presenter(s):Charles Kerber, MD | |
2:50 PM - 3:00 PM | Panel Discussion/Q&A (Combined Sessions 19 and 20) End of Program C-2 |
END OF SESSION 20 | |
SESSION 21 SCHEDULE | |
Tuesday
SESSION 21:
HOT NEW SHORT SUMMARY TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE (ALL TALKS ARE 4 ¾ MINUTES)
Moderators:Neal S. Cayne, MD / Richard F. Neville, MD
|
|
x | |
3:00 PM - 3:05 PM | Key Steps For Success With Radial Artery Access For Remote Visceral, Renal Or Lower Extremity Lesion Treatment |
Presenter(s):Marcelo Guimaraes, MD, MBA, FSIR | |
3:05 PM - 3:10 PM | Mortality Rates After Paclitaxel Coated Device Use Only In Patients With Critical Limb Ischemia (CLI): A Systematic Review And Meta-Analysis Of Randomized Controlled Trials Shows No Increased Mortality With Paclitaxel Coated Devices |
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD | |
3:10 PM - 3:15 PM | How To Use Microcatheters To Facilitate Complex Peripheral Interventions |
Presenter(s):Jos C. van den Berg, MD, PhD | |
3:15 PM - 3:20 PM | Why And When Angiographic Final Evaluation Of Interventional Treatment Is Inadequate: What Else Is Needed And When |
Presenter(s):Gary M. Ansel, MD | |
3:20 PM - 3:25 PM | DEBATE: CO2 As A Contrast Agent Is Valuable For Lower Extremity Angiography And Treatments If Used Appropriately |
Presenter(s):Palma M. Shaw, MD | |
3:25 PM - 3:30 PM | DEBATE: Not So: CO2 As A Lower Extremity Contrast Agent Is Unnecessary And Has Downsides |
Presenter(s):Ali Amin, MD, RVT, FACS, FACC | |
3:30 PM - 3:35 PM | Importance Of Technical Factors In Use Of Drug Coated Balloons (DCBs): Value Of IVUS And DCB Undersizing |
Presenter(s):Jihad A. Mustapha, MD | |
3:35 PM - 3:40 PM | Local Anesthetic Injection Into Lesion Site Facilitates PTA And Stent Placement: How To Do It (Video Presentation) |
Presenter(s):Andrej Schmidt, MD | |
3:40 PM - 3:45 PM | Panel Discussion |
3:45 PM - 3:50 PM | Value Of Tack Optimized Balloon Angioplasty In Lower Extremity Interventions: When Should They Be Used And When Not (Tacks From Intact Vascular) |
Presenter(s):Lawrence A. Garcia, MD | |
3:50 PM - 3:55 PM | The .014 Lutonix Balloon (From Becton Dickinson) Is Safe And Effective For Below The Knee (BTK) Lesions Up To 24 Months |
Presenter(s):Dierk Scheinert, MD | |
3:55 PM - 4:00 PM | The Optimal Stent And Techniques For Treating Occlusive Lesions In Heavily Calcified Superficial Femoral Arteries |
Presenter(s):Hany Zayed, MD | |
4:00 PM - 4:05 PM | How Best To Use DCBs To Treat Femoro-Popliteal Lesions |
Presenter(s):Fabrizio Fanelli, MD, EBIR | |
4:05 PM - 4:10 PM | What Is Small Artery Disease (SAD) And What Are Good Therapeutic Options For Treating SAD Occurring In Patients With Chronic Limb Threatening Ischemic (CLTI) |
Presenter(s):Marianne Brodmann, MD | |
4:10 PM - 4:15 PM | Heel Ulceration And Ischemic Gangrene Involving The Achilles Tendon Should Not Be An Indication For A BTK Amputation: How To Save Such A Limb |
Presenter(s):Mark G. Davies, MD | |
4:15 PM - 4:20 PM | Popliteal Artery-To-Distal Bypass For Limb Salvage; Status In 2020: Technical Tips And Value: When Is It Better Than Endovascular Treatments |
Presenter(s):Francesco Spinelli, MD | |
4:20 PM - 4:25 PM | Hybrid Lower Extremity Revascularizations: When And Why Are They Better Than Endo Approaches |
Presenter(s):Joseph S. Giglia, MD | |
4:25 PM - 4:30 PM | Panel Discussion |
END OF SESSION 21 | |
SESSION 22 SCHEDULE | |
Tuesday
SESSION 22:
MORE HOT NEW SHORT SUMMARY TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND CHRONIC LIMB THREATENING ISCHEMIA (CLTI) - ALL TALKS ARE 4 ¾ MINUTES
Moderators:Brian G. DeRubertis, MD / Peter A. Schneider, MD
|
|
x | |
4:30 PM - 4:35 PM | CLTI Is A Global Epidemic; How Can A CLTI Program Decrease Its Morbidity |
Presenter(s):Barry T. Katzen, MD | |
4:35 PM - 4:40 PM | What Is The Best Treatment For Young Patients With Symptomatic PAD: How Should Females Be Revascularized Differently From Males |
Presenter(s):William P. Robinson, MD | |
4:40 PM - 4:45 PM | Bare Metal Stents (BMSs) Still Have A Role In The Superficial Femoral Artery (SFA): In Precisely What Circumstances |
Presenter(s):Lawrence A. Garcia, MD | |
4:45 PM - 4:50 PM | Value Of External Duplex Ultrasound And Other Technical Factors In Optimizing BTK DCB Angioplasty |
Presenter(s):Francesco Liistro, MD | |
4:50 PM - 4:55 PM | How To Size Lower Extremity Target Arteries For Endo Treatments Accurately Using Intravascular Ultrasound (IVUS): Why It Is Important |
Presenter(s):Jos C. van den Berg, MD, PhD | |
4:55 PM - 5:00 PM | Lower Extremity Interventions (PTA, Stents, Atherectomy) Under IVUS Guidance: Its Costs, Value And Limitations |
Presenter(s):Ignacio Escotto, MD | |
5:00 PM - 5:05 PM | Panel Discussion |
5:05 PM - 5:10 PM | Patterns Of Calcification In BTK Arteries: How They Influence Endovascular Treatments |
Presenter(s):Jihad A. Mustapha, MD | |
5:10 PM - 5:15 PM | Best Treatment For Heavily Calcified Occlusive Lesions And When Are Re-Entry Devices Needed With Retrograde Recanalizations: Tips On How To Use Them |
Presenter(s):Erwin Blessing, MD | |
5:15 PM - 5:20 PM | How To Do Bypass Surgery To Heavily Non-Compressible Calcified Target Arteries |
Presenter(s):Enrico Ascher, MD / Frank J. Veith, MD | |
5:20 PM - 5:25 PM | Bailout Techniques For Problems Encountered With Subintimal Angioplasty For Chronic Total Occlusions (CTOs): Like Inability To Re-Enter The True Lumen |
Presenter(s):Ali Amin, MD, RVT, FACS, FACC | |
5:25 PM - 5:30 PM | 2-Year Results With Sirolimus Coated Drug Eluting Stents (DES) For Fempop Lesions: The ILLUMINA Trial |
Presenter(s):Andrea Kahlberg, MD | |
5:30 PM - 5:35 PM | Early Failure Of Endovascular Treatment Of Tibial Disease With CLTI Is Associated With Increased Amputation Rates: How Can It Be Predicted And Is An Open Bypass A Solution |
Presenter(s):Mark G. Davies, MD | |
5:35 PM - 5:40 PM | Contemporary Comparative Results Of In Situ Versus Reversed Vein Bypasses: When Is One Better Than The Other |
Presenter(s):Carlo Pratesi, MD | |
5:40 PM - 5:45 PM | Distal Bypasses Under Nerve Block Without General Anesthesia Improves Results Of Bypasses For CLTI |
Presenter(s):Nobuyoshi Azuma, MD | |
5:45 PM - 5:50 PM | Alternate Approaches To Lower Extremity Arteries When Standard Approaches Are Blocked By Scarring Or Infection |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
5:50 PM - 5:55 PM | Challenge Of Getting Endovascular Revascularization To Achieve Healing Of Ischemic Wounds: Value Of A Wound Center In A Limb Salvage Program |
Presenter(s):Robert B. McLafferty, MD, MBA | |
5:55 PM - 6:00 PM | Panel Discussion End of Program C-3 |
END OF SESSION 22 | |
Wednesday, November 17, 2021
Print Entire 2020 Program:
|
|
SESSION 23 SCHEDULE | |
Wednesday
SESSION 23:
GENERALITIES IN THE ENDOVASCULAR AND OPEN TREATMENT OF LOWER EXTREMITY OCCLUSIVE DISEASE AND CLTI (5 AND 4 ¾-MINUTE SHORT SUMMARY [SS] TALKS)
Moderators:Enrico Ascher, MD / Andrej Schmidt, MD
|
|
x | |
6:40 AM - 6:45 AM | How Do Prior Endovascular Interventions Effect Future Lower Extremity Bypass Outcomes For CLTI |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
6:46 AM - 6:51 AM | Do Diabetic Patients With CLTI And Substantial Foot Necrosis Have Time For An Endovascular First Strategy: Why Primary Open Bypass Treatment Is Better |
Presenter(s):Katariina M. Noronen, MD, PhD | |
6:52 AM - 6:57 AM | Statins Decrease Rates Of Mortality, Amputation, MACE And Strokes And Increase Procedural Patency Rates In CLTI Patients: What Is The Best Drug And Dose |
Presenter(s):Richard Bulbulia, MA, MD, FRCS | |
6:58 AM - 7:03 AM | Key New Developments In Endovascular Treatments For CLTI |
Presenter(s):Sahil A. Parikh, MD | |
7:04 AM - 7:09 AM | Small Artery Disease (SAD) Medial Artery Calcification (MAC) And elow The Ankle (BTA) Disease: Major Causes Of CLTI With A Poor Prognosis: How Are They Best Treated Endovascularly |
Presenter(s):Roberto Ferraresi, MD | |
OPTIMAL TECHNIQUES FOR VESSEL PREP FOR ENDOVASCULAR TREATMENTS | |
7:10 AM - 7:15 AM | [SS] Optimal Different Techniques Of Vessel Prep For Plain Old Balloon Angioplasty (POBA), Drug Coated Balloon (DCB) Treatment And Drug Eluting Stent (DES) Treatment |
Presenter(s):Fabrizio Fanelli, MD, EBIR | |
7:15 AM - 7:20 AM | [SS] Technical Tips For Vessel Prep Before DCBs And DESs: It Is Different And Not Simple |
Presenter(s):Erwin Blessing, MD | |
7:20 AM - 7:25 AM | Thirteen Technical Tips For Safe Radial Access For Renal/Visceral And Lower Extremity Interventions: How Far Distally In The Leg Can Lesions Be Treated |
Presenter(s):Craig M. Walker, MD | |
7:26 AM - 7:31 AM | What Are The Downsides To Trans-Radial Or Pedal Access |
Presenter(s):Gary M. Ansel, MD | |
TECHNICAL TIPS ON GUIDEWIRE CHOICE AND USAGE | |
7:32 AM - 7:37 AM | [SS] Guidewire Tips For Treating SFA And Popliteal Artery Lesions Including CTOs |
Presenter(s):Marco G. Manzi, MD | |
7:37 AM - 7:42 AM | [SS] Guidewire Tips For Treating BTK And Crural Artery Lesions |
Presenter(s):Craig M. Walker, MD | |
7:42 AM - 7:47 AM | [SS] Guidewire Tips For Treating Lesions Below the Ankle (BTA): Sliding, Piercing, Dissecting, Retrograde Maneuvers |
Presenter(s):Roberto Ferraresi, MD | |
7:47 AM - 7:53 AM | Panel Discussion |
END OF SESSION 23 | |
SESSION 24 SCHEDULE | |
Wednesday
SESSION 24:
NEW DEVELOPMENTS IN ATHERECTOMY, STENTS (UNCOATED, COATED AND BIORESORBABLE) (ALL TALKS ARE 5 MINUTES)
Moderators:Craig M. Walker, MD / Iris Baumgartner, MD
|
|
x | |
PROGRESS IN ATHERECTOMY | |
7:53 AM - 7:58 AM | New Developments In Laser Atherectomy: What Makes It Different: When Is It Beneficial With Certainty |
Presenter(s):George L. Adams, MD | |
7:59 AM - 8:04 AM | Value Of Phoenix Atherectomy And Stellarex DCB For Infrapopliteal Lesions: Why IVUS Guidance Is Beneficial: 1-Yea Results In CLTI Patients |
Presenter(s):Michael K.W. Lichtenberg, MD / Thomas Zeller, MD | |
8:05 AM - 8:10 AM | Optical Coherence Tomography (OCT) Guided Atherectomy (Pantheris) For In Stent Restenosis (ISR): Why It Is More Effective Treatment: From The INSIGHT Trial |
Presenter(s):Todd R. Vogel, MD, MPH | |
8:11 AM - 8:16 AM | Current Role Of Atherectomy In Treating Lower Extremity CLTI: A Vascular Surgeon’s View |
Presenter(s):James F. McKinsey, MD | |
UPDATE ON THE SUPERA STENT | |
8:17 AM - 8:23 AM | Update On The Advantages Of The Supera Vasculomimetic (VMI) Stent For Treating Long Complex Fempop Occlusive Lesions: Is There Value To DCB Vessel Prep First |
Presenter(s):Peter C.J. Goverde, MD | |
8:23 AM - 8:28 AM | Value And Technical Tips To Make The Supera Stent Work In Curved And Angulated Non-SFA Lesion Locations |
Presenter(s):Rajiv Parakh, MBBS, MS, FRCS | |
DRUG ELUTING STENTS FOR BTK LESIONS | |
8:29 AM - 8:34 AM | 10-Year Experience With Everolimus DESs To Treat Long Infrapopliteal Lesions Causing CLTI: Indications, Results, Value And Limitations |
Presenter(s):Robert A. Lookstein, MD, MHCDL, FSIR, FAHA | |
8:35 AM - 8:40 AM | Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5-7 Years: From The DISAPEAR Trial And A Meta-Analysis Of The Absorb Stent From Abbott |
Presenter(s):Steven Kum, MD / Ramon L. Varcoe, MBBS, MS, FRACS, PhD | |
8:41 AM - 8:46 AM | What Is The Future For Bioresorbable DESs To Treat BTK Lesions: Good Long-Term Results Justify A New Trial: The LIFE-BTK Trial With The Esprit Stent From Abbott |
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD / Sahil A. Parikh, MD / Brian G. DeRubertis, MD | |
8:47 AM - 8:52 AM | A 3-French Compatible Microstent (From Micro Medical) For Antegrade Or Retrograde Insertion To Treat Tibial Artery Lesions: The STAND Trial |
Presenter(s):Robert E. Beasley, MD, FSIR, FSCAI | |
8:53 AM - 9:00 AM | Panel Discussion |
END OF SESSION 24 | |
SESSION 25 SCHEDULE | |
Wednesday
SESSION 25:
LOWER EXTREMITY TOPICS RELATED TO THE DRUG COATED DEVICES CAUSING INCREASED MORTALITY CONTROVERSY: DO PACLITAXEL COATED DEVICES CAUSE INCREASED MORTALITY (5 AND 4 ¾-MINUTE SHORT SUMMARY [SS] TALKS)
Moderators:Kenneth Ouriel, MD, MBA / Sahil A. Parikh, MD
|
|
x | |
9:00 AM - 9:05 AM | Older And More Recent Meta-Analyses Reveal An Increased Mortality Signal In Patients Receiving Paclitaxel Coated Devices Compared To Uncoated Devices: The More Recent Study Of DCBs In BTK Arteries Showed Increased Mortality And Amputation Rates After Only 1 Year |
Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR | |
9:06 AM - 9:11 AM | How Do Paclitaxel And Limus Drugs Work And Differ In Safety And Effectiveness In Inhibiting Intimal Hyperplasia Induced By Treatment |
Presenter(s):Juan F. Granada, MD | |
9:12 AM - 9:17 AM | Summary Of The Present Status Of The Paclitaxel Mortality Controversy With DCBs And DESs Treatments In The SFA And BTK Arteries |
Presenter(s):Andrew Holden, MBChB | |
9:18 AM - 9:23 AM | Alternatives To Paclitaxel Coated Devices For Limiting Intimal Hyperplasia After Treatment: Sirolimus Coating, Bioresorbables And Advential Drug Delivery With The Bullfrog Device: Is The Paclitaxel Mortality Signal Real |
Presenter(s):William A. Gray, MD | |
9:24 AM - 9:29 AM | Real World Big Data Patient-Level Evidence Confirms No Harm From Paclitaxel Coated Devices For Treating Fempop Disease: Update On Medicare Data From Over 150,000 Patients |
Presenter(s):Eric A. Secemsky, MD, MSc / Robert Yeh, MD | |
9:30 AM - 9:35 AM | Large Population Based German Multicenter Study Of Paclitaxel Coated BTK DCBs And DESs Indicates Decreased Mortality And Amputation Rates Compared To Uncoated Devices |
Presenter(s):Christian A. Behrendt, MD | |
RELEVANT COMMENTS AS SHORT SUMMARY [SS] TOPICS (4 ¾-MINUTE TALKS) | |
9:36 AM - 9:41 AM | [SS] The Paclitaxel Increased Mortality Effect Reported By Dr. Katsanos et al. Seems Not To Be Confirmed By Added Data |
Presenter(s):Peter A. Schneider, MD | |
9:41 AM - 9:46 AM | [SS] Is The Paclitaxel Increased Mortality Signal Incorrect: The Updated Collected VIVA Data Do Not Confirm It |
Presenter(s):Gary M. Ansel, MD | |
9:46 AM - 9:51 AM | [SS] The Current Japanese View On The Paclitaxel Mortality Signal |
Presenter(s):Osamu Iida, MD | |
9:51 AM - 9:56 AM | [SS] VQI Data Do Not Support The Paclitaxel Increased Mortality Signal |
Presenter(s):Daniel Bertges, MD / Jack L. Cronenwett, MD | |
9:56 AM - 10:01 AM | [SS] Progress And Problems With A Sustained Release Limus DCB: 2-Year Results With The Magic Touch DCB: From The SIRONA Study |
Presenter(s):Dierk Scheinert, MD / Thomas Zeller, MD | |
10:01 AM - 10:08 AM | Panel Discussion |
10:08 AM - 10:18 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 25 | |
SESSION 26 SCHEDULE | |
Wednesday
SESSION 26:
NEW DEVELOPMENTS IN DRUG COATED BALLOONS (DCBs) AND DRUG ELUTING STENTS (DESs): UPDATES ON RANDOMIZED CONTROLLED TRIALS (RCTs) AND BTK LESION TREATMENTS WITH DCBs AND DESs (5-MINUTE TALKS)
Moderators:Joseph L. Mills, MD / John R. Laird, MD
|
|
x | |
NEW INFORMATION ON DCBs AND DESs FOR FEMPOP LESIONS: UPDATES ON RCTs | |
10:18 AM - 10:23 AM | Cost Effectiveness Of Drug Eluting Technologies For Femoropopliteal Lesions: They Are Worth The Increased Device Costs |
Presenter(s):Stefan Müller-Hülsbeck, MD | |
10:24 AM - 10:29 AM | Stellarex (Philips) DCBs With Low Dose Paclitaxel Is Safe And Has Higher Patency Rates Than POBA With Fempop Lesions At 4 Years In The ILLUMENATE RCT |
Presenter(s):Sean P. Lyden, MD | |
10:30 AM - 10:35 AM | Pooled Data From The In.Pact RCT DCB Trials For SFA-Pop Lesions Show Safety And Efficacy For 5 Years Compared To POBA: Continued Use Is Justified |
Presenter(s):Peter A. Schneider, MD / John R. Laird, MD | |
10:36 AM - 10:41 AM | New Findings From The DRASTICO Study Comparing DESs To DCBs For Fempop Lesions: 4-Year Results With TASC A/B Lesions Versus TASC C/D Lesions |
Presenter(s):Francesco Liistro, MD | |
10:42 AM - 10:47 AM | Value Of In.Pact DCBs For Long Complex SFA-Pop Lesions Including ISR And CTOs: Technical Tips And Contraindications: From The Global Registry |
Presenter(s):Gunnar Tepe, MD / Marianne Brodmann, MD | |
10:48 AM - 10:53 AM | Update On The Randomized Head To Head Comparison Of In.Pact (Medtronic) And Ranger (Boston Scientific) DCBs For Complex SFA Lesions: 2-Year Results Of The COMPARE RCT: Similar Results With Different Paclitaxel Dosages |
Presenter(s):Dierk Scheinert, MD / Sabine Steiner, MD | |
10:54 AM - 10:59 AM | Update On The Global RANGER II RCT Comparing Ranger DCBs With POBA |
Presenter(s):Marianne Brodmann, MD | |
11:00 AM - 11:05 AM | New Information On The Safety And Effectiveness Of The Cook Zilver PTX DES Based On Global Trials Including A RCT: When Is It The Best Treatment |
Presenter(s):Michael D. Dake, MD | |
11:06 AM - 11:11 AM | 3-Year Results Of The IMPERIAL RCT Head To Head Comparison Of The Zilver PTX DES (Cook) With The Eluvia DES (Boston Scientific): Both Are Safe And Effective: Is There A Difference |
Presenter(s):William A. Gray, MD / Stefan Müller-Hülsbeck, MD / Thomas Zeller, MD | |
11:12 AM - 11:18 AM | Panel Discussion |
NEW INFORMATION ON BTK DCBs AND DESs | |
11:18 AM - 11:23 AM | Advances In BTK Drug Delivery Technology And DCBs: What Have We Learned From The In.Pact Deep BTK DCB Trial And Challenges With Treating CLTI Patients |
Presenter(s):Thomas Zeller, MD | |
11:24 AM - 11:29 AM | 1-Year Results Of The Lutonix 0.14 DCB (Becton Dickinson) RCT Versus POBA Mostly For CLTI: DCB Has Equal Safety But 6-Month Patency Advantage Not Present At 1 Year |
Presenter(s):Patrick J. Geraghty, MD / Jihad A. Mustapha, MD / Marianne Brodmann, MD / William A. Gray, MD / Dierk Scheinert, MD | |
11:30 AM - 11:35 AM | 2-Year Results Of Global Registry Of Lutonix BTK DCBs Mostly For CLTI Show Safety And Reasonable Effectiveness |
Presenter(s):Dierk Scheinert, MD / Michael K.W. Lichtenberg, MD | |
11:36 AM - 11:41 AM | 1-Year Results From The AcoArt II BTK DCB RCT Show Safety (No Increased Mortality) And Improved Patency Versus POBA |
Presenter(s):Wei Guo, MD / Francesco Liistro, MD | |
11:42 AM - 11:47 AM | Why BTK DCB Trials Do Not Show Uniformly Better Results: Technical Factors Matter |
Presenter(s):Francesco Liistro, MD | |
11:48 AM - 11:53 AM | Update On The SAVAL Trial With A Self-Expanding DES (From Boston Scientific) For BTK Occlusive Lesions |
Presenter(s):Jihad A. Mustapha, MD / Miguel F. Montero-Baker, MD | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 26 | |
SESSION 27 SCHEDULE | |
Wednesday
SESSION 27:
PROGRESS IN EXOTIC AND EXTREME NEW TREATMENTS FOR VERY DISTAL LOWER EXTREMITY DISEASE CAUSING ADVANCED CLTI: HOW TO SAVE THE “NO OPTION FOR TREATMENT” LIMB OR THE “DESERT FOOT” WITH NO PATENT TARGET ARTERIES
Moderators:Daniel G. Clair, MD / Marco G. Manzi, MD
|
|
x | |
1:00 PM - 1:05 PM | No Option CLTI: What Is It: What Are The Actual Options For Treatment |
Presenter(s):Hisham Rashid, FRCS, FRCS(Gen) | |
1:06 PM - 1:11 PM | Contemporary Survival After Below-Knee Amputation (BKA), Above-Knee Amputation (AKA), Bilateral Amputations For Trauma; For Vascular Disease: It Is Worthwhile Saving Limbs Especially In Vascular Patients |
Presenter(s):Philip P. Goodney, MD, MS | |
VALUE OF PROSTHETIC (PTFE) TIBIAL BYPASSES | |
1:12 PM - 1:17 PM | Value Of Spliced Vein Grafts Versus PTFE Grafts For Bypasses: When A Single Autologous Vein Is Inadequate |
Presenter(s):Joseph L. Mills, MD | |
1:18 PM - 1:23 PM | PTFE Tibial And Peroneal Artery Bypasses Can Save No Option Limbs Which Would Otherwise Require Amputation: They Can Have Long-Term Patency And Limb Salvage And Are Worthwhile |
Presenter(s):Gregg S. Landis, MD / Richard F. Neville, MD / Neal S. Cayne, MD / Nicholas J. Gargiulo III, MD, RPVI, RVT, RDMS, FACS / Frank J. Veith, MD | |
1:24 PM - 1:29 PM | For Patients Facing Amputation With No Endo Options Or Useable Vein, PTFE Tibial Bypasses Are A Worthwhile Option |
Presenter(s):R. Clement Darling III, MD | |
1:30 PM - 1:35 PM | Current Outcomes With PTFE Bypasses To Infrapopliteal (Tibial) Targets: Is There Variability Between Surgeons And Institutions |
Presenter(s):Matthew T. Menard, MD | |
UPDATE ON FOOT VEIN ARTERIALIZATION FOR CLTI | |
1:36 PM - 1:41 PM | What Is The Real Prevalence Of No Option Anatomy Among The CLTI Population: What Is The Role For Foot Vein Arterialization: How Is It Best Done |
Presenter(s):Peter A. Schneider, MD | |
1:42 PM - 1:47 PM | Role And Value Of Vein Arterialization: Best Way To Do It And Long-Term Results: From The Pioneer |
Presenter(s):Pramook Mutirangura, FRCS (Edinburgh) | |
1:48 PM - 1:53 PM | Pathophysiology Of Venous Arterialization And Neo Angiogenesis For No Option CLTI: How To Predict When It Will Work And When It Won’t |
Presenter(s):Roberto Ferraresi, MD | |
1:54 PM - 1:59 PM | 2-Year Registry Results With Deep Vein Arterialization With The LimFlow Device For CLTI With Gangrene Shows Reasonable Limb Salvage And Wound Healing |
Presenter(s):Andrej Schmidt, MD | |
2:00 PM - 2:05 PM | How To Perform The LimFlow Procedure: Equipment Required And Technical Tips |
Presenter(s):Miguel F. Montero-Baker, MD | |
2:06 PM - 2:11 PM | Deep Vein Arterialization And Valve Lysis By Surgical Means For No Option Desert Feet With Gangrene: How To Do It And Results |
Presenter(s):Richard F. Neville, MD | |
2:12 PM - 2:18 PM | Panel Discussion |
END OF SESSION 27 | |
SESSION 28 SCHEDULE | |
Wednesday
SESSION 28:
NEW DEVELOPMENTS IN STENTS; PROSTHETIC GRAFTS; ENDOVASCULAR BYPASSES; STENT GRAFTS AND TREATMENT OF IN STENT RESTENOSIS (ISR)
Moderators:Glenn Jacobowitz, MD / Mark A. Adelman, MD
|
|
x | |
2:18 PM - 2:23 PM | 3-Year Results From The BioMimics 3D Swirling Flow Stent In The MIMICS-2 Study: Who Needs Paclitaxel |
Presenter(s):Peter Gaines, MD / Michael K.W. Lichtenberg, MD / Timothy M. Sullivan, MD | |
ARTERIAL PTFE BYPASSES | |
2:24 PM - 2:29 PM | RCT Comparing Heparin Bonded PTFE (Propaten) Grafts With Plain PTFE Grafts For BTK CLTI Bypasses: Is Heparin Bonding Helpful |
Presenter(s):Yann Gouëffic, MD, PhD | |
2:30 PM - 2:35 PM | Hybrid Fluoroscopically Guided Improved Method For Restoring Patency To Occluded PTFE Bypasses: It’s Less Invasive And More Effective |
Presenter(s):Neal S. Cayne, MD / Frank J. Veith, MD | |
PERCUTANEOUS BYPASSES | |
2:36 PM - 2:41 PM | Percutaneous (PQ) Tranvenous Fempop PTFE Bypasses With The Torus 2 Device: How It Works And Status Of The DETOUR And TORUS Trials In The US And Europe |
Presenter(s):Ehrin Armstrong, MD / Daniel G. Clair, MD / Peter A. Schneider, MD | |
2:42 PM - 2:47 PM | 3-Year Results Of The Detour PQ Fempop Arterial Bypass Routed Through The Femoral Vein: Will It Make Open Bypass Obsolete |
Presenter(s):Dainis K. Krievins, MD | |
2:48 PM - 2:53 PM | A Novel Technique For PQ Fempop Bypass Routing The PTFE Bypass Through The Soft Tissue Of The Thigh: How To Do It And Early Results |
Presenter(s):Pierre Saradon, MD / Jean-Pierre Becquemin, MD, FRCS | |
2:54 PM - 2:58 PM | Panel Discussion |
NEW INFORMATION ON STENT-GRAFTS | |
2:58 PM - 3:03 PM | 2-Year Results Of The SUPER B RCT Shows That Viabahn Stent-Grafts Have Patency Rates As Good As Open Fempop PTFE Bypasses But Require More Reinterventions: How To Make Viabahns Work Best |
Presenter(s):Michel M.P. Reijnen, MD, PhD | |
3:04 PM - 3:09 PM | Advantages And Limitations Of The Gore Viabahn VBX Balloon Expandable (BE) Covered Stent For Treating Complex SFA Disease: Comparison With The Self-Expanding Viabahn: 1-Year Results From The IVORY Japanese Trial |
Presenter(s):Osamu Iida, MD | |
3:10 PM - 3:15 PM | Advantages, Limitations And Results Of Gore VBX BE Stent-Graft For Occlusive Disease In Various Vascular Beds And For F/B/EVAR Branches: Comparison With Other Stent-Grafts |
Presenter(s):Rocco Giudice, MD / Ciro Ferrer, MD, PhD | |
TREATMENT OF IN STENT RESTENOSIS (ISR) | |
3:16 PM - 3:02 PM | How Best To Treat Long Difficult ISR In Complex SFA Lesions |
Presenter(s):Sonia Ronchey, MD,PhD | |
3:22 PM - 3:27 PM | The Excimer Laser For Treating ISR: It Has A Role In Grossing And Debulking Difficult Lesions: Technical Tips |
Presenter(s):Craig M. Walker, MD | |
3:28 PM - 3:33 PM | Laser Atherectomy May Facilitate Endovascular Treatment Of ISR But Does Not Provide Long-Term Benefit: How Should ISR Be Treated |
Presenter(s):Russell H. Samson, MD, RVT, FACS | |
3:34 PM - 3:48 PM | Panel Discussion And Break Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 28 | |
SESSION 29 SCHEDULE | |
Wednesday
SESSION 29:
LOWER EXTREMITY TRIALS; GUIDELINES; FOOT PERFUSION EVALUATION METHODS AND VALUE OF ANGIOSOMES
Moderators:Mark K. Eskandari, MD / Gregg S. Landis, MD
|
|
x | |
3:48 PM - 3:53 PM | Update On The BEST-CLI RCT Comparing Endovascular And Open Treatment Of Lower Extremity Ischemia: Current Status, Challenges And What Will Be Its Value |
Presenter(s):Alik Farber, MD, MBA / Matthew T. Menard, MD / Kenneth Rosenfield, MD | |
3:54 PM - 3:59 PM | The Japanese SPINACH Registry Shows Why WIFI Wound Severity Helps To Select Open Versus Endovascular Treatment And Predicts Patient Survival |
Presenter(s):Nobuyoshi Azuma, MD | |
4:00 PM - 4:05 PM | The New Global Vascular Guidelines For CLTI Are Better Than Obsolete TASC Guidelines Because Treatment Recommendations, Revascularization Strategies And Needs For The Future Are Not Based On Lesion Anatomy But Are Nuanced By Other Factors |
Presenter(s):Michael S. Conte, MD | |
METHODS FOR EVALUATING FOOT PERFUSION | |
4:06 PM - 4:11 PM | Measuring Foot Perfusion After Endo Treatments For CLTI With Perfusion Angiography And Smart Software: Why It Is Important And How To Do It |
Presenter(s):Jim Reekers, MD, PhD | |
4:12 PM - 4:17 PM | Indocyanine Green Fluorescence (IGC-FL) Is A Good Way To Measure Foot Perfusion After Treatment: How It Explains Why The Angiosome Concept Is Important After Endo Treatments But Not After Bypasses |
Presenter(s):Maarit Venermo, MD, PhD | |
4:18 PM - 4:23 PM | How And Why To Measure Foot Perfusion During Endo Treatments: Hyperspectral Imaging, O2 Sensors, Etc: When Is The Angiosome Concept Helpful; When Not |
Presenter(s):Marianne Brodmann, MD | |
4:24 PM - 4:29 PM | What Are The Best Ways To Evaluate CLTI Treatment Outcomes: Physiology, Wound Healing, Anatomy (Angiography Or Ultrasound), MACE Or MALE: Why It Matters |
Presenter(s):Ido Weinberg, MD, MSc | |
4:30 PM - 4:35 PM | Pedal Arch Patency Is Key To Predicting Limb Salvage With Endovascular Treatment For CLTI With Tissue Necrosis: How Is It Best Evaluated |
Presenter(s):Hasan H. Dosluoglu, MD / Linda Harris, MD | |
4:36 PM - 4:41 PM | Foot Perfusion Measurements Show Why Open Bypasses Are Better Than Endovascular Treatments For CLTI |
Presenter(s):Werner Lang, MD | |
4:42 PM - 4:48 PM | Panel Discussion |
END OF SESSION 29 | |
SESSION 30 SCHEDULE | |
Wednesday
SESSION 30:
NEW DEVELOPMENTS IN THE TREATMENT OF INTERMITTENT CLAUDICATION AND ACUTE LIMB ISCHEMIA
Moderators:Michael S. Conte, MD / Matthew T. Menard, MD
|
|
x | |
INTERMITTENT CLAUDICATION (IC) | |
4:48 PM - 4:53 PM | DEBATE: A RCT After 2 Years Shows That Stent Treatment For Intermittent Claudication (IC) Improves Quality Of Life More Than Medical Treatment And Exercise |
Presenter(s):Hans Lindgren, MD, PhD | |
4:54 PM - 5:00 PM | DEBATE: Interventions For IC Are Safe But Lead To Greater Decreased Function And Increased Limb Loss |
Presenter(s):Jeffrey J. Siracuse, MD | |
5:00 PM - 5:05 PM | Overuse Of Vascular Interventions For IC Is A Measure Of Poor Care: How Is This Determined |
Presenter(s):Caitlin W. Hicks, MD, MS / James H. Black, III, MD | |
5:06 PM - 5:11 PM | Value Of Neuromuscular Electrical Stimulation (NMES) To Treat IC: It Works And How |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FACPh, F | |
5:12 PM - 5:16 PM | Panel Discussion |
ACUTE LIMB ISCHEMIA (ALI) (SEE ALSO SESSION 63) | |
5:16 PM - 5:21 PM | Key Points From The New European Guidelines For Diagnosis And Treatment Of ALI In The Upper And Lower Limbs: When To Use Which Treatments |
Presenter(s):Martin Bjorck, MD, PhD | |
5:22 PM - 5:27 PM | Update On Thrombosuction Devices For Treating ALI: Which Device In Which Circumstance: Advantages And Limitations |
Presenter(s):Athanasios Katsargyris, MD / Eric L.G. Verhoeven, MD, PhD | |
5:28 PM - 5:33 PM | Endovascular Mechanical Thrombectomy Is Obviating The Need For Thrombolytics In ALI: Which Device Is Best When And Why |
Presenter(s):Patrick E. Muck, MD, FACS | |
5:34 PM - 5:39 PM | Aspiration Thrombectomy Devices And Techniques For ALI: Are Thrombolytics And Fogarty Balloon Catheters Obsolete |
Presenter(s):Maria A. Ruffino, MD, EBIR | |
5:40 PM - 5:45 PM | Penumbra Indigo Clot Aspiration System To Treat ALI: Why Is It A Game Changer: Technical Tips For Usage |
Presenter(s):James F. Benenati, MD | |
5:46 PM - 5:51 PM | Value And Technical Tips For Using The Indigo Clot Removal System Before Treating ISR And Other Lesions With Balloon And Stents |
Presenter(s):Frank R. Arko, MD | |
5:52 PM - 5:57 PM | How To Treat ALI Under Duplex Ultrasound Guidance: Advantages And Limitations |
Presenter(s):Natalie A. Marks, MD, RPVI, RVT, FSVM / Enrico Ascher, MD | |
5:58 PM - 6:02 PM | Panel Discussion End of Program D |
END OF SESSION 30 | |
SESSION 31 SCHEDULE | |
Wednesday
SESSION 31:
ADVANCES IN MEDICAL TREATMENTS, NEW ANTI-ATHEROGENIC DRUGS, VALUE OF RIVAROXABAN AND PREVENTING MIs IN VASCULAR SURGERY PATIENTS
Moderators:Caron B. Rockman, MD / Ido Weinberg, MD, MSc
|
|
x | |
6:40 AM - 6:45 AM | What Adequate And Ideal Lipid Levels Should We Strive For In PAD Patients: How To Get There |
Presenter(s):Marianne Brodmann, MD | |
6:46 AM - 6:51 AM | When, Why And How To Lower High Triglyceride Levels: Value Of Vascepa To Decrease Cardiac Risk In Vascular Patients: Based On The REDUCE-IT RCT |
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC | |
6:52 AM - 6:57 AM | Risks And Consequences Of Perioperative Myocardial Infarctions (MIs) In Open Vascular Surgery Patients: What Can Be Done To Decrease MI Incidence And Their Morbidity And Mortality When They Occur |
Presenter(s):Peter Henke, MD | |
6:58 AM - 7:03 AM | Update On LDL-C Lowering During A Lifetime: How Low To Strive For; How Young To Start If High; How Old To Continue Statins |
Presenter(s):J. David Spence, MD | |
7:04 AM - 7:09 AM | DEBATE: LDL-C Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful |
Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC | |
7:10 AM - 7:15 AM | DEBATE: Not So: LDL-C Lowering With Statins And Other Drugs Stabilizes And Shrinks Plaques And Decreases Morbid Vascular Events: Stopping Statins Increases Patients’ Risk Of MI And Death |
Presenter(s):Ron Waksman, MD | |
7:16 AM - 7:21 AM | Low Dose Rivaroxaban (Bayer) And Aspirin Improve Survival And Decrease Major Adverse Limb Events (MALE) After Endo and Open Treatments For PAD/CLTI: From The VOYAGER RCT |
Presenter(s):Sebastian E. Debus, MD, PhD / Marianne Brodmann, MD | |
7:22 AM - 7:27 AM | How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And Compass Trials |
Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
7:28 AM - 7:33 AM | New Adjunctive Drugs (Plus Statins) To Lower LDL-Cholesterol (LDL-C) In Vascular Patients: Inclisiran, Bempedoic Acid And Ezetimbe: How Do They Work And When And How To Use Them: Level Of LDL-C To Strive For |
Presenter(s):Richard Bulbulia, MA, MD, FRCS | |
7:34 AM - 7:42 AM | Panel Discussion |
END OF SESSION 31 | |
SESSION 32 SCHEDULE | |
Wednesday
SESSION 32:
CATHETER BASED TREATMENTS OF RESISTANT HYPERTENSION; MANAGEMENT OF CARDIAC PROBLEMS, SMOKING AND TRANSFUSION IN VASCULAR SURGERY PATIENTS; MORTALITY RISK IN STROKE PATIENTS; VASCULAR AND CARDIAC COMPLICATIONS OF COVID-19
Moderators:Ron Waksman, MD / Michael R. Jaff, DO
|
|
x | |
UPDATE ON RENAL DENERVATION FOR HYPERTENSION | |
7:42 AM - 7:47 AM | Current Status Of Renal Denervation For Drug Resistant Hypertension: Why The Simplicity Spyral Radiofrequency Denervation System Is Different: Status Of The SPYRAL HTN-OFF MED RCT (Versus Sham) |
Presenter(s):Sahil A. Parikh, MD | |
7:48 AM - 7:53 AM | Updates On Other Methods Of Renal Denervation: Chemical (Alcohol) Infusion Via The Peregrine Catheter (Ablative Solutions) And Ultrasound Via The Paradise Catheter (ReCor Medical) |
Presenter(s):Horst Sievert, MD | |
7:54 AM - 7:59 AM | Preop Cardiac Evaluation With CT-Based Fractional Flow Reserve (FFRCT) And Selective Coronary Revascularization Saves Lives In Patients Undergoing Procedures For CLTI And Carotid Disease |
Presenter(s):Christopher K. Zarins, MD / Dainis K. Krievins, MD | |
8:00 AM - 8:05 AM | The ISCHEMIA RCT Shows No Difference In Survival For Best Medical Treatment Versus Intervention In Patients With Stable Angina And Moderate Coronary Disease – Although Quality Of Life Is Better After Intervention: Will The Trial Change Practice |
Presenter(s):Judith S. Hochman, MD | |
8:06 AM - 8:11 AM | How And Why Do Thoracic Stent-Grafts For TEVAR Negatively Affect The Heart |
Presenter(s):Frans L. Moll, MD, PhD | |
8:12 AM - 8:17 AM | When Should Smoking Be Stopped Before AAA Repair; Before Lower Extremity Bypass: At Least 4 Weeks Because Duration Of Cessation Matters |
Presenter(s):Jeffrey J. Siracuse, MD | |
8:18 AM - 8:23 AM | Permissive Transfusion Strategies Increase Mortality And Serious Adverse Events After Major Vascular And General Surgery Operative Interventions |
Presenter(s):Panos Kougias, MD, MSc | |
8:25 AM - 8:29 AM | How To Quantitate Late Mortality Risk In Asymptomatic Carotid Stenosis (ACS) Patients: Why It’s Important In Decision Making And What To Do About It Other Than Treating ACS Patients Non-Invasively |
Presenter(s):Andrew N. Nicolaides, MS, FRCS | |
8:30 AM - 8:35 AM | Vascular Complications Of COVID-19 Infections: What Is Known And Unknown: How To Diagnose And Treat |
Presenter(s):Michael E. Barfield, MD | |
8:36 AM - 8:41 AM | Cardiac Complications Of COVID-19 Infections: What Is Their Genesis: Diagnosis And Treatment |
Presenter(s):Roxana Mehran, MD | |
8:42 AM - 8:50 AM | Panel Discussion |
8:50 AM - 9:06 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 32 | |
SESSION 33 SCHEDULE | |
Wednesday
SESSION 33:
PROGRESS IN MANAGING ENDOLEAKS: UNDERSTANDING THEIR CONSEQUENCES AND PREDICTING, PREVENTING AND TREATING THEM
Moderators:Timur P. Sarac, MD / Michel Makaroun, MD
|
|
x | |
TO TREAT OR NOT TO TREAT TYPE 2 ENDOLEAKS | |
9:06 AM - 9:11 AM | Most Type 2 Endoleaks Are Benign: The Case Can Be Made That By Treating Type 2 Endoleaks The Harm And Cost Of Such Treatment Outweighs The Benefits: When If Ever Should They Be Treated |
Presenter(s):Michel M.P. Reijnen, MD, PhD | |
TREATING TYPE 1 ENDOLEAKS | |
9:12 AM - 9:17 AM | Type 1A Endoleaks After EVAR Are Predictable And Preventable: How To Do So |
Presenter(s):Michael J. Singh, MD | |
9:18 AM - 9:23 AM | When And How To Treat Type 1 Endoleaks With Embolization: Technical Tips |
Presenter(s):Robert A. Morgan, MD | |
9:24 AM - 9:29 AM | When And How To Use Embolization Coils To Treat Type 1A Endoleaks Successfully: When Won’t Coils Work: How To Diagnose Type 1A Endoleaks Accurately |
Presenter(s):Sigrid Nikol, MD | |
9:30 AM - 9:35 AM | How To Minimize Gutter Type 1A Endoleaks With Chimney EVAR (Ch/EVAR): How To Treat Them When They Occur: When Not To Treat Them |
Presenter(s):Konstantinos P. Donas, MD | |
9:36 AM - 9:41 AM | Fibrin Glue Sac Filling Technique During EVAR To Prevent All Endoleaks: It Should Be Routine And Is A Game Changer Based On A Multicenter Trial: How To Do It |
Presenter(s):Qingsheng Lu, MD | |
ROLE OF INFLAMMATION | |
9:42 AM - 9:47 AM | The Role Of Inflammation In Causing Late Endoleaks: How To Evaluate It And How Should It Influence Treatment |
Presenter(s):Furuzan Numan, MD | |
9:48 AM - 9:53 AM | Panel Discussion |
PREVENTION OF TYPE 2 ENDOLEAKS AFTER EVAR | |
9:53 AM - 9:58 AM | A RCT Shows The Advantages Of Inferior Mesenteric Artery (IMA) And Lumbar Embolization: Confirmed By A Japanese RCT: When And How To Do It |
Presenter(s):Dominique Fabre, MD, PhD / Stephan Haulon, MD | |
9:59 AM - 10:04 AM | Preventing Threatening Type 2 Endoleaks By IMA Embolization When AAA Sac And IMA Are Large: Indications And Technical Tips And Evidence |
Presenter(s):Toru Kuratani, MD, PhD | |
10:05 AM - 10:10 AM | With A Large IMA (> 3mm), When Should It Be Embolized; When Should It Be Revascularized And Why |
Presenter(s):Piotr M. Kasprzak, MD | |
10:11 AM - 10:16 AM | Selective Coiling Of IMA And Lumbar Arteries Decrease Harmful Type 2 Endoleaks: When And How To Do It |
Presenter(s):Götz M. Richter, MD, PhD | |
10:17 AM - 10:22 AM | Panel Discussion |
TREATMENT OF TYPE 2 ENDOLEAKS AFTER EVAR | |
10:22 AM - 10:27 AM | How Duplex Ultrasound Velocities In Type 2 Endoleaks Determine Behavior And Help In Treatment: Technical Tips |
Presenter(s):Ross Milner, MD | |
10:28 AM - 10:33 AM | Glue Embolization Is Effective Treatment For Most Threatening Type 2 Endoleaks: When And How Best To Do It |
Presenter(s):Neal S. Cayne, MD | |
10:34 AM - 10:39 AM | Transcaval Access To AAA Sacs For Treatment Of Type 2 Endoleaks After EVAR: When And How To Do It |
Presenter(s):Adam Beck, MD | |
10:40 AM - 10:45 AM | How To Best Leverage 3D Fusion Software (GE) To Get Into The Nidus And Treat Type 2 Endoleaks: Best Embolic Agent And Value Of Transcaval Access |
Presenter(s):Mark W. Mewissen, MD, RVT | |
10:46 AM - 10:51 AM | Transgraft Approach To Treat Type 2 Endoleaks: Indications, Equipment, Advantages And Precautions |
Presenter(s):James F. McKinsey, MD | |
10:52 AM - 10:57 AM | Laser Assisted Transgraft Onyx Embolization Of Type 2 Endoleaks: Indications, Equipment And Technique |
Presenter(s):Zvonimir Krajcer, MD, FACC | |
10:58 AM - 11:03 AM | With Type 2 Endoleaks And Sac Expansion Open Sacotomy And Branch Ligation Is The Best Treatment: Why And What Precautions Are Needed To Be Sure There Is Not Occult Type 1 Leak |
Presenter(s):Zachary M. Arthurs, MD | |
11:04 AM - 11:12 AM | Panel Discussion |
END OF SESSION 33 | |
SESSION 34 SCHEDULE | |
Wednesday
SESSION 34:
TCT RECORDED LIVE COMPLEX AND CHALLENGING ENDOVASCULAR CASES
Moderators:Juan F. Granada, MD / Sahil A. Parikh, MD
|
|
x | |
11:12 AM - 12:00 PM | PROGRAM TO BE DETERMINED |
END OF SESSION 34 | |
SESSION 35 SCHEDULE | |
Wednesday
SESSION 35:
VIDEO SESSION: RECORDED LIVE CHALLENGING ENDOVASCULAR CASES AND INNOVATIVE TECHNIQUES
Moderators:TBD
|
|
x | |
PART 1 – PLINIO ROSSI’S RECORDED LIVE CASE SESSION | |
Moderator(s): Fabrizio Fanelli, MD, EBIR / Andrew Holden, MBChB / Carlo Setacci, MD | |
1:00 PM - 1:25 PM | PROGRAM TO BE DETERMINED |
PART 2 – RECORDED LIVE CASES FROM LINC AND LEIPZIG | |
Moderator(s): Dierk Scheinert, MD / Giancarlo Biamino, MD, PhD / Andrej Schmidt, MD | |
1:25 PM - 1:50 PM | PROGRAM TO BE DETERMINED |
END OF SESSION 35 | |
SESSION 36 SCHEDULE | |
Wednesday
SESSION 36:
ISSUES IMPORTANT TO HISTORY, VASCULAR SURGICAL LEADERSHIP, SCIENCE, TRAINING AND CAREERS
Moderators:Kim J. Hodgson, MD / Bruce A. Perler, MD, MBA
|
|
x | |
HISTORICAL NOTE | |
1:50 PM - 1:55 PM | What Vascular Injury Killed Martin Luther King, Jr. And Why He Might Have Survived Today |
Presenter(s):Cynthia K. Shortell, MD | |
1:56 PM - 2:01 PM | How To Succeed In Academic Vascular Surgery: Don’t Be A Revolutionary |
Presenter(s):Ronald L. Dalman, MD | |
2:02 PM - 2:07 PM | How To Become President Of A Major Vascular Society Or The SVS |
Presenter(s):Anil P. Hingorani, MD | |
2:08 PM - 2:13 PM | Vascular Surgery In The Democratic Republic Of The Congo: An Amazing Story |
Presenter(s):Jesse M. Manunga, MD | |
2:14 PM - 2:19 PM | RCTs And Meta-Analyses Can Be Flawed And Biased: They Should Only Be Viewed With Other Evidence And Common Sense |
Presenter(s):George S. Lavenson, MD | |
2:20 PM - 2:25 PM | Why Systematic Reviews And Meta-Analyses Can Be Misleading: What To Do About It |
Presenter(s):Janet T. Powell, MD, PhD | |
ISSUES IN VASCULAR TRAINING | |
2:26 PM - 2:31 PM | Coming Crisis In Vascular Surgical Training – In Both 5+2 And 0+5 Programs: What Can Be Done About It |
Presenter(s):Michael B. Silva, Jr., MD | |
2:32 PM - 2:37 PM | How To Remedy The Deficiency Vascular Fellows And Residents Have In Numbers Of Open Vascular Surgical Operations |
Presenter(s):Malachi Sheahan, MD | |
2:38 PM - 2:43 PM | Ten Golden Rules To Train Vascular Surgeons In Distal Bypass Procedures In 2020 |
Presenter(s):Francesco Spinelli, MD | |
2:44 PM - 2:49 PM | Ten Top Tips For Establishing An Independent Research Initiative In Vascular Surgery After Training |
Presenter(s):Philip P. Goodney, MD, MS | |
2:50 PM - 2:58 PM | Panel Discussion And Break Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 36 | |
SESSION 37 SCHEDULE | |
Wednesday
SESSION 37:
MORE ISSUE RELATED TOPICS IMPORTANT TO VASCULAR SURGEONS AND VASCULAR SPECIALISTS; ISSUES RELATED TO OUTPATIENT CENTERS OR OFFICE BASED LABS (OBLs)
Moderators:Peter Gloviczki, MD / Enrico Ascher, MD
|
|
x | |
2:58 PM - 3:03 PM | Heart And Vascular Centers Are Artificial Entities That Disadvantage Vascular Surgeons |
Presenter(s):Malachi Sheahan, MD | |
3:04 PM - 3:09 PM | The Wellness Of Vascular Surgeons: Physical And Mental: How To Monitor It And How To Promote It And Prevent Burnout |
Presenter(s):Samuel R. Money, MD, MBA | |
3:10 PM - 3:15 PM | Unfilled Promises With Devices, Drugs And Treatments: Initial Hype That Is Not Fulfilled: It Is Often Hidden: More Transparency Is Needed: A Few Examples |
Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC | |
3:16 PM - 3:21 PM | Advances In Telecare For Vascular Surgeons: What Is The Best Technology: What Does The Future Hold And What Was The Impact Of The COVID-19 Shutdowns |
Presenter(s):John (Jeb) W. Hallett, MD | |
3:22 PM - 3:27 PM | How To Improve Operating Room Efficiency For Vascular Surgical Operations: Why It Is So Widespread And Hard To Fix |
Presenter(s):Panos Kougias, MD, MSc | |
3:28 PM - 3:33 PM | Why Is The Per Capita Use Of EVAR And TAVR Dramatically Higher In New York State, USA Than Ontario, Canada |
Presenter(s):Sean P. Roddy, MD / Robert M. Zwolak, MD, PhD | |
3:34 PM - 3:39 PM | How To Avoid Lawsuits In Vascular Surgery And Other Vascular Specialties |
Presenter(s):Russell H. Samson, MD, RVT, FACS | |
3:40 PM - 3:45 PM | Panel Discussion |
ISSUES RELATED TO OUTPATIENT CENTERS AND OBLs | |
3:45 PM - 3:50 PM | Why And How Do Outpatient Angio Suites And OBLs Fail |
Presenter(s):Sam S. Ahn, MD, FACS, MBA | |
3:51 PM - 3:56 PM | Tips And Tricks For Performing High Risk Lower Extremity Endovascular Procedures Safely And Successfully In An Outpatient Setting |
Presenter(s):Anil P. Hingorani, MD / Enrico Ascher, MD | |
3:57 PM - 4:02 PM | A Balanced View Of Atherectomy In Outpatient Facilities And OBLs In 2020: Is The Procedure Overused And Why |
Presenter(s):Krishna Jain, MD | |
4:03 PM - 4:08 PM | Inherent Conflicts Of Interest In OBLs: Why They Occur And Are Bad For Patients: How To Counteract Them |
Presenter(s):O. William Brown, MD, JD | |
4:09 PM - 4:13 PM | Panel Discussion |
END OF SESSION 37 | |
SESSION 38 SCHEDULE | |
Wednesday
SESSION 38:
UPDATES AND ISSUES IMPORTANT TO ALL VASCULAR SURGEONS AND SPECIALISTS: FUTURE REIMBURSEMENT; ETHICS OF INSURANCE; VASCULAR REGISTRIES AND THE VQI, VALUE OF GUIDELINES, ENDPOINTS; INDUSTRY RELATIONS; IMPACT OF GOVERNMENT (ACA) AND REGULATORY AGENCIES (FDA)
Moderators:Jack L. Cronenwett, MD / Robert M. Zwolak, MD, PhD
|
|
x | |
4:13 PM - 4:18 PM | What Obstacles And Blows Are Vascular Surgeons And Other Vascular Specialists Facing In 2021: Will Planned Increased Reimbursement For Office And Hospital Visits Cause Decreases In Procedural Reimbursements |
Presenter(s):Sean P. Roddy, MD | |
4:19 PM - 4:24 PM | How Can Vascular Surgeons Identify High Risk, High Cost Patients And Help Health Care Systems Control Costs: How To Prevent Inappropriate Treatments In These Patients |
Presenter(s):Lee Kirksey, MD | |
4:25 PM - 4:30 PM | Update On Valuable New Information From The International Consortium of Vascular Registries (ICVR) |
Presenter(s):Adam Beck, MD | |
4:31 PM - 4:36 PM | The Role And Value Of Guidelines In Vascular Practice; Why Guidelines Can Be Misleading; How Should They Be Written To Not Be |
Presenter(s):Anders Wanhainen, MD, PhD | |
4:37 PM - 4:42 PM | The Ethics Of The Health Insurance Business Models To Reduce Costs: Patients Are Not Being Well Served: What Can Be Done About It |
Presenter(s):James W. Jones, MD, PhD, MHA | |
4:43 PM - 4:48 PM | Importance Of Clinical Endpoints (Like Wound Healing, Amputation) Rather Than Proxy Endpoints (Like TLR) In Evaluating New Endovascular Technology And Its Incremental Benefits |
Presenter(s):Jim Reekers, MD, PhD | |
4:49 PM - 4:54 PM | Effects Of The Affordable Care Act (ACA) On Vascular Surgical Outcomes: Does The Medicaid Expansion Of The ACA Improve Outcomes Or Not |
Presenter(s):Mohammad H. Eslami, MD, MPH | |
4:55 PM - 5:00 PM | Despite What The New York Times And Others Say, Close Relationships Of Vascular Surgeons With Industry Are Ethical And Beneficial To Patients And Society: Pitfalls To Avoid |
Presenter(s):Bruce A. Perler, MD, MBA | |
5:01 PM - 5:06 PM | Panel Discussion |
5:06 PM - 5:11 PM | Propensity Score Matching Studies: How Do They Work And What Are Their Strengths And Weaknesses |
Presenter(s):Charles C. Miller, PhD | |
REGULALTORY ISSUES | |
5:12 PM - 5:17 PM | Historical Perspective Over The Last 25 Years On FDA Approvals Of EVAR Devices Submitted By Investigators And Industry: Lessons Learned To Guide Future Applications |
Presenter(s):Dorothy B. Abel, BSBME | |
5:18 PM - 5:23 PM | The New (2020) European Regulations For Medical Device Approval: Will They Impede Approval Of Endovascular Treatments |
Presenter(s):Jim Reekers, MD, PhD | |
5:24 PM - 5:29 PM | Are The Quality, Safety And Effectiveness Of Generic Drugs Equating Those Of The Patented Original Drugs: How Is The FDA Assuring Equivalence; Should The FDA Do More |
Presenter(s):Valerie M. Merkle, PhD | |
JOURNAL ISSUES | |
5:30 PM - 5:35 PM | How To Get A Paper Accepted In A High Impact Journal Like The JVS: Does Bias Ever Matter |
Presenter(s):Peter Gloviczki, MD | |
5:36 PM - 5:41 PM | Non-Compliance With The SVS AAA Practice Guidelines Is Common: How Does It Impact On Outcomes |
Presenter(s):Elliot L. Chaikof, MD, PhD | |
VQI TOPICS | |
5:42 PM - 5:47 PM | Recent Challenges And Accomplishments Of The SVS VQI: A Worthy Organization |
Presenter(s):Jens Eldrup-Jorgensen, MD / Jack L. Cronenwett, MD | |
5:48 PM - 5:53 PM | Using The SVS VQI To Improve The Practice Of Vascular Surgery: What Is The Concept Of CAPT And How Can It Help |
Presenter(s):Fred A. Weaver, MD, MMM | |
5:54 PM - 6:00 PM | Panel Discussion End of Program E |
END OF SESSION 38 | |
SESSION 39 SCHEDULE | |
Wednesday
SESSION 39:
MORE TOPICS RELATED TO THE THORACIC AORTA, AORTIC DISSECTIONS, INTRAMURAL HEMATOMAS (IMHs), PENETRATING AORTIC ULCERS (PAU) AND THEIR TREATMENT
|
|
x | |
6:50 AM - 6:55 AM | Aortic Arch Type And Adequacy Of The Proximal Seal Zone Are Important Determinants Of TEVAR Outcomes In Treatment Of TBADs |
Presenter(s):Firas F. Mussa, MD | |
6:56 AM - 7:01 AM | False Lumen Area >50% Of Total Aortic Cross-Section Area At The Tracheal Bifurcation At Time Of TEVAR For TBAD Is A Predictor Of Early Death: How To Decrease This Mortality |
Presenter(s):Johnny Steuer, MD, PhD | |
7:02 AM - 7:07 AM | Value Of Stent-Grafts In Genetically Triggered Aortopathy |
Presenter(s):Cherrie Z. Abraham, MD | |
7:08 AM - 7:13 AM | How Best To Deal With A Persistent Or Enlarging False Lumen After TEVAR For TBAD |
Presenter(s):Nicola Mangialardi, MD | |
7:14 AM - 7:19 AM | Update On Use And Value Of The Candy Plug Endovascular Device To Treat Chronic TBADs With A TAAA |
Presenter(s):Tilo Koelbel, MD, PhD | |
7:20 AM - 7:25 AM | Panel Discussion |
7:25 AM - 7:30 AM | Staged Hybrid Single Lumen Reconstruction Is The Best Treatment For Complex Chronic TBAD With Visceral Segment Involvement Of The Aorta: How To Do It, Advantages And Results |
Presenter(s):Sherif A.H. Sultan, MD, FRCS, EBQS-VASC | |
7:31 AM - 7:36 AM | Reinterventions After TEVAR For TBADs: How To Decrease Them At The Index Procedure And How Planning Helps |
Presenter(s):Bijan Modarai, PhD, FRCS | |
7:37 AM - 7:42 AM | Adjunctive Peripheral And Visceral Interventions During TEVAR For Complicated TBADs: Indications, Technical Tips And Results |
Presenter(s):Mark K. Eskandari, MD | |
7:43 AM - 7:48 AM | Update On Intramural Hematoma (IMH): Etiology, Natural History And Indications For TEVAR |
Presenter(s):Frank J. Criado, MD | |
7:49 AM - 7:54 AM | Natural History And Optimal Treatment For Penetrating Aortic Ulcers (PAUs) When To Observe And When To Treat With TEVAR |
Presenter(s):Colin D. Bicknell, MD, FRCS | |
7:55 AM - 8:00 AM | Panel Discussion |
END OF SESSION 39 | |
SESSION 40 SCHEDULE | |
Wednesday
SESSION 40:
MORE ADVANCES RELATED TO SESSIONS INVOLVING THE ASCENDING AORTA AND THE AORTIC ARCH; AORTIC DISSECTIONS AND THEIR TREATMENT
Moderators:Rodney A. White, MD / Joseph E. Bavaria, MD
|
|
x | |
8:00 AM - 8:05 AM | Value Of Transcranial Doppler (TCD) For TEVAR And Endo Procedures Involving The Ascending Aorta And Aortic Arch |
Presenter(s):Alan B. Lumsden, MD, FACS | |
8:06 AM - 8:11 AM | Antegrade Stent-Graft Delivery For Treating Acute Type A Dissections: When Is It Advantageous And How To Do It |
Presenter(s):Ourania Preventza, MD / Joseph S. Coselli, MD | |
8:12 AM - 8:17 AM | Role Of Bare Metal Stents (Ascyrus Medical) For Repair Of Acute Type A Dissections: Indications And Results |
Presenter(s):Grayson H. Wheatley, MD | |
8:18 AM - 8:23 AM | Caval Balloon Occlusion: A Better Way Than Rapid Pacing To Permit Precise Stent-Graft Placement In The Proximal Aorta: How To Do It And Is It Better For The Heart |
Presenter(s):Bjõrn Sonesson, MD, PhD | |
8:24 AM - 8:29 AM | For Precise TEVAR In The Aortic Arch Rapid Pacing And Caval Occlusion Are NOT Needed: Valsalva And PEEP By Anesthesiologist Do Just As Well And Are Simple: Technical Tips |
Presenter(s):Nikolaos Tsilimparis, MD; PhD | |
8:30 AM - 8:35 AM | Panel Discussion |
8:35 AM - 8:40 AM | Arch Lesion Repair With Single, Double Or 3-Branched Devices: When Is Each Best And Why |
Presenter(s):Gustavo S. Oderich, MD, FACS | |
8:41 AM - 8:46 AM | Chimney Technique For Dealing With Total Arch Lesions And Dissections: How To Make It Work, Limitations And Results |
Presenter(s):Ivo Petrov, MD, PhD | |
8:47 AM - 8:52 AM | Laser Fenestration Option For TEVAR Involving The Great Arch Branches: When Is It Better Than Branched Endografts: Technique And Results |
Presenter(s):Timothy A. Resch, MD, PhD | |
8:53 AM - 8:58 AM | For Aortic Arch Repairs In Situ Fenestration Is Superior To Chimney TEVAR: New Technology From Life Tech For Doing It |
Presenter(s):Ralf R. Kolvenbach, MD | |
8:59 AM - 9:04 AM | For Distal Aortic Arch Pathology Custom Fenestrated Grafts (From Cook) Are The Best Repair Technique: Why |
Presenter(s):Nikolaos Tsilimparis, MD; PhD | |
9:05 AM - 9:11 AM | Panel Discussion |
9:11 AM - 9:24 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 40 | |
SESSION 41 SCHEDULE | |
Wednesday
SESSION 41:
OPEN AND ENDO TREATMENT OF COMPLEX AAAs (JUXTA, PARA- AND SUPRA-RENAL) AND TAAAs; NEW DEVICES FOR THEIR TREATMENT
Moderators:Giovanni B. Torsello, MD / Gustavo S. Oderich, MD, FACS
|
|
x | |
COMPLEX AAAs AND TAAAs | |
9:24 AM - 9:29 AM | Open Repair Is The Best Way To Treat Short Neck, No Neck And Pararenal AAAs: Why Is This So |
Presenter(s):Laurent Chiche, MD, FEBVS | |
9:30 AM - 9:35 AM | Long-Term Survival Results After Type II TAAA Endovascular Repair: When Is The Procedure Contraindicated |
Presenter(s):Matthew J. Eagleton, MD | |
9:36 AM - 9:41 AM | How To Make 3 Chimney EVAR With Involvement Of The SMA Safe And Effective |
Presenter(s):Konstantinos P. Donas, MD | |
9:42 AM - 9:47 AM | Value Of Ch/EVAR For Juxtarenal AAAs: They Are As Safe And Effective As Any Other Procedure And Simpler |
Presenter(s):Joost A. van Herwaarden, MD, PhD | |
9:48 AM - 9:53 AM | Advances In Endovascular TAAA Repair In Canada: Making The Procedure Safe And Diagnosing And Fixing Late Type 3 Endoleaks |
Presenter(s):Thomas F. Lindsay, MDCM, FRCS, FACS | |
9:54 AM - 9:59 AM | Comparison Of Endo And Open Repair Of Post Dissection TAAAs: Which Procedure Is Best And When |
Presenter(s):Fabio Verzini, MD, PhD | |
10:00 AM - 10:05 AM | Comparative Morbidity And Mortality Outcomes Of Open, Hybrid And F/B/EVAR For Type II And III TAAAs Justify Greater Use Of F/B/EVAR For These Complex Lesions |
Presenter(s):Gilbert R. Upchurch, MD / Dean Arnaoutakis, MD / Salvatore T. Scali, MD | |
10:06 AM - 10:12 AM | Panel Discussion |
TOPICS RELATED TO INTERESTING NEW DEVICES | |
10:12 AM - 10:17 AM | A New Hybrid Device (Thoracoflo From Terumo Aortic) For TAAA Repair: How It Works, Early Clinical Experience And Advantages |
Presenter(s):Sebastian E. Debus, MD, PhD | |
10:18 AM - 10:23 AM | How To Prevent Patch Aneurysms After Open TAAA Repair With Long Antegrade Grafts: How To Treat Them When They Occur |
Presenter(s):Thomas C. Bower, MD / Manju Kalra, MBBS | |
10:24 AM - 10:29 AM | Why AAA Sac Shrinkage Is Better After EVAR With The Treo (From Terumo Aortic) Endograft |
Presenter(s):Michael C. Stoner, MD | |
10:30 AM - 10:35 AM | Update On The Colt Manifold Device For TAAAs, Complex AAAs, Failed EVARs And Failed EVAS Procedures: How Does It Work And Results |
Presenter(s):Piotr Szopinski, MD, PhD | |
10:36 AM - 10:41 AM | We Flow Device For Juxtarenal AAA Repair: A New Approach: How Does It Work And Early Results |
Presenter(s):Wei Guo, MD | |
10:42 AM - 10:48 AM | Panel Discussion |
END OF SESSION 41 | |
SESSION 42 SCHEDULE | |
Wednesday
SESSION 42:
PROGRESS IN TREATING ILIAC ANEURYSMS; ILIAC BRANCHED DEVICES (IBDs); UPDATE ON MULTILAYER FLOW MODULATING (MLFM) AND OTHER BARE STENTS FOR TREATING ANEURYSMS AND DISSECTIONS
Moderators:Thomas S. Maldonado, MD / Nicholas J.W. Cheshire, MD
|
|
x | |
TREATMENT OF ILIAC ANEURYSMS AND IBDs | |
10:48 AM - 10:53 AM | DEBATE: How Best To Treat Iliac Aneurysms In 2020: There Is Not Much Of A Need For Open Surgery |
Presenter(s):Stefan Müller-Hülsbeck, MD | |
10:54 AM - 10:59 AM | DEBATE: There Is A Role For Open Surgery In The Treatment Of Iliac Aneurysms: What Is It And Technical Tips |
Presenter(s):Heron E. Rodriguez, MD | |
11:00 AM - 11:05 AM | Long-Term Experience With Cook IBD For The Treatment Of Common Iliac Aneurysms: Advantages And Limitations |
Presenter(s):Giovanni B. Torsello, MD | |
11:06 AM - 11:11 AM | Terumo Aortic Customized Iliac Branched Device: How Is It Different From Other IBDs: Advantages And Limitations |
Presenter(s):Afshin Assadian, MD | |
11:12 AM - 11:17 AM | Update On The Gore IBE Excluder For Treating Iliac Aneurysms And Preserving Hypogastric Artery Flow: Advantages And Limitations: From The European ICEBERG Registry |
Presenter(s):Michel M.P. Reijnen, MD, PhD | |
11:18 AM - 11:23 AM | Long-Term Comparison Of The Cook Zenith And Gore Excluder IBDs: Advantages And Limitations Of Both |
Presenter(s):Giovanni Pratesi, MD | |
11:24 AM - 11:30 AM | Panel Discussion |
UPDATE ON MULTILAYER FLOW MODULATING (MLFM) BARE STENTS | |
11:30 AM - 11:35 AM | Why MLFM Bare Stents Should Be The Treatment Of Choice For Visceral, Peripheral And Iliac Aneurysms: Advantages And Has Rupture Been Universally Prevented |
Presenter(s):Michel C. Henry, MD | |
11:36 AM - 11:41 AM | MLFM Bare Stent (From Cardiatis) Is A Promising Treatment For Acute Aortic Dissections: What Is the Evidence In Support |
Presenter(s):Rodney A. White, MD | |
11:42 AM - 11:47 AM | Improved Outcomes Of Type A Aortic Dissections With Use Of Bare Stents (Cardiatis And Ascyrus): They Decrease Malperfusion, Promote Aortic Remodeling And Prevent Strokes: How Do They Work |
Presenter(s):Ralf R. Kolvenbach, MD | |
11:48 AM - 11:53 AM | Update On The Long-Term Results Of The MLFM Bare Stents (Cardiatis) In The Treatment Of TAAAs: Are They Proving Safe And Effective Mid And Long-Term: What Is Their Role |
Presenter(s):Claude D. Vaislic, MD | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break -2nd Floor PromenadeVisit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 42 | |
SESSION 43 SCHEDULE | |
Wednesday
SESSION 43:
MORE NEW DEVELOPMENTS IN AAA TREATMENT AND STANDARD EVAR: A NEW DEVICE TO SLOW AAA GROWTH; AAA NECK DILATATION AFTER EVAR; VALUE OF LOW PROFILE AAA ENDOGRAFTS; LINK TO CANCER; IMPROVED ULTRASOUND SURVEILLANCE AND ALL AAAs ARE NOT TIME BOMBS WAITING TO EXPLODE
Moderators:Juan C. Parodi, MD / Claude Mialhe, MD
|
|
x | |
1:00 PM - 1:05 PM | A Novel New Technology (Nectero) To Slow AAA Growth; How Does It Work And Early Clinical Results |
Presenter(s):Venkatesh G. Ramaiah, MD | |
AAA NECK BEHAVIOR AFTER EVAR | |
1:06 PM - 1:11 PM | Impact Of Oversizing And Level Of Fixation (Infra Versus Supra-Renal) On Aortic Neck Behavior: How Do These Variables Affect EVAR Outcomes: From A 10-Year Study |
Presenter(s):Carlos F. Bechara, MD | |
1:12 PM - 1:17 PM | Aortic Neck Dilatation Is Different After F/EVAR And EVAR: What Is The Reason And Why Is It Important For Outcomes |
Presenter(s):Thomas S. Maldonado, MD | |
1:18 PM - 1:23 PM | Major Aortic Neck Dilatation Occurs Equally After EVAR And Open Repair: From The DREAN RCT: This ONLY Occurs After EVAR With Self-Expanding Endografts |
Presenter(s):Jan D. Blankensteijn, MD | |
1:24 PM - 1:29 PM | Do AAA Necks Dilate After F/EVAR For Juxtarenal AAAs: What Are The Good Or Bad Consequences For Procedural Outcomes |
Presenter(s):Benjamin W. Starnes, MD | |
1:30 PM - 1:35 PM | DEBATE: Low Profile Devices For EVAR Are Failing: Their Future Is Questionable |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
1:36 PM - 1:41 PM | DEBATE: Not So: Ovation Stent-Graft (From Endologix) Have Good 5-Year Results With No Neck Dilatation Or Migration Even With Challenging Neck Anatomy: Based On A Multicenter International Study Of A Low Profile Endograft |
Presenter(s):Mahmoud B. Malas, MD, MHS | |
1:42 PM - 1:47 PM | Current Status Of The Link Between EVAR And Cancer: Is It Real And What Is Its Etiology |
Presenter(s):Janet T. Powell, MD, PhD | |
1:48 PM - 1:53 PM | Why 3D Ultrasound Should Replace CTA For AAA Post EVAR Surveillance And Other Purposes: Advantages And Limitations |
Presenter(s):Henrik Sillesen, MD, DMSc | |
1:54 PM - 1:59 PM | Presenting AAAs As Ticking Time Bombs Or Unexploded Grenades Is Wrong-Headed, Inaccurate And Harmful |
Presenter(s):Frank J. Criado, MD | |
2:00 PM - 2:06 PM | Panel Discussion |
END OF SESSION 43 | |
SESSION 44 SCHEDULE | |
Wednesday
SESSION 44:
MORE NEW DEVELOPMENTS IN AAAs: HOW DO THEIR NECK AND SAC SIZE AND THROMBUS LOAD EFFECT PROGNOSIS AFTER EVAR AND EVAS; OTHER RELATED AAA TOPICS
Moderators:Ali F. AbuRahma, MD / Janet T. Powell, MD, PhD
|
|
x | |
AAA NECK AND SAC THROMBUS LOAD | |
2:06 PM - 2:11 PM | Impact Of Thrombus In AAA Sac And Neck On AAA Behavior And EVAR Outcomes: How To Quantitate Thrombus Load And Distribution |
Presenter(s):Nicos Labropoulos, BSc (Med), PhD, DIC, RVT | |
2:12 PM - 2:17 PM | DEBATE: Large Amount Of AAA Sac Thrombus Promotes Morbidity Without Rupture And Rupture: What Is The Mechanism And How To Quantitate Thrombus Load |
Presenter(s):David H. Deaton, MD, FACS | |
2:18 PM - 2:23 PM | DEBATE: Large Flow Lumenal Space In AAA Sac With Minimal Mural Thrombus Is Associated With Adverse Events After EVAR: It Is More Important Than AAA Sac Size: Thrombus May Be Protective |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
2:24 PM - 2:29 PM | Graft Infolding: A Unique EVAR Complication: How To Prevent It and How To Treat It |
Presenter(s):Ashraf Mansour, MD | |
2:30 PM - 2:35 PM | Large AAA Necks (> 29 mm) Increase Migration And Leak Risks After EVAR With Self-Expanding Endografts Due To Neck Dilatation: Not So With Anatomically Adaptive (Polymer) Sealing Endografts (Ovation) Which Are Not Followed With Neck Dilatation |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
2:36 PM - 2:41 PM | Does Doxycycline Stabilize AAA Neck Diameter: From The NTACT Trial |
Presenter(s):Jon S. Matsumura, MD | |
2:42 PM - 2:47 PM | EVAS With Sac Filling Technology (Nellix) Has Lower Late Mortality Than EVAR With Other Endografts – Especially With Large AAAs: What Is The Mechanism Thought To Be |
Presenter(s):Marc L. Schermerhorn, MD | |
2:48 PM - 2:53 PM | Technical Tips To Perform SAFE Large Sheath Percutaneous Femoral Access For Complex AAA EVAR In Obese Or Scarred Groins – Even With Calcified Arteries |
Presenter(s):Barend M.E. Mees, MD, PhD | |
2:54 PM - 2:59 PM | 4X Increased 18F FDG Uptake On PET CT In Female AAA Patients Compared To Males Indicates Increased Aortic Wall Inflammation: Does This Explain Increased Rupture Risk In Females: Implications For Treatment |
Presenter(s):Natzi Sakalihasan, MD, PhD | |
3:00 PM - 3:06 PM | Panel Discussion |
3:06 PM - 3:15 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 44 | |
SESSION 45 SCHEDULE | |
Wednesday
SESSION 45:
SHORT HOT AORTIC TOPICS (4 ¾-MINUTE FAST PACED TALKS)
Moderators:Timothy A.M. Chuter, DM / Luis A. Sanchez, MD
|
|
x | |
3:15 PM - 3:20 PM | Large Diameter AAAs Negatively Impacts Patient Survival After EVAR: Is Inflammation Involved And What Can Be Done About It |
Presenter(s):Matt M. Thompson, MD | |
3:20 PM - 3:25 PM | A Large Proportion Of EVARs Are Performed On Small AAAs: What Are The Implications And What Should Be Done About It |
Presenter(s):Salvatore T. Scali, MD | |
3:25 PM - 3:30 PM | Late Delayed Renal Artery Revascularization After Inadvertent Occlusion During Complex EVAR Is Worthwhile: Collaterals Keep The Kidney Viable Although No Urine Is Produced |
Presenter(s):Nikolaos Tsilimparis, MD; PhD | |
3:30 PM - 3:35 PM | Global Trends In AAA Mortality: What Reasons Explain These Trends |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FACPh, F | |
3:35 PM - 3:40 PM | How Can A Long-Term Aortic Risk (LEAR) Model Predict Mortality And Complication Risks And Guide Surveillance: Can The Model Be Made Device Specific |
Presenter(s):Pete Holt, MD, PhD | |
3:40 PM - 3:45 PM | Update On Status Of Retrograde And Prograde In Situ Fenestration For Arch Aneurysms And TAAAs: How To Do Them |
Presenter(s):Jean M. Panneton, MD | |
3:45 PM - 3:50 PM | Long-Term Propensity Matched Comparison Of Open Repair And F/B/EVAR For Pararenal And Paravisceral AAAs |
Presenter(s):Giovanni G.T. Tinelli, MD, PhD | |
3:50 PM - 3:55 PM | Panel Discussion |
3:55 PM - 4:00 PM | Safe Anticoagulation In F/B/EVAR Patients Requiring Spinal Fluid Drainage |
Presenter(s):Afshin Assadian, MD | |
4:00 PM - 4:05 PM | Visceral Debranching With A Simple Aortic Endograft Is The Best Way To Treat TAAAs In Good Risk Patients: How To Do It Safely |
Presenter(s):Guillermo A. Escobar, MD | |
4:05 PM - 4:10 PM | Update On Maintaining Euglycemia To Decrease Spinal Cord Ischemia With Complex AAA And TAAA Repairs |
Presenter(s):Jade S. Hiramoto, MD | |
4:10 PM - 4:15 PM | Incidence And Etiology Of Cerebrovascular Injuries With Acute TBADs With And Without Treatment |
Presenter(s):Loay S. Kabbani, MD, MHSA | |
4:15 PM - 4:20 PM | EVAR, F/EVAR And B/EVAR Results In Females: Are There Still Differences |
Presenter(s):Athanasios Katsargyris, MD / Eric L.G. Verhoeven, MD, PhD | |
4:20 PM - 4:25 PM | Update On Performing EVAR With Only IVUS Guidance To Decrease Radiation: Technical Tips And 3-Year Results |
Presenter(s):Jörg Tessarek, MD | |
4:25 PM - 4:30 PM | Risk Factors And Late Clinical Consequences Of AAA Neck Dilatation >6 Years After EVAR With Self-Expanding Endografts: Does The Neck Keep Dilating After The Spring Is Gone: What Are The Differences Between Excluder And Endurant Endografts |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
4:30 PM - 4:35 PM | Panel Discussion |
END OF SESSION 45 | |
SESSION 46 SCHEDULE | |
Wednesday
SESSION 46:
MORE SHORT HOT NEW TOPICS RELATED TO AORTIC DISEASE AND ITS TREATMENT (4 ¾-MINUTE FAST PACED TALKS)
Moderators:Fred A. Weaver, MD, MMM / Michael L. Marin, MD
|
|
x | |
4:35 PM - 4:40 PM | Role Of Endovascular And Open Treatment For Mid Aortic Syndrome In Children, Teenagers And Young Adults |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
4:40 PM - 4:45 PM | Endovascular Repair Of Thoracic Aneurysms With TEVAR Outside IFUs: Value And Limitations: From A Multicenter Study |
Presenter(s):Fabio Verzini, MD, PhD | |
4:45 PM - 4:50 PM | A New Gene Family In AAA Smooth Muscle Is Related To Aneurysm Diameter And Rupture: Could It Be A Screening Tool |
Presenter(s):Kak Khee Yeung, MD, PhD | |
4:50 PM - 4:55 PM | Impact Of Iliac Aneurysms On The Treatment Of Complex AAAs |
Presenter(s):Matthew J. Eagleton, MD | |
4:55 PM - 5:00 PM | How To Make Ch/EVAR Work: A Standard Protocol Helps: What Are The Best Endografts For The Aorta; For The Branches: How To Prevent Gutter Endoleaks |
Presenter(s):Konstantinos P. Donas, MD | |
5:00 PM - 5:05 PM | How To Treat AAAs With Large (>34 mm Diameter) Necks: When EVAR; When F/EVAR; When Open |
Presenter(s):Rabih A. Chaer, MD | |
5:05 PM - 5:10 PM | 3-Stage Concept For Treating Mega-Aortic Syndrome: Frozen Elephant Trunk (FET), TEVAR, Distal Open Repair: Results |
Presenter(s):Martin Czerny, MD | |
5:10 PM - 5:15 PM | Panel Discussion |
5:15 PM - 5:20 PM | How Should Intramural Hematomas (IMHs) In The Ascending Aorta And Arch Be Treated |
Presenter(s):Jennifer L. Perri, MD, MBA / Timothy A.M. Chuter, DM | |
5:20 PM - 5:25 PM | How To Set Up A Large Multispecialty Acute Aortic Disease Network: How Does It Improve Results |
Presenter(s):Jean-Marc Alsac, MD, PhD | |
5:25 PM - 5:30 PM | How To Safely Stent The Large Fenestration Of A ZFEN Endograft When It Is Crossed By Struts: Indications For Doing So And Late Results |
Presenter(s):Luis A. Sanchez, MD | |
5:30 PM - 5:35 PM | An Unrecognized Mechanism For Causing Aortic Dissections: Shock Wave Energy Rather Than Increased Arterial Pressure Causes The Tear: How Does It Work And How To Decrease The Risk |
Presenter(s):Erno Remsey-Semmelweis, MD | |
5:35 PM - 5:40 PM | Are Low Profile Devices For EVAR And TEVAR Improving Or Worsening Outcomes |
Presenter(s):Naoki Fujimura, MD, PhD | |
5:40 PM - 5:45 PM | The Sandwich-Periscope Technique For Left Subclavian Revascularization With Zone 2 TEVAR: It May Be The Best Way And How To Do It |
Presenter(s):Sukgu Han, MD | |
5:45 PM - 5:50 PM | Comparison Of Endo And Open (Carotid-Subclavian Bypass) Treatments For Subclavian Artery Stenosis And Occlusions: Safety, Durability And Costs |
Presenter(s):Ali F. AbuRahma, MD | |
5:50 PM - 5:55 PM | Panel Discussion End of Program F |
END OF SESSION 46 | |
Thursday, November 18, 2021
Print Entire 2020 Program:
|
|
SESSION 47 SCHEDULE | |
Thursday
SESSION 47:
EXCITING NEW OR REDISCOVERED TECHNIQUES, DEVICES OR CONCEPTS
Moderators:Frans L. Moll, MD, PhD / Frank J. Veith, MD
|
|
x | |
6:50 AM - 6:55 AM | Combating Bias In Medical And Vascular Studies And Therapeutic Decision Making: Why It Is Such A Big Deal And What To Do About It |
Presenter(s):Matthew T. Menard, MD | |
6:56 AM - 7:01 AM | Update On Remote Monitoring Of Vascular Grafts: Where Is It At And Where Is It Going |
Presenter(s):Richard F. Neville, MD | |
7:02 AM - 7:07 AM | New Wearable Technologies For Telemonitoring Vascular Diseases And Their Treatments: They Will Improve Care And Decrease Hospitalization And Office Visits |
Presenter(s):Celia Riga, MD, FRCS | |
7:08 AM - 7:13 AM | Value Of Digital Health In Vascular Disease Management: Virtual And Otherwise |
Presenter(s):Tony S. Das, MD | |
7:14 AM - 7:19 AM | Vascular Surgical Risks Of Shoulder Reconstructive Surgery: What Are They And How Should They Be Managed |
Presenter(s):Jacques Busquet, MD | |
7:20 AM - 7:25 AM | Why Carotid Plaque Morphology Differ In Patients With An Acute MI And Those With Intermittent Claudication: Why It Matters |
Presenter(s):Henrik Sillesen, MD, DMSc | |
7:26 AM - 7:31 AM | Panel Discussion |
7:31 AM - 7:36 AM | Relining Occluded Vein Grafts With Viabahn (Gore) Stent-Grafts Or Supera (Abbott) Bare Stents Can Restore Patency And Avoid Thrombolysis: Techniques And Results |
Presenter(s):Hans Lindgren, MD, PhD | |
7:37 AM - 7:42 AM | Measuring Aortic Diameters Is Inaccurate And Subjective: Even With Newer Imaging Technology, One Can Make The Diameter What You Want: What Are The Implications |
Presenter(s):Janet T. Powell, MD, PhD | |
7:43 AM - 7:48 AM | The Temporary Perfuse Dual Chamber Stent-Graft For Clamp Free Aortic Surgery, Drug Delivery And Other Uses: How Does It Work |
Presenter(s):Bryan W. Tillman, MD, PhD | |
7:49 AM - 7:54 AM | Provider Skill Is Not Getting Appropriate Attention In The Health Care Value Equation Of Value = Outcome/Cost: What To Do About It |
Presenter(s):Lars B. Lonn, MD, PhD | |
7:55 AM - 8:00 AM | Effect Of Increased Hydration And Protein Intake On Lower Extremity Arteriosclerotic Ischemia With IC And CLTI: What Is the Evidence And The Mechanism: Will It Change The Game And Decrease The Need For Stents And Bypasses |
Presenter(s):Juan C. Parodi, MD | |
8:01 AM - 8:06 AM | Update On Isolated Limb Perfusion To Enable Amputated Limb Reimplantation |
Presenter(s):Zachary M. Arthurs, MD | |
8:07 AM - 8:12 AM | Panel Discussion |
END OF SESSION 47 | |
SESSION 48 SCHEDULE | |
Thursday
SESSION 48:
PROGRESS IN FENESTRATED AND BRANCHED EVAR (F/B/EVAR) AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS
Moderators:James F. McKinsey, MD / Timothy A.M. Chuter, DM
|
|
x | |
8:12 AM - 8:17 AM | Lower Extremity Ischemic Complications After F/B/EVAR: Etiology And How To Avoid Them |
Presenter(s):Thomas S. Maldonado, MD | |
8:18 AM - 8:23 AM | F/B/EVAR Treatment Of FAILED EVAR: A Safer Better Way To Treat: How Has The Aortic Research Consortium Helped To Promote Solutions To This And Other Problems |
Presenter(s):Andres Schanzer, MD | |
8:24 AM - 8:29 AM | When Is Ch/EVAR Indicated And Equally Effective To F/EVAR For Juxta And Pararenal AAAs In Terms Of Outcomes And Cost: Why Are Opinions On Ch/EVAR So Divergent |
Presenter(s):Konstantinos P. Donas, MD | |
8:30 AM - 8:35 AM | Status Of Automated Planning Software For F/EVAR Endografts From Aortica (Terumo Aortic): Design Features And Advantages Of A F/EVAR Dedicated Bridging Stent-Graft |
Presenter(s):Benjamin W. Starnes, MD | |
8:36 AM - 8:41 AM | Mortality From Aneurysm Rupture While Waiting For A Customized F/B/EVAR Endograft: Strategy To Prevent: Are There Reasons For Open Repairs In A High Volume F/B/EVAR Center |
Presenter(s):Eric L.G. Verhoeven, MD, PhD | |
8:42 AM - 8:47 AM | Why Balloon Expandable Bridging Stent-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A US Perspective |
Presenter(s):Mark A. Farber, MD | |
8:48 AM - 8:53 AM | Why Balloon Expandable Bridging Stents-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A European Perspective |
Presenter(s):Mauro Gargiulo, MD | |
8:54 AM - 8:59 AM | What Is The Best Bridging Covered Stent (Stent-Graft) For F/B/EVAR Based On An In Vitro Fatigue Testing Model And Other Considerations |
Presenter(s):Martin J. Austermann, MD | |
9:00 AM - 9:05 AM | With Complex AAAs, When F/B/EVAR; When Parallel Grafts; When Open Repair: All Have Their Pros And Cons |
Presenter(s):Chang Shu, MD | |
9:06 AM - 9:11 AM | Technical Tips For F/B/EVAR Repairs Of TAAAs Complicating TBADs |
Presenter(s):Götz M. Richter, MD, PhD | |
9:12 AM - 9:17 AM | How To Safely And Effectively Treat TAAAs With Off-The-Shelf (OTS) Devices Including Chimney And Sandwich Stent-Grafts: The Docking Station Approach: How To Do It And Midterm Results |
Presenter(s):Manish Mehta, MD, MPH | |
9:18 AM - 9:26 AM | Panel Discussion |
9:26 AM - 9:38 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 48 | |
SESSION 49 SCHEDULE | |
Thursday
SESSION 49:
MORE PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS
Moderators:Gustavo S. Oderich, MD, FACS / Frank J. Veith, MD
|
|
x | |
9:38 AM - 9:43 AM | Percutaneous Femoral And Axillary Access For Complex Endovascular AAA Repair: How To Safely Do It Safely And To Downsize Femoral Sheaths To Restore Lower Extremity Flow |
Presenter(s):Darren B. Schneider, MD | |
9:44 AM - 9:49 AM | Present Status Of Parallel Grafts For Complex AAAs And TAAAs: How To Do These Repairs Safely And Effectively: Results To Date |
Presenter(s):Armando C. Lobato, MD, PhD | |
9:50 AM - 9:55 AM | Value And Advantages Of Preloaded Wires And Catheters For F/B/EVAR: How Do They Work; Are There Pitfalls |
Presenter(s):Mark A. Farber, MD | |
9:56 AM - 10:01 AM | DEBATE: The Case Against Ch/EVAR And Parallel Grafts For Complex AAA And TAAA Repairs: F/B/EVAR Is Much Better |
Presenter(s):Adam Beck, MD | |
10:02 AM - 10:07 AM | DEBATE: Nonsense! Ch/EVAR And Parallel Grafts If Done Right Are As Safe And Effective As F/B/EVAR And In Some Cases Better And Cheaper |
Presenter(s):Edward Y. Woo, MD | |
10:08 AM - 10:13 AM | F/EVAR Is Sometimes Justified In Patients >80: How About >90 |
Presenter(s):Clark J. Zeebregts, MD, PhD | |
10:14 AM - 10:19 AM | DEBATE: Increasing The Number Of Fenestrations In F/EVAR Beyond 2 Improves Outcomes Without Increasing Downsides |
Presenter(s):Eric L.G. Verhoeven, MD, PhD | |
10:20 AM - 10:25 AM | DEBATE: Not So! 2 Branch F/EVAR Is Sometimes Better And Has Fewer Complications And Downsides In Some Cases: Which Ones |
Presenter(s):Timothy A. Resch, MD, PhD | |
10:26 AM - 10:31 AM | Technical Tips To Deploy F/EVAR Endografts Precisely With Tortuous Anatomy: How To Compensate For Endograft Rotation And Still Match Fenestrations To Branch Orifices Perfectly |
Presenter(s):Bjõrn Sonesson, MD, PhD | |
10:32 AM - 10:37 AM | Advantages Of Steerable (Variable Curve) Sheaths For Complex AAA And TAAA Repairs And TBADs: Which One Is Best And Why: Pitfalls And How To Prevent Them |
Presenter(s):W. Anthony Lee, MD | |
10:38 AM - 10:43 AM | Technical Tips And Precautions For Using Steerable (Variable Curve) Sheaths For B/EVAR: Why They May Not Work And How To Make Them Work |
Presenter(s):Geert Willem H. Schurink, MD, PhD | |
10:44 AM - 10:52 AM | Panel Discussion |
END OF SESSION 49 | |
SESSION 50 SCHEDULE | |
Thursday
SESSION 50:
A TRIBUTE TO OUR MILITARY AND MILITARY PHYSICIANS: SOME MILITARY HISTORY; TREATMENT OF MILITARY AND CIVILIAN VASCULAR INJURIES AND CONTROL OF HEMORRHAGE; INNOVATIVE TECHNOLOGIES SUPPORTED BY THE DEFENSE DEPARTMENT
Moderators:Eric A. Elster, MD / Todd E. Rasmussen, MD, FACS
|
|
x | |
10:52 AM - 11:03 AM | The Vietnam Battle Of Ia Drang (November 14-16, 1965): Why Was It Fought And Why Was It Significant (11-Minute Talk) |
Presenter(s):Wayne F. Yakes, MD | |
11:04 AM - 11:09 AM | Department of Defense Effort To Support Vascular Surgery Research And US National Preparedness For Mass Casualties |
Presenter(s):Todd E. Rasmussen, MD, FACS | |
11:10 AM - 11:15 AM | Update On Endovascular Resuscitation And Control Of Bleeding: What Is New And Different: What Is The EVTM Society |
Presenter(s):Tal M. Hörer, MD, PhD | |
11:16 AM - 11:21 AM | Update On Civilian REBOA (Resuscitative Endovascular Balloon Occlusion Of The Aorta) For Treatment Of Hemorrhage And Trauma: What Is New And Different: When And Where Should It Be Used And By Whom |
Presenter(s):Joseph J. DuBose, MD | |
11:22 AM - 11:27 AM | Is REBOA A Panacea For Battlefield Hemorrhage Or Not Yet Ready For Prime Time Use |
Presenter(s):Brandon Propper, MD / Zachary M. Arthurs, MD / Todd E. Rasmussen, MD, FACS | |
11:28 AM - 11:33 AM | Current Advances In The Treatment Of Blast And High Velocity Gun Shot Injuries |
Presenter(s):Paul W. White, MD | |
11:34 AM - 11:39 AM | Update On The Retrievable Rescue Stent Graft To Control Massive Aortic Or Caval Bleeding: How Does It Work And Present Status |
Presenter(s):Bryan W. Tillman, MD, PhD | |
11:40 AM - 11:45 AM | Major Amputation Prosthetics Can Be Fixed Into Bone: How Does Osteointegration Work And How Is Infection Avoided |
Presenter(s):Zachary M. Arthurs, MD / Todd E. Rasmussen, MD, FACS | |
11:46 AM - 11:51 AM | Update On Tissue Engineered Biological Arterial Grafts (Humacyte): How Well Are They Working In Patients And In What Vascular Bed |
Presenter(s):Jeffrey H. Lawson, MD, PhD | |
11:52 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 50 | |
SESSION 51 SCHEDULE | |
Thursday
SESSION 51:
PROGRESS IN THE TREATMENT OF RUPTURED INFRARENAL AAAs, COMPLEX AAAs, TAAAs AND RELATED TOPICS
|
|
x | |
1:00 PM - 1:05 PM | Value, Limitations And Technical Tips For Using The Nellix Endograft For Ruptured AAAs |
Presenter(s):Tal M. Hörer, MD, PhD | |
1:06 PM - 1:11 PM | The Incidence Of Ruptured AAAs Is Decreasing And So Is Their Mortality: Why Are These 2 Facts So |
Presenter(s):Ross Milner, MD | |
1:12 PM - 1:17 PM | Statins Decrease The Growth Rate And Rupture Risk Of AAAs As Well As The Perioperative Mortality: Who Should Receive Them, When And At What Dose |
Presenter(s):Thomas L. Forbes, MD | |
1:18 PM - 1:23 PM | Impact Of Weekends On Treatment Method (Endo Versus Open Repair) And Outcomes (Early And Late) Of Treatment For Ruptured AAAs |
Presenter(s):Sebastian E. Debus, MD, PhD | |
1:24 PM - 1:29 PM | Long-Term Results Of The AJAX RCT Comparing EVAR With Open Repair For Ruptured AAAs: EVAR Wins In The End – Especially In Patients >80 |
Presenter(s):Willem Wisselink, MD | |
1:30 PM - 1:35 PM | Variation In Use Of EVAR Versus Open Repair For Ruptured AAAs Depends On Training And Bias Rather Than Data Logic Or Facts: EVAR Is Clearly The Best Treatment If It Can Be Done |
Presenter(s):Martin Malina, MD, PhD | |
1:36 PM - 1:41 PM | EVAR Should Be The Standard Of Care For Most Ruptured AAAs: Reasons Why It Is Not So And How To Overcome Them |
Presenter(s):Hans-Henning Eckstein, MD, PhD | |
1:42 PM - 1:47 PM | EVAR Is A Better Treatment For Ruptured AAAs Than Open Repair In Most Patients: The Mortality Benefit Of EVAR Is Increasing More Recently: Based On A Meta-Analysis |
Presenter(s):George A. Antoniou, MD, PhD, MSc, FEBVS | |
1:48 PM - 1:53 PM | DEBATE: With Ruptured Complex AAAs And TAAAs, Off-The-Shelf F/B/EVAR Is The Best Treatment |
Presenter(s):Mark A. Farber, MD | |
1:54 PM - 1:59 PM | DEBATE: Not So: With Ruptured Complex AAAs And TAAAs Parallel Grafts Are Simpler, More Effective And Less Costly |
Presenter(s):Konstantinos P. Donas, MD | |
2:00 PM - 2:06 PM | Panel Discussion |
END OF SESSION 51 | |
SESSION 52 SCHEDULE | |
Thursday
SESSION 52:
MORE NEW DEVELOPMENTS IN RUPTURED AAAs AND TAAAs; WHAT IS AND SHOULD BE HAPPENING WITH AAA SCREENING
Moderators:Keith D. Calligaro, MD / Manish Mehta, MD, MPH
|
|
x | |
NEW DEVELOPMENTS IN AAA SCREENING | |
2:06 PM - 2:11 PM | Why The Current US PSTF Guidelines For AAA Screening Are Insufficient: Many At Risk Patients Are Not Screened |
Presenter(s):Malachi Sheahan, MD | |
2:12 PM - 2:17 PM | Update On Current Screening For AAAs In The US: Most Ruptured AAAs Occur In Patients Not Being Screened: How Should US PSTF Recommendations Be Changed |
Presenter(s):Marc L. Schermerhorn, MD | |
2:18 PM - 2:23 PM | Flaws In AAA Screening In Finland Result In AAA Ruptures In Patients Too Young For Screening And Whose AAAs Are Too Small To Reach Threshold For Repair |
Presenter(s):Maarit Venermo, MD, PhD | |
2:24 PM - 2:29 PM | Why AAA Screening Should Be Expanded To More Females, Younger Men And Older Men |
Presenter(s):Thomas F.X. O'Donnell, MD | |
MORE ABOUT AAA RUPTURES AND THEIR TREATMENT | |
2:30 PM - 2:35 PM | AAA Rupture After EVAR Behaves Differently From De Novo Rupture: How Should Treatment Be Modified In Patients With Post EVAR Ruptures |
Presenter(s):Piotr Szopinski, MD, PhD | |
2:36 PM - 2:41 PM | Update On Treating All (100%) Ruptured AAAs With EVAR: The Orebro Experience Shows It Is The Best Treatment And Lowers The Turndown Rate |
Presenter(s):Thomas Larzon, MD, PhD / Mario L. Lachat, MD / Zoran Rancic, MD, PhD / Tal M. Hörer, MD, PhD | |
2:42 PM - 2:47 PM | Experience With Cook t-Branched OTS Endograft To Treat Ruptured Pararenal AAAs And TAAAs: Advantages, Limitations And Results |
Presenter(s):Ciro Ferrer, MD, PhD / Rocco Giudice, MD | |
2:48 PM - 2:53 PM | In Situ Laser Fenestration To Facilitate Endograft Treatment Of Ruptured TAAAs: When Is It Needed; How To Do It And Results |
Presenter(s):Stephan Haulon, MD / Dominique Fabre, MD, PhD | |
2:54 PM - 2:59 PM | Open Repair For AAAs Should Not Be Used In Patients >80 Unless Their AAA Is >6 cm And They Are At Risk Of Rupture Or Ruptured: These Restrictions Do Not Apply To EVAR |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
3:00 PM - 3:05 PM | Emergency Treatment Of Aortic Rupture From Chronic TBAD Using The Candy Plug Technique: Technical Tips And Results |
Presenter(s):Andrej Schmidt, MD / Daniela Branzan, MD | |
3:06 PM - 3:11 PM | Update On Advances In Treatment Of Abdominal Compartment Syndrome Associated With Ruptured AAAs: When And How To Treat Medically And When And How To Treat With Opening The Abdomen |
Presenter(s):Martin Bjorck, MD, PhD | |
3:12 PM - 3:20 PM | Panel Discussion |
3:20 PM - 3:30 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 52 | |
SESSION 53 SCHEDULE | |
Thursday
SESSION 53:
EXCITING NEW OR UPDATED CONCEPTS, TECHNIQUES AND TREATMENTS
Moderators:Nicholas J.W. Cheshire, MD / Reese A. Wain, MD
|
|
x | |
3:30 PM - 3:35 PM | The No Intervention Option For Treatment Is More Commonly Elected For Women Than Men With CLTI, AAAs, Ruptured AAAs And Thoracic Aneurysms: It Is Wrong Headed And Unfair |
Presenter(s):Janet T. Powell, MD, PhD | |
3:36 PM - 3:41 PM | Transradial Approaches For Complex Lower Extremity Interventions: CTSOs, Iliac, Fempop And BTK Lesions Can Be Treated: How To Make Them Work And Precautions: Advantages Of The Terumo R2P System |
Presenter(s):David O'Connor, MD | |
3:42 PM - 3:47 PM | New Endovascular Treatments For Pulsatile Tinnitus: What Are The Options |
Presenter(s):Athos Patsalides, MD, MPH | |
3:48 PM - 3:53 PM | The Spur Stent System (Reflow Medical): A Temporary Stent With Pins To Penetrate The Arterial Wall And Facilitate DCB Drug Delivery: How Does It Work And Results To Date |
Presenter(s):Gunnar Tepe, MD / Marianne Brodmann, MD / Andrew Holden, MBChB / Thomas Zeller, MD | |
3:54 PM - 3:59 PM | The Serrenator Balloon Catheter (From Cagent Vascular) For Vessel Prep In BTK Arteries: It Makes Microserrations And Prevents Dissections With PTA: Current Status: The PRELUDER Trial |
Presenter(s):Andrew Holden, MBChB | |
4:00 PM - 4:05 PM | What Is The OR Black Box System For Measuring Endovascular Operator Performance: How Does It Work And Should It Be In Every Hybrid Angio Suite |
Presenter(s):Isabelle van Herzeele, MD, PhD | |
4:06 PM - 4:11 PM | Update On A Clampless Sutureless Technique For Performing Aorto-Iliac Anastomosis Using Endograft Connectors: The VORTEC Technique – Useful When Arterial Control And Suturing Is Impossible |
Presenter(s):Mario L. Lachat, MD | |
4:12 PM - 4:17 PM | Technical Tips For Safe Endovascular Treatment Of Hepatic Artery Stenosis After Liver Transplantation |
Presenter(s):W. Charles Sternbergh III, MD | |
4:18 PM - 4:23 PM | Current Status Of Left Gastric Embolization To Treat Obesity: Where Is It And What Will Its Role Be |
Presenter(s):Robert E. Beasley, MD, FSIR, FSCAI | |
4:24 PM - 4:29 PM | The Many Possible Uses Of Femoral Veins For Arterial Procedures: How To Harvest Them Safely |
Presenter(s):Timur P. Sarac, MD | |
4:30 PM - 4:38 PM | Panel Discussion |
END OF SESSION 53 | |
SESSION 54 SCHEDULE | |
Thursday
SESSION 54:
PROGRESS IN RADIATION SAFETY AND MORE NEW CONCEPTS, DEVICES AND TECHNIQUES
|
|
x | |
PROGRESS IN RADIATION SAFETY | |
4:38 PM - 4:43 PM | Endovascular Team Radiation Safety Performance: How To Monitor It: It Is More Than Dose Measurement |
Presenter(s):Isabelle van Herzeele, MD, PhD | |
4:44 PM - 4:49 PM | Myths And Facts Regarding Radiation Protection And Safety |
Presenter(s):Lindsay Machan, MD | |
4:50 PM - 4:55 PM | New ESVS Radiation Safety Guidelines: Why Are They Needed And How Will They Be Helpful |
Presenter(s):Bijan Modarai, PhD, FRCS | |
4:56 PM - 5:01 PM | Simple Radiation Protection Techniques For All Interventionalists To Use |
Presenter(s):Ripal T. Gandhi, MD, FSVM, FSIR | |
5:02 PM - 5:05 PM | Panel Discussion |
NEW CONCEPTS, ETC. | |
5:05 PM - 5:10 PM | With Esophageal Cancer, When Is Prophylactic TEVAR Indicated To Prevent An Aorto-Esophageal Fistula |
Presenter(s):I-Hui Wu, MD, PhD | |
5:11 PM - 5:16 PM | Endovascular Emergency Treatment Of Carotid Blowout From Head And Neck Cancer Or Carotid Patch Infections: Planning, Preparation And Technical Tips Are Essential |
Presenter(s):Michael B. Silva, Jr., MD | |
5:17 PM - 5:22 PM | Value Of Repetitive Digital Photo Documentation Of The Ischemic Foot: It Improves Decisions And Outcomes |
Presenter(s):Martin Malina, MD, PhD | |
5:23 PM - 5:28 PM | Minimizing Contrast Induced Nephropathy With EVAR By Contrast Dilution |
Presenter(s):Naoki Fujimura, MD, PhD | |
5:29 PM - 5:34 PM | What Is The Cut Needle: How Does It Work And Why Does It Facilitate Difficult Vascular Access: Clinical Experience And Cost |
Presenter(s):Vicente Riambau, MD, PhD | |
5:35 PM - 5:40 PM | Current Status Of AFX-3 And Ovation (With Anatomy Adaptive Sealing) Endografts (Both From Endologix) For AAA Repairs: Advantages And Limitations Of Each |
Presenter(s):Francesco Speziale, MD | |
5:41 PM - 5:46 PM | TBD |
5:47 PM - 5:54 PM | Panel Discussion End of Program G |
END OF SESSION 54 | |
SESSION 55 SCHEDULE | |
Thursday
SESSION 55:
NEW OR IMPROVED DEVICES FOR INFRARENAL AAA REPAIR WITH STANDARD EVAR (5-MINUTE TALKS)
Moderators:Wesley S. Moore, MD / Juan C. Parodi, MD
|
|
x | |
6:50 AM - 6:55 AM | Treo Endograft (From Terumo Aortic) For Standard Infrarenal EVAR: Characteristics, Advantages And Status Of US IDE |
Presenter(s):Matthew J. Eagleton, MD | |
6:56 AM - 7:01 AM | Value Of Treo Endograft (From Terumo Aortic)) In Highly Angled Necks: What Makes It Different And Results |
Presenter(s):Vicente Riambau, MD, PhD | |
7:02 AM - 7:07 AM | Status In The US Of The Gore Conformable Excluder With Variable Neck Angulation Control For AAAs With Imperfect Necks |
Presenter(s):Robert Y. Rhee, MD | |
7:08 AM - 7:13 AM | Status Of The Gore Conformable Excluder For EVAR In Europe: Results From The EXCEL And BSET Registries |
Presenter(s):Marc R.H.M. van Sambeek, MD, PhD / Colin D. Bicknell, MD, FRCS | |
7:14 AM - 7:19 AM | When Does The Gore Conformable Excluder For EVAR Really Make A Difference: How Does It Work |
Presenter(s):Michael P. Jenkins, MBBS, BSc, MS, FRCS, FEBVS | |
7:20 AM - 7:25 AM | Altura Endograft With Kissing Proximal Stents For Standard EVAR: Advantages And Limitations: From An Experience With 150 Patients And Up To 5-Year Follow-Up |
Presenter(s):Dainis K. Krievins, MD | |
7:26 AM - 7:31 AM | Advantages And Limitations Of The Cook ZENITH Alpha Endograft For EVAR: Based On European Multicenter Experience |
Presenter(s):Marc R.H.M. van Sambeek, MD, PhD / Philippe W.M. Cuypers, MD, PhD | |
7:32 AM - 7:38 AM | Panel Discussion |
7:38 AM - 7:43 AM | How And Why Do The Endurant Endograft Results For EVAR In France Differ From The Global Results: What Are The Implications |
Presenter(s):Jean-Pierre Becquemin, MD, FRCS | |
7:44 AM - 7:49 AM | AAA Repairs With The Endurant Endograft Outside The IFU Can Provide Acceptable Results In Some Patients: When Is This So And When Not |
Presenter(s):Marc R.H.M. van Sambeek, MD, PhD | |
7:50 AM - 7:55 AM | Head To Head Comparison Of Endurant And Excluder Endografts For EVAR In Challenging Asian AAA Anatomy |
Presenter(s):Naoki Fujimura, MD, PhD | |
7:56 AM - 8:01 AM | Update LEOPARD RCT Results Show That AFX Endografts Compare Favorably To Standard Proximally Fixed Endografts For AAA Repair |
Presenter(s):Christopher J. Kwolek, MD, MBA | |
8:02 AM - 8:07 AM | AFX Endografts Work Well In Conical (Flared) AAA Necks: Why And Results |
Presenter(s):Naoki Fujimura, MD, PhD | |
8:08 AM - 8:14 AM | Panel Discussion |
END OF SESSION 55 | |
SESSION 56 SCHEDULE | |
Thursday
SESSION 56:
NEW OR UPDATED DEVICES FOR STANDARD EVAR, EVAS (ENDOVASCULAR ANEURYSM SEALING) AND F/EVAR
Moderators:Jerry Goldstone, MD, FACS, FRCSEd / Ramon Berguer, MD, PhD
|
|
x | |
8:14 AM - 8:19 AM | Alto Endograft (From Endologix) For Standard EVAR: This Latest Modification Of The Ovation Endograft Has More Proximal Polymer Sealing Rings: Results From The ELEVATE Trial And 3-4-Year Results From The New Zealand Experience Show Advantages |
Presenter(s):Sean P. Lyden, MD / Andrew Holden, MBChB | |
8:20 AM - 8:25 AM | Combination Of Ovation Endograft And Bare Metal Renal Stent For Difficult AAA Neck Unsuitable For F/EVAR |
Presenter(s):Gianmarco de Donato, MD | |
8:26 AM - 8:31 AM | Experience With The Nellix Endograft In 120 Patients With Up To 10 Years Follow-Up: What Is The Devices’ Future |
Presenter(s):Dainis K. Krievins, MD | |
8:32 AM - 8:37 AM | Current Status And Value Of Chimney EVAS (Ch/EVAS): From The ASCEND Trial Data: Status Of The CHEVAS ONE IDE Trial Of Ch/EVAS In Complex AAA Repairs |
Presenter(s):Joseph V. Lombardi, MD / Pete Holt, MD, PhD / Ian Loftus, MD / Michel M.P. Reijnen, MD, PhD | |
8:38 AM - 8:43 AM | Comparison Of Ch/EVAS And Ch/EVAR: When Is Ch/EVAS Indicated: Advantages And Limitations |
Presenter(s):Barend M.E. Mees, MD, PhD | |
8:44 AM - 8:49 AM | Update On Multicenter Results With F/EVAR Using The Fenestrated Anaconda Endograft: From The Global FACT Registry: Advantages And Limitations |
Presenter(s):Clark J. Zeebregts, MD, PhD / Michel M.P. Reijnen, MD, PhD | |
8:50 AM - 8:55 AM | Value Of The Fenestrated Anaconda Endograft For Treating Failed EVAR |
Presenter(s):Afshin Assadian, MD | |
8:56 AM - 9:01 AM | Update On The Incraft Endograft For Standard Infrarenal EVAR: Is Its Low Profile An Advantage |
Presenter(s):Matteo Orrico, MD / Nicola Mangialardi, MD | |
9:02 AM - 9:07 AM | Long-Term Outcomes Of The Cook pBranch OTS Device For F/EVAR: Advantages And Limitations |
Presenter(s):Timothy A. Resch, MD, PhD | |
9:08 AM - 9:15 AM | Panel Discussion |
9:15 AM - 9:26 AM | Break – Visit Pavilions And Exhibits (2nd and 3rd Floors) |
END OF SESSION 56 | |
SESSION 57 SCHEDULE | |
Thursday
SESSION 57:
NEW OR IMPROVED DEVICES FOR THE ASCENDING AORTA, THE AORTIC ARCH OR NEAR THE ARCH
Moderators:Michel Makaroun, MD / Rodney A. White, MD
|
|
x | |
9:26 AM - 9:31 AM | Nexus OTS Endograft From Endospan For Treating Zone 1 Lesions Of The Aortic Arch: How Does It Work And 2-Year Clinical Results: Status In The US |
Presenter(s):Andrew Holden, MBChB / Daniel G. Clair, MD | |
9:32 AM - 9:37 AM | Update On The Status Of The Custom Relay Branch Endograft (Terumo Aortic) For Arch TEVAR: The European Experience: What Are The Advantages For Deployment, Apposition And Sealing |
Presenter(s):Vicente Riambau, MD, PhD / Afshin Assadian, MD / Mo S. Hamady, MD, FRCR, EBIR, FSIR | |
9:38 AM - 9:43 AM | Status In The US Of The RelayBranch Investigational Device For Repair Of Aortic Arch Lesions: How Many Branches Can And Should Be Revascularized: Advantages And Limitations |
Presenter(s):Luis A. Sanchez, MD / Eric E. Roselli, MD | |
9:44 AM - 9:49 AM | Long-Term Safety And Durable Effectiveness Of Relay (Terumo Aortic) Scalloped Endograft For TEVAR Treatment Of Lesions In Or Near The Aortic Arch |
Presenter(s):Mo S. Hamady, MD, FRCR, EBIR, FSIR / Jean-Marc Alsac, MD, PhD | |
9:50 AM - 9:55 AM | Status In The US Of The Gore Conformable CTAG Endograft With Variable Angulation Control In The Aortic Arch: How Does It Work And Advantages |
Presenter(s):Jean Bismuth, MD | |
9:56 AM - 10:01 AM | When And How To Use The Gore Conformable CTAG Endograft Optimally: Are There Downsides |
Presenter(s):Sukgu Han, MD | |
10:02 AM - 10:07 AM | Indications, Value And Limitations Of Single Branched TEVAR Devices For Revascularizing The Left Subclavian Artery: Are They Worth The Effort And Cost |
Presenter(s):Gustavo S. Oderich, MD, FACS | |
10:08 AM - 10:15 AM | Panel Discussion |
END OF SESSION 57 | |
SESSION 58 SCHEDULE | |
Thursday
SESSION 58:
NEW OR IMPROVED DEVICES FOR THORACIC AORTIC LESION REPAIRS (TEVAR) AND FOR THORACOABDOMINAL ANEURYSM (TAAA) REPAIRS (ALL TALKS ARE 4 ¾-MINUTES)
Moderators:Giovanni B. Torsello, MD / James F. McKinsey, MD
|
|
x | |
DEVICES FOR TEVAR | |
10:15 AM - 10:20 AM | Low Profile Devices for TEVAR: Advantages And Disadvantages Based On Long-Term Results |
Presenter(s):Giovanni B. Torsello, MD | |
10:20 AM - 10:25 AM | 6-Year Experience With The Cook ZENITH Alpha Thoracic Endograft For TEVAR In 400 Patients: How To Achieve Long-Term Durably Good Results |
Presenter(s):Germano Melissano, MD / Roberto Chiesa, MD | |
10:25 AM - 10:30 AM | Current Status Of Valiant Nation Low Profile Endograft For TEVAR: Features And Advantages |
Presenter(s):Ali Azizzadeh, MD | |
10:30 AM - 10:35 AM | Value Of Valiant Navion Endograft For TEVAR In Fragile Aortas: Why It Is Better |
Presenter(s):Ross Milner, MD | |
10:35 AM - 10:40 AM | Real World Results, Advantages And Limitations Of The Valiant Navion Endograft For TEVAR From A Multicenter Study |
Presenter(s):Giovanni G.T. Tinelli, MD, PhD / Yamume Tshomba, MD | |
10:40 AM - 10:46 AM | Panel Discussion |
10:46 AM - 10:51 AM | The Relay Pro (Terumo Aortic) Endograft For TEVAR And Its Advantages In Treating TBADs: Why Is It Better Than The Older Relay Plus Device |
Presenter(s):Edward Y. Woo, MD | |
10:51 AM - 10:56 AM | Patient Specific Custom Designed Relay Pro Endografts (Terumo Aortic): How Do They Work And What Are Their Advantages In Various Circumstances |
Presenter(s):David M. Williams, MD | |
10:56 AM - 11:01 AM | Relay Endografts (Terumo Aortic) For TEVAR: Why Do They Provide Better Wall Apposition For Sealing |
Presenter(s):Afshin Assadian, MD | |
11:01 AM - 11:06 AM | European Experience With The Gore CTAG Conformable Endograft For TEVAR With Variable Angulation Control Proximally: When And How Does It Improve Results |
Presenter(s):Vicente Riambau, MD, PhD | |
11:06 AM - 11:11 AM | New Polymer Filled Low Profile Endograft Device With O-Ring Sealing: How Does It Work And Why Is It Better |
Presenter(s):Piotr Szopinski, MD, PhD | |
11:11 AM - 11:17 AM | Panel Discussion |
NEW OR IMPROVED ENDO DEVICES FOR TAAA REPAIRS | |
11:17 AM - 11:22 AM | To Treat Complex TAAAs A Combination Of A Relay (Terumo Aortic) TEVAR And A Fenestrated Anaconda Is Best: How Are The SMA And Celiac Axis Revascularized |
Presenter(s):Mo S. Hamady, MD, FRCR, EBIR, FSIR | |
11:22 AM - 11:27 AM | Status Of The Cook t-Branch OTS Endograft For TAAA Repairs: Advantages And Limitations Based On A Meta-Analysis |
Presenter(s):Nikolaos Tsilimparis, MD; PhD | |
11:27 AM - 11:32 AM | Experience With The Cook t-Branch OTS Endograft Device For Juxta- And Pararenal AAAs: Advantages And Limitations |
Presenter(s):Matteo Orrico, MD / Nicola Mangialardi, MD | |
11:32 AM - 11:37 AM | Comparison Of 3 OTS Endografts For Urgent TAAA Repairs: TAMBE (Gore) Versus E-nside (Jotec) Versus t-Branch (Cook): Advantages And Disadvantages Of Each |
Presenter(s):Luca Bertoglio, MD / Germano Melissano, MD / Roberto Chiesa, MD | |
11:37 AM - 11:42 AM | Valiant Manifold OTS Endograft (Medtronic) Device For Repairing TAAAs: How Does It Work And Early Clinical Experience In The US |
Presenter(s):Murray L. Shames, MD | |
11:42 AM - 11:47 AM | Unitary Manifold Endograft System For Complex Type 4 TAAAs And Failed EVARs: How Does It Work And 2-Year Results |
Presenter(s):Patrick W. Kelly, MD | |
11:47 AM - 11:52 AM | Novel OTS Life Tech Endograft For TAAA Repair: How Does It Work And What Makes It Different |
Presenter(s):Ralf R. Kolvenbach, MD | |
11:52 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 58 | |
SESSION 59 SCHEDULE | |
Thursday
SESSION 59:
NEW OR UPDATED INFORMATION ON BALLOON EXPANDABLE COVERED STENTS, LOWER EXTREMITY PROSTHETIC GRAFTS, BIORESORBABLE GRAFTS, PERIGRAFT SEROMA AND VALUE OF A PROSTHETIC PERIGRAFT SIROLIMUS PATCH [SEE ALSO SESSION 28] PATCH (ALL TALKS ARE 5 MINUTES)
Moderators:Ali F. AbuRahma, MD / Patrick J. Lamparello, MD
|
|
x | |
STENT-GRAFTS | |
1:00 PM - 1:05 PM | Why Are VBX Balloon Expandable Stent-Grafts (From Gore) Different And Better Than Other Covered Stents In Various Vascular Beds |
Presenter(s):James F. McKinsey, MD | |
1:06 PM - 1:11 PM | Safety Of MRI EarlyAfter Deployment Of Various Bridging Covered Stents In Complex AAA Repairs |
Presenter(s):Maria A. Ruffino, MD, EBIR | |
PROSTHETIC GRAFTS | |
1:12 PM - 1:17 PM | Final 3-Year Results Of The ZILVERPASS RCT Comparing Prosthetic PTFE Bypasses With Zilver PTX (Cook) Stents To Treat Long Fempop Lesions: Should Open Prosthetic Bypass Be Abandoned |
Presenter(s):Michel J. Bosiers, MD / Marc Bosiers, MD | |
1:18 PM - 1:23 PM | The 3DH Spiral Flow Prostheti Graft: Does It Prevent Neointimal Hyperplasia In Leg Bypasses Or A-V Access |
Presenter(s):Hosam F. El Sayed, MD | |
1:24 PM - 1:29 PM | Heparin Coated (Propaten) PTFE Grafts (Gore) Versus Autologous Vein Grafts For Bypasses To Targets Above And Below The Knee: Are The Heparin Coated Grafts Worth The Cost |
Presenter(s):David J. Dexter, MD | |
1:30 PM - 1:35 PM | Bioabsorbable Arterial Grafts (Xeltis Grafts): How Do They Work And What Is Their Potential |
Presenter(s):Frans L. Moll, MD, PhD | |
1:36 PM - 1:41 PM | Perigraft Seromas After PTFE Lower Extremity And Aortic Arterial Grafts: Frequency, Etiology And What To Do About Them |
Presenter(s):Jae S. Cho, MD | |
1:42 PM - 1:47 PM | Update On External Sirolimus Patch Wrap-Around For PTFE Graft Anastomoses: Do They Decrease Neointimal Hyperplasia |
Presenter(s):Sriram S. Iyer, MD, FACC | |
1:48 PM - 1:54 PM | Panel Discussion |
END OF SESSION 59 | |
SESSION 60 SCHEDULE | |
Thursday
SESSION 60:
NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ATHERECTOMY, STENTS, TACKS, ACCESSORIES, ETC. (SEE ALSO SESSIONS 23-27)
Moderators:Kenneth Ouriel, MD, MBA / Enrico Ascher, MD
|
|
x | |
ATHERECTOMY RELATED TOPICS | |
1:54 PM - 1:59 PM | Value Of Directional Or Rotational Atherectomy And DCBs With Complex Lesions And CLTI: Which Lesions And How Do We Know This Combination Helps |
Presenter(s):Venita Chandra, MD | |
2:00 PM - 2:05 PM | Value And Limitations Of 355 nm Auryon B-Laser™ (From AngioDynamics): It Enables Safe Crossing Of Difficult Lesions Not Crossed With A Guidewire: How Does It Work And Clinical Results |
Presenter(s):Luis R. Leon, MD, RVT, FACS | |
2:06 PM - 2:11 PM | Orbital And Laser Atherectomy: Indications, Advantages And Precautions With Above Knee BTK De Novo Lesions And ISR |
Presenter(s):Craig M. Walker, MD | |
2:12 PM - 2:17 PM | Value Of Atherectomy And DCBs: Interim Results Of The REALITY Trial |
Presenter(s):Brian G. DeRubertis, MD | |
ANCILLARY TECHNIQUES | |
2:18 PM - 2:23 PM | Value of Wingman Catheter (Reflow Medical) For Crossing Difficult Lesions: How Does It Work And Results |
Presenter(s):John R. Laird, MD | |
2:24 PM - 2:29 PM | Value of New Dedicated Special Tools And Devices To Facilitate Trans-Radial Access For Lower Extremity Lesion Treatments: How Far Distally Can It Be Effective |
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD | |
2:30 PM - 2:36 PM | Panel Discussion |
NEW INFORMATION ON STENTS | |
2:36 PM - 2:41 PM | Advantages Of Supera (Vasculomimetic – VMI) Stent For Complex Fempop Occlusive Lesions: Technical Tips: They Work Even In The Subintimal Position |
Presenter(s):Erwin Blessing, MD | |
2:42 PM - 2:47 PM | Value Of The Supera VMI Stent For Common Femoral Artery (CFA) Occlusive Lesions: Better Than Endarterectomy: 2-Year Results And Status Of The SUPERSURG RCT (Versus Open Surgery) |
Presenter(s):Koen R. Deloose, MD | |
2:48 PM - 2:53 PM | Value Of Multiloc Ministents To Treat Post Balloon Dissections: How Do They Work And How Do They Compare To Tacks |
Presenter(s):Thomas Zeller, MD | |
2:54 PM - 2:59 PM | Value And Advantages Of Eluvia DESs (Boston Scientific) For Lower Extremity Occlusive Lesions: When To Use Them And How To Optimize Their Results |
Presenter(s):Steven Kum, MD | |
3:00 PM - 3:05 PM | RCT Comparing A New Bare Metal Stent – Misago Versus Zilver PTX DESs For Fempop Lesions: 2-Year Results Of The BATTLE Trial: Misago Stents Can Be Deployed Via Radial Access |
Presenter(s):Yann Gouëffic, MD, PhD | |
3:06 PM - 3:12 PM | Panel Discussion |
3:12 PM - 3:24 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 60 | |
SESSION 61 SCHEDULE | |
Thursday
SESSION 61:
NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ANGIOPLASTY BALLOONS
Moderators:John R. Laird, MD / Thomas Zeller, MD
|
|
x | |
3:24 PM - 3:29 PM | Chocolate Touch DCBs (From TriReme Medical): How Do They Work, Advantages And Updated Clinical Results |
Presenter(s):Andrew Holden, MBChB | |
3:30 PM - 3:35 PM | Value Of High-Pressure Non-Compliant Balloons For BTK Arterial Lesion Treatment: Why They Work Better And Other Technical Tips |
Presenter(s):Steven Kum, MD | |
3:36 PM - 3:41 PM | Update On The TANGO Trial Using The Bullfrog Balloon Device (Mercator Medical Systems) To Inject Sirolimus Drug Into Lesion Wall Before Angioplasty: How Does It Work And Results |
Presenter(s):Ehrin Armstrong, MD | |
3:42 PM - 3:47 PM | Value Of The Passeo-18Lux DCB For Treating BTK Lesions With Or Without Bare Metal Stents |
Presenter(s):Gunnar Tepe, MD | |
3:48 PM - 3:53 PM | Unfavorable Balloon Wrap (Candy) Cause Dissections With Angioplasty: What Is The Mechanism: How Can It Be Recognized And Dissection Avoided: The Chocolate DCB Is One Way |
Presenter(s):Jos C. van den Berg, MD, PhD | |
3:54 PM - 3:59 PM | The Importance Of Dissection In Angioplasty Treatment Of BTK Lesions: How To Prevent And Treat Such Dissections: The Value Of Tacks (From Intact Vascular): How Do They Work |
Presenter(s):Andrew Holden, MBChB | |
4:00 PM - 4:05 PM | 12-Month Results Of TOBA II BTK Trial Of The Tack Device To Decrease Dissections With Balloon Angioplasty Of BTK Lesions Show Safety And 80% Patency |
Presenter(s):Patrick J. Geraghty, MD | |
4:06 PM - 4:12 PM | Panel Discussion |
END OF SESSION 61 | |
SESSION 62 SCHEDULE | |
Thursday
SESSION 62:
NEW OR IMPROVED DEVICES AND TECHNIQUES TO PREVENT OR TREAT ENDOLEAKS OR DEVICE MIGRATION: ENDOANCHORS, ETC.
Moderators:William D. Jordan Jr., MD / Jean-Paul de Vries, MD, PhD
|
|
x | |
4:12 PM - 4:17 PM | Prophylactic Endoanchors (Medtronic) With TEVAR For Complex Anatomy Improves Outcomes: Technical Tips For Their Use In TEVAR |
Presenter(s):Jean M. Panneton, MD | |
4:18 PM - 4:23 PM | New Developments From The ANCHOR Registry With Over 5 Years Of Follow-Up Show The Value Of Endoanchors When Used Prophylactically For Certain Indications Prevent Endoleaks And Migration: What Are Those Indications |
Presenter(s):William D. Jordan Jr., MD | |
4:24 PM - 4:29 PM | New Developments From The ANCHOR Registry With >5 Years Follow-Up Show That Endoanchors Can Be Used To Treat Endoleaks And Migration Effectively In Hostile Neck Anatomy: The Proof |
Presenter(s):Jean-Paul de Vries, MD, PhD | |
4:30 PM - 4:35 PM | Vesteck – The Next Generation Of Endoanchor Technology: How Does It Work And Where Does It Stand |
Presenter(s):David H. Deaton, MD, FACS | |
4:36 PM - 4:41 PM | Balloon Optimized Molding For Better Deployment And Sealing Of Ovation Alto Low Profile Endografts For EVAR: How To Do It And How It Helps Prevent Endoleaks and Migration |
Presenter(s):David J. Minion, MD | |
4:42 PM - 4:48 PM | Panel Discussion |
END OF SESSION 62 | |
SESSION 63 SCHEDULE | |
Thursday
SESSION 63:
NEW OR IMPROVED ENDOVASCULAR DEVICES FOR CLOT REMOVAL OR EMBOLIZATION (SEE ALSO SESSION 30)
Moderators:Claudio J. Schonholz, MD / James F. Benenati, MD
|
|
x | |
CLOT REMOVING DEVICES | |
4:48 PM - 4:53 PM | Percutaneous Embolectomy Or Thrombectomy With The Indigo System (From Penumbra): What Makes It Different, Technical Tips, Results And Limitations |
Presenter(s):David J. Dexter, MD | |
4:54 PM - 4:59 PM | Newer Pharmaco-Mechanical Endovascular Clot Removal Systems: When And Why Is Each Device Best To Use |
Presenter(s):Guillermo A. Escobar, MD | |
5:00 PM - 5:05 PM | Catheter Based Vacuum Assisted Thrombectomy For Acute Limb Ischemia: How Does It Work: Advantages And Limitations: From A Multicenter Study |
Presenter(s):Carlo Setacci, MD / Gianmarco de Donato, MD | |
VASCUAR OCCLUSIVE DEVICES | |
5:06 PM - 5:11 PM | Technical Tips For Effective Coil Embolization: Importance Of Dense Packing; Coils With Fibers Versus Plain Metal Coils; Value And Indications For Different Coils |
Presenter(s):James F. Benenati, MD / Constantino Pena, MD | |
5:12 PM - 5:17 PM | Why Ruby Coils, The Penumbra Occlusion Device (POD) And Packing Coils Have Different Uses And Why They Are Valuable And Cost Effective For Different Lesions: Technical Tips For Optimizing |
Presenter(s):Sean P. Lyden, MD | |
5:18 PM - 5:23 PM | Caterpillar™ Embolic Plug (From Bard): How Does It Work: Advantages And Clinical Results |
Presenter(s):Andrew Holden, MBChB | |
5:24 PM - 5:29 PM | How To Treat Type 1A Endoleaks With Ruby Coils: When Will They Work; When Will They Not: Technical Tips |
Presenter(s):Mazin Foteh , MD | |
5:30 PM - 5:35 PM | How To Insert Large Vessel Embolization Devices (PODs) Through Low Profile Access |
Presenter(s):Frank R. Arko, MD | |
5:36 PM - 5:44 PM | Panel Discussion End of Program H |
END OF SESSION 63 | |
SESSION 64 SCHEDULE | |
Thursday
SESSION 64:
VENOUS CLINICAL EXAMINATION AND HEMODYNAMICS
|
|
x | |
7:00 AM - 7:04 AM | Introduction To Veins At VEITH |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
7:05 AM - 7:10 AM | AVF CEAP Revision 2020 |
Presenter(s):Marc A. Passman, MD | |
7:11 AM - 7:16 AM | CEAP, VCSS, HASTI: Their Significance And How To Utilize |
Presenter(s):Lowell S. Kabnick, MD, RPhS, FACS, FAVLS | |
7:17 AM - 7:22 AM | Physiology Of Venous Return |
Presenter(s):Brajesh K. Lal, MD | |
7:23 AM - 7:28 AM | What Are The Causes Of Symptoms In CEAP C Zero Class Of Patients: Implications For Therapy |
Presenter(s):Andrew N. Nicolaides, MS, FRCS | |
7:29 AM - 7:34 AM | How To Measure DUS Venous Reflux Volume: Is It More Important Than Reflux Time |
Presenter(s):Sergio Gianesini, MD, PhD, FACS | |
7:35 AM - 7:40 AM | Status Of The Evidence For C2 Intervention |
Presenter(s):Peter Gloviczki, MD | |
7:41 AM - 7:46 AM | An Algorithm To Predict Disease Severity In C2 Patients |
Presenter(s):Mikel Sadek, MD | |
7:47 AM - 7:52 AM | Evidence Summary On The Pathophysiology Of Varicose Veins |
Presenter(s):Thomas W. Wakefield, MD | |
7:53 AM - 7:58 AM | CVD: A Clinical Approach Algorithm |
Presenter(s):Seshadri Raju, MD | |
7:59 AM - 8:04 AM | Understanding Venous Physiology Helps Guide Therapy |
Presenter(s):Fedor Lurie, MD, PhD | |
8:05 AM - 8:10 AM | Non-Venous Causes Of The Swollen Extremity |
Presenter(s):Andrea T. Obi, MD | |
8:11 AM - 8:16 AM | Quality Of Life Tools Reflect Disease Severity, But They Can Be Improved |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FACPh, F | |
8:17 AM - 8:22 AM | Panel Discussion |
END OF SESSION 64 | |
SESSION 65 SCHEDULE | |
Thursday
SESSION 65:
VENOUS IMAGING AND BIOLOGY
Moderators:Raghu Kolluri, MD / Joseph D. Raffetto, MD
|
|
x | |
8:23 AM - 8:28 AM | Identifying Reflux Pathways With Duplex Ultrasound Mapping |
Presenter(s):Neil M. Khilnani, MD | |
8:29 AM - 8:34 AM | Are They Venous Ulcers |
Presenter(s):Raghu Kolluri, MD | |
8:35 AM - 8:40 AM | Venous Consensus Project Update |
Presenter(s):Lawrence V. Hofmann, MD | |
8:41 AM - 8:46 AM | Ambulatory Venous Pressure, Air Plethysmography, And The Role Of Calf Venous Pump In Chronic Venous Disease |
Presenter(s):Seshadri Raju, MD | |
8:47 AM - 8:52 AM | Role Of Foot Static Disorders In Chronic Venous Disease |
Presenter(s):Nicos Labropoulos, BSc (Med), PhD, DIC, RVT | |
8:53 AM - 8:58 AM | Inflammation And CVD |
Presenter(s):Joseph D. Raffetto, MD | |
8:59 AM - 9:04 AM | Does Deep Venous Reflux Matter With Superficial Ablation |
Presenter(s):Peter Henke, MD | |
9:05 AM - 9:10 AM | Genetics Involving VV And VLU |
Presenter(s):Joseph D. Raffetto, MD | |
9:11 AM - 9:16 AM | A New Noninvasive Method To Measure Lower Limb Venous Outflow Resistance |
Presenter(s):Andrew N. Nicolaides, MS, FRCS | |
9:17 AM - 9:22 AM | Value Of Coordinated Registry Network: Information Obtained |
Presenter(s):Steve Elias, MD | |
9:23 AM - 9:28 AM | Panel Discussion |
END OF SESSION 65 | |
SESSION 66 SCHEDULE | |
Thursday
SESSION 66:
SUPERFICIAL VEIN TREATMENT STRATEGIES AND TECHNIQUES
|
|
x | |
9:29 AM - 9:34 AM | Results Of Randomized Controlled Trial MOCA Versus Cyanoacrylate |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FACPh, F | |
9:35 AM - 9:40 AM | “Choosing Wisely” Items For Chemical Or Thermal Ablation In The Treatment Of The Incompetent Saphenous Veins And Recurrence |
Presenter(s):Claudine M. Hamel-Desnos, MD | |
9:41 AM - 9:46 AM | Rethinking Endovenous Techniques To Define Cost-Effectiveness |
Presenter(s):Armando Mansilha, MD, PhD, FEBVS | |
9:47 AM - 9:52 AM | Saphenous Sparing: Instructions For Users |
Presenter(s):Sergio Gianesini, MD, PhD, FACS | |
9:53 AM - 9:58 AM | Important Factors And Misconceptions In Skin End Organ Damage |
Presenter(s):Nicos Labropoulos, BSc (Med), PhD, DIC, RVT | |
9:59 AM - 10:04 AM | What Drugs Do I Recommend For Symptomatic Venous Disease |
Presenter(s):Jorge H. Ulloa, MD, FACS | |
10:05 AM - 10:10 AM | Ablative Procedures And Cost Effectiveness |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FACPh, F | |
10:11 AM - 10:16 AM | SVT Treatment During Pregnancy: Treatment Choices |
Presenter(s):Ellen D. Dillavou, MD | |
10:17 AM - 10:22 AM | Vein Histopathology: 5.5 Years After Cyanoacrylate Closure |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
10:23 AM - 10:28 AM | Saphenous Ablation On Anticoagulation; Is It Safe, Effective And Durable |
Presenter(s):Glenn Jacobowitz, MD | |
10:29 AM - 10:34 AM | Panel Discussion |
END OF SESSION 66 | |
SESSION 67 SCHEDULE | |
Thursday
SESSION 67:
THERMAL AND NON-THERMAL ABLATION
|
|
x | |
THERMAL AND NON-THERMAL ABLATION I | |
10:35 AM - 10:40 AM | Decision Making In Saphenous Ablation: What To Use When |
Presenter(s):Ellen D. Dillavou, MD | |
10:41 AM - 10:46 AM | HIFU: Is It Ready For Prime Time |
Presenter(s):Mark S. Whiteley, MS, FRCS | |
10:47 AM - 10:52 AM | Tips, Tricks And Limitations: HIFU |
Presenter(s):Mark S. Whiteley, MS, FRCS | |
10:53 AM - 10:58 AM | Tips, Tricks And Limitations: Perforator Ablation |
Presenter(s):Steve Elias, MD | |
10:59 AM - 11:04 AM | Tips, Tricks And Limitations: Varithena |
Presenter(s):Edward G. Mackay, MD | |
11:05 AM - 11:10 AM | Tips, Tricks, And Limitations: Ultrasound Guided Foam Sclerotherapy |
Presenter(s):Jean Luc Gerard, MD | |
11:11 AM - 11:16 AM | Panel Discussion |
THERMAL AND NON-THERMAL ABLATION II | |
Moderator(s): Alan M. Dietzek, MD, RPVI, FACS / Steve Elias, MD | |
11:17 AM - 11:22 AM | Tips, Tricks, And Limitations: Liquid Sclerotherapy |
Presenter(s):Victor M. Canata, MD | |
11:23 AM - 11:28 AM | Tips, Tricks And Limitations: Clarivein |
Presenter(s):Steve Elias, MD | |
11:29 AM - 11:34 AM | Tips, Tricks And Limitations: Laser Truncal Ablation |
Presenter(s):Lowell S. Kabnick, MD, RPhS, FACS, FAVLS | |
11:35 AM - 11:40 AM | Tips, Tricks And Limitations: Radiofrequency Ablation |
Presenter(s):Alan M. Dietzek, MD, RPVI, FACS | |
11:41 AM - 11:46 AM | Tips, Tricks And Limitations: Brazilian Phlebectomy |
Presenter(s):Gutenberg A. Gurgel, MSc, MD | |
11:47 AM - 11:52 AM | Tips, Tricks And Limitations: Phlebogrif |
Presenter(s):Lorena Grillo, MD | |
11:53 AM - 11:58 AM | Tips, Tricks And Limitations: VenaSeal |
Presenter(s):Alun H. Davies, MA, DM, DSc, FRCS, FHEA, FEBVS, FACPh, F | |
11:59 AM - 12:04 PM | Safety And Efficacy Of Endovenous Ablations In Octogenarians, Nonagenarians, And Centenarians |
Presenter(s):Enrico Ascher, MD | |
12:05 PM - 12:10 PM | SVT Management In 2020: Anything New |
Presenter(s):Manj S. Gohel, MD, FRCS, FEBVS | |
12:11 PM - 12:16 PM | Panel Discussion |
12:16 PM - 12:45 PM | Lunch Break – 2nd Floor Promenade Visit Exhibit And Pavilions (2nd and 3rd Floors) |
END OF SESSION 67 | |
SESSION 68 SCHEDULE | |
Thursday
SESSION 68:
SPIDER VEINS, TRUNCAL VEINS, TRIBUTARY VEINS, EXOTIC VEIN TREATMENT
Moderators:Kathleen D. Gibson, MD / Edward G. Mackay, MD
|
|
x | |
12:45 PM - 12:50 PM | Foam Therapies (PCF Versus PEM): When To Use And Does It Make A Difference |
Presenter(s):Edward G. Mackay, MD | |
12:51 PM - 12:56 PM | Patient Preferences For Thermal Ablation Versus Non-Thermal, Non-Tumescent Varicose Vein Treatments: A Choice-Based Conjoint (CBS) Analysis |
Presenter(s):Peter J. Pappas, MD | |
12:57 PM - 1:02 PM | Randomized Controlled Study Of EVLA And Foam In the SSV-Fovelass Study: 3-Year Results |
Presenter(s):Claudine M. Hamel-Desnos, MD | |
1:03 PM - 1:08 PM | CLACS In Paraguay Results Of The Aesthetic Phlebology Trial |
Presenter(s):Victor M. Canata, MD | |
1:09 PM - 1:14 PM | Superficial Ablation Outcomes (5 Years) In 13,000 Patients |
Presenter(s):Peter J. Pappas, MD | |
1:15 PM - 1:20 PM | Labial Varices: Choices And How I Do It |
Presenter(s):Ellen D. Dillavou, MD | |
1:21 PM - 1:26 PM | Which Saphenous Vein Recanalization Should Be Treated |
Presenter(s):Kathleen D. Gibson, MD | |
1:27 PM - 1:32 PM | Is Combination Therapy Laser And Sclerotherapy More Efficacious For Telangiectatic Treatment |
Presenter(s):Gutenberg A. Gurgel, MSc, MD | |
1:33 PM - 1:38 PM | Panel Discussion |
END OF SESSION 68 | |
SESSION 69 SCHEDULE | |
Thursday
SESSION 69:
VENOUS SOCIETAL AND GOVERNANCE
Moderators:Kathleen J. Ozsvath, M.D. / Harold J. Welch, MD
|
|
x | |
1:39 PM - 1:44 PM | CMS Policy Update On Non-Thermal Ablation |
Presenter(s):Harold J. Welch, MD | |
1:45 PM - 1:50 PM | The Future Of Venous Reimbursement In A Non-Fee For Service Environment |
Presenter(s):Thomas F. O'Donnell, Jr., MD | |
1:51 PM - 1:56 PM | What Evidence Is There For Compression Prior To Insurance Approval |
Presenter(s):Saum A. Rahimi, MD | |
1:57 PM - 2:02 PM | Can We Use The Data From VQI VVR To Advocate For Coverage Of Venous Procedures |
Presenter(s):Nicholas H. Osborne, MD, MS | |
2:03 PM - 2:08 PM | Who Should Fund The Management Of C2 Disease And Why |
Presenter(s):Sarah Onida, MD, PhD | |
2:09 PM - 2:14 PM | The Irony Of Overtreatment And Undertreatment In Venous Disease: What Can Be Done |
Presenter(s):Manj S. Gohel, MD, FRCS, FEBVS | |
2:15 PM - 2:20 PM | Results Of Appropriateness Criteria (AVF) I |
Presenter(s):Elna M. Masuda, MD | |
2:21 PM - 2:26 PM | Results Of Appropriateness Criteria (AVF) II |
Presenter(s):Kathleen J. Ozsvath, M.D. | |
2:27 PM - 2:32 PM | Shifting From Overutilization To Underutilization: Deeper Dive Into Improving Wisely |
Presenter(s):Margaret Mann, MD | |
2:33 PM - 2:38 PM | Focused Practice Designation – Venous Disease Treatment |
Presenter(s):Brajesh K. Lal, MD | |
2:39 PM - 2:44 PM | Prior Authorization As A Utilization Management Tool For Elective Superficial Venous Procedures Is Worthless |
Presenter(s):Todd Berland, MD | |
2:45 PM - 2:50 PM | Panel Discussion |
END OF SESSION 69 | |
SESSION 70 SCHEDULE | |
Thursday
SESSION 70:
MORE SUPERFICIAL VEIN TREATMENT STRATEGIES AND TECHNIQUES
|
|
x | |
2:51 PM - 2:56 PM | From The AVF And SVS: EHIT Recommendations |
Presenter(s):Lowell S. Kabnick, MD, RPhS, FACS, FAVLS | |
2:57 PM - 3:02 PM | Physician Compounded Foam Sclerotherapy |
Presenter(s):Margaret Mann, MD | |
3:03 PM - 3:08 PM | Saphenous Incompetence With Post-Thrombotic Deep Veins |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
3:09 PM - 3:14 PM | Which Factors Increase VTE Risk For Superficial Venous Procedures |
Presenter(s):Manj S. Gohel, MD, FRCS, FEBVS | |
3:15 PM - 3:20 PM | Ablation Outcomes In Obese Patients |
Presenter(s):Peter J. Pappas, MD | |
3:21 PM - 3:26 PM | Varithena® VLU Registry: The Effects Of Polidocanol Endovenous Microfoam On Wound Healing And Recurrence |
Presenter(s):Raghu Kolluri, MD | |
3:27 PM - 3:32 PM | Varicose Veins Among Klippel Trenaunay Syndrome: What You Should Know About |
Presenter(s):Byung-Boong Lee, MD | |
3:33 PM - 3:38 PM | Radiofrequency Ablation Increases The Incidence Of Endothermal Heat Induced Thrombosis |
Presenter(s):Anil P. Hingorani, MD | |
3:39 PM - 3:44 PM | European College Of Phlebology Guideline for Truncal Ablation |
Presenter(s):Kursat A. Bozkurt, MD | |
3:45 PM - 3:50 PM | Risk Factors For EHIT And Recanalization: An Analysis Of 10,000 Patients |
Presenter(s):Anil P. Hingorani, MD | |
3:50 PM - 3:55 PM | Panel Discussion |
END OF SESSION 70 | |
SESSION 71 SCHEDULE | |
Thursday
SESSION 71:
VENOUS CLINICAL TRIALS, LYMPHATIC, VEIN TREATMENT STRATEGIES
Moderators:Bo G. Eklof, MD, PhD / Peter Gloviczki, MD
|
|
x | |
3:56 PM - 4:01 PM | Thermal Ablation RCTs: Summary |
Presenter(s):Bo G. Eklof, MD, PhD | |
4:02 PM - 4:07 PM | What Venous Trials Do We Need |
Presenter(s):Mark H. Meissner, MD | |
4:08 PM - 4:13 PM | Unilateral, Bilateral, Staged Endovenous Ablation – VQI Data |
Presenter(s):Nicholas H. Osborne, MD, MS | |
4:14 PM - 4:19 PM | The Recalcitrant Ulcer: Our 52-Week Analysis |
Presenter(s):Thomas F. O'Donnell, Jr., MD | |
4:20 PM - 4:25 PM | First Experience: Russian Glue “Cyanoacrylate” |
Presenter(s):Evgeny Shaydakov, MD, PhD | |
4:26 PM - 4:31 PM | VenaSeal Spectrum Study: RCT Study Overview |
Presenter(s):Manj S. Gohel, MD, FRCS, FEBVS | |
4:32 PM - 4:37 PM | Treating Low And Moderate Severity Venous Disease Is Beneficial – Data From The VQI VVR |
Presenter(s):Nicholas H. Osborne, MD, MS | |
4:38 PM - 4:43 PM | A Newer Laser Fiber: All Fibers Are Not The Same |
Presenter(s):Evgeny Shaydakov, MD, PhD | |
4:44 PM - 4:49 PM | What Articles Are JVS-VL Looking For and How Can You Write A Paper That Will Be Accepted And Published |
Presenter(s):Peter Gloviczki, MD | |
4:50 PM - 4:55 PM | Panel Discussion |
LIPEDEMA, LYMPHEDEMA, PHLEBOLYMPHEDEMA | |
Moderator(s): Joseph A. Caprini, MD / Thomas F. O'Donnell, Jr., MD | |
4:56 PM - 5:01 PM | Diagnosis Of Lipedema And Treatment |
Presenter(s):Steven M. Dean, DO | |
5:02 PM - 5:07 PM | Overview Of Lymphatic Anatomy, Physiology And Imaging Techniques |
Presenter(s):Thomas F. O'Donnell, Jr., MD | |
5:08 PM - 5:13 PM | Clinical Characteristics Of Lower Extremity Lymphedema |
Presenter(s):Steven M. Dean, DO | |
5:14 PM - 5:19 PM | Evidence Based Compression Recommendations For Lymphedema |
Presenter(s):Joseph A. Caprini, MD | |
5:20 PM - 5:25 PM | Venolymphatic Edema And Its Treatment Options |
Presenter(s):Raghu Kolluri, MD | |
5:26 PM - 5:31 PM | Phlebolymphedema: Hallmark Of Combined Insufficiency Of Venous-Lymphatic System |
Presenter(s):Byung-Boong Lee, MD | |
5:32 PM - 5:37 PM | Moel Lavallee Syndrome |
Presenter(s):Lourdes Reina, MD | |
5:38 PM - 5:43 PM | Advanced Pneumatic Compression: Continued Improvement In Quality Of Life |
Presenter(s):Thomas S. Maldonado, MD | |
5:44 PM - 5:49 PM | Panel Discussion |
EXAMINING THE EVIDENCE | |
Moderator(s): Jean Luc Gerard, MD / Lorena Grillo, MD | |
5:50 PM - 5:55 PM | Bone Perforator: What Is The Significance |
Presenter(s):Jean Luc Gerard, MD | |
5:56 PM - 6:01 PM | Is Saphenous Vein Stripping A Cost-Effective Treatment |
Presenter(s):Lourdes Reina, MD | |
6:02 PM - 6:07 PM | Ablative Risks Prior And After Flying: What Do You Tell Your Patients |
Presenter(s):Sarah Onida, MD, PhD | |
6:08 PM - 6:13 PM | 1470mm Laser And Wound Care Trial |
Presenter(s):Lorena Grillo, MD | |
6:14 PM - 6:20 PM | Panel Discussion End of Program I |
END OF SESSION 71 | |
SESSION 72 SCHEDULE | |
Thursday
SESSION 72:
ACUTE STROKE IMAGING AND TRIAGE
Moderators:TBD
|
|
x | |
8:00 AM - 8:05 AM | Introduction |
Presenter(s):Allan L. Brook, MD | |
8:06 AM - 8:16 AM | Which Stroke Patients Need A CT Perfusion Study |
8:17 AM - 8:27 AM | MRI Has Unique Benefits: Let Me Explain |
8:28 AM - 8:38 AM | Perfusion Imaging For Dummies |
8:39 AM - 8:49 AM | Latest Stroke Trial Updates |
8:50 AM - 9:00 AM | Stroke Triage Direct To CSC |
9:01 AM - 9:11 AM | Stroke Triage Direct To The Angio Suite |
9:12 AM - 9:22 AM | Innovative And Novel Stroke Therapies That Are In The Pipeline |
9:23 AM - 9:33 AM | Lessons Learned On Patient Selection |
9:34 AM - 9:44 AM | Stroke Devices And Nuances |
9:45 AM - 9:55 AM | Robotics Are Here To Stay And What To Expect |
9:56 AM - 10:01 AM | DEBATE: A VIZ AI Is The Best Triage System |
10:02 AM - 10:07 AM | DEBATE: RAPID Is The Best Triage System |
10:08 AM - 10:15 AM | Panel Discussion |
10:15 AM - 10:26 AM | Break – Visit Exhibits And Exhibits (2nd and 3rd Floors) |
END OF SESSION 72 | |
SESSION 73 SCHEDULE | |
Thursday
SESSION 73:
COVID AND OTHER INFECTIOUS RELATED CEREBROVASCULAR ISSUES
Moderators:TBD
|
|
x | |
10:26 AM - 10:36 AM | COVID-19: Overview Of What Happened |
10:37 AM - 10:47 AM | COVID-19: An Ischemic Stroke |
10:48 AM - 10:58 AM | COVID-19 And Hemorrhagic Stroke |
10:59 AM - 11:09 AM | COVID-19: Practice Workflows And Systems Of Care |
11:10 AM - 11:20 AM | Vasculitis: Imaging And Diagnosis |
11:21 AM - 11:31 AM | Mycotic Aneurysms: Treatment Strategies |
11:32 AM - 11:42 AM | Improving Outcomes Is Based Solely On Brain Physiology, Clot Type, Intrinsic Vessel Pathology, And Collaterals |
11:43 AM - 11:53 AM | How CSC Organized Medicine Helped Prepare Us For The COVID Onslaught |
11:54 AM - 12:04 PM | Panel Discussion |
12:04 PM - 1:00 PM | Lunch Break – 2nd Floor PromenadeVisit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 73 | |
SESSION 74 SCHEDULE | |
Thursday
SESSION 74:
CAROTID AND CEREBROVASCULAR HOT TOPICS AND LITERATURE REVIEW
Moderators:TBD
|
|
x | |
1:00 PM - 1:10 PM | TCAR: Technical Pearls And Why It’s The Latest Trending Vascular Procedure |
1:11 PM - 1:21 PM | TCAR: Why Not Just Do An Endarterectomy |
1:22 PM - 1:32 PM | Hemicraniectomy: Why It Is Not a Lost Art |
1:33 PM - 1:43 PM | Have We Finally Figured Out Who Needs Carotid Revascularization |
END OF SESSION 74 | |
SESSION 75 SCHEDULE | |
Thursday
SESSION 75:
BRAIN ANEURYSM
Moderators:TBD
|
|
x | |
1:44 PM - 1:54 PM | Update On Latest Literature |
1:55 PM - 2:05 PM | Next Generation Flow Diverters |
2:06 PM - 2:16 PM | State-Of-The-Art Imaging Of Aneurysms |
2:17 PM - 2:27 PM | Intrasaccular Devices: Overview And Indications |
2:28 PM - 2:38 PM | Unruptured Aneurysms: Why Do We Treat These |
2:39 PM - 2:49 PM | What Aneurysms Are Best For Open Surgery And Why |
END OF SESSION 75 | |
SESSION 76 SCHEDULE | |
Thursday
SESSION 76:
COMPLICATION, AVOIDANCE AND TECHNIQUES
Moderators:TBD
|
|
x | |
2:49 PM - 2:59 PM | The SAH I Learned The Most From |
3:00 PM - 3:10 PM | Improving Thrombectomy: How To Avoid Embolic Strokes In Different Territories |
3:11 PM - 3:21 PM | Carotid Blowout: How To Treat And How To Avoid |
3:22 PM - 3:32 PM | Lessons Learned On Using Flow Diverters In SAH, And Getting Out Of Tough Situations |
END OF SESSION 76 | |
SESSION 77 SCHEDULE | |
Thursday
SESSION 77:
NEUROINTERVENTIONAL ONCOLOGY
Moderators:TBD
|
|
x | |
3:32 PM - 3:43 PM | Anatomy Of The Skull Base For Dummies |
3:44 PM - 3:54 PM | Collateral Physiologic Flow: Connections You Must Know To Avoid Disasters |
3:55 PM - 4:05 PM | Subdural Hematoma Theory And Percutaneous Treatment |
4:06 PM - 4:16 PM | Tinnitus: The Endovascular Specialist And Their Role |
4:17 PM - 4:27 PM | Intracranial Atherosclerosis: Is It Prime Time For The Next Prospective Trial |
4:28 PM - 4:38 PM | Dural Sinus Thrombosis/Stenosis: When And Why I Treat |
4:39 PM - 4:49 PM | Intraarterial Head And Neck Chemotherapy: Its Role 2020 |
END OF SESSION 77 | |
SESSION 78 SCHEDULE | |
Thursday
SESSION 78:
LATEST SCIENCE, LITERATURE AND NEWEST DEVICES
Moderators:TBD
|
|
x | |
4:50 PM - 5:00 PM | Anatomic Variations And The True Meaning Of Basic Knowledge |
5:01 PM - 5:11 PM | Venous Anatomy And Why It Is Important To Review |
5:12 PM - 5:22 PM | Disparities In The Five Boroughs |
5:23 PM - 5:40 PM | Panel DiscussionEnd of Program J |
END OF SESSION 78 | |
Friday, November 19, 2021
Print Entire 2020 Program:
|
|
SESSION 79 SCHEDULE | |
Friday
SESSION 79:
PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) ASSOCIATED WITH THE TREATMENT OF THORACIC, THORACOABDOMINAL AND COMPLEX ABDOMINAL ANEURYSMS
|
|
x | |
6:40 AM - 6:45 AM | A Multidisciplinary Approach To Prevent SCI During Endovascular TAAA Repairs |
Presenter(s):Patrick W. Kelly, MD | |
6:46 AM - 6:51 AM | Strategies To Minimize Paraplegia After TAAA Repairs: How A Biomarker Can Help |
Presenter(s):Bijan Modarai, PhD, FRCS / Adam Beck, MD | |
6:52 AM - 6:57 AM | New Developments In Preventing SCI With Endo And Open TAAA Repairs |
Presenter(s):Germano Melissano, MD / Roberto Chiesa, MD | |
6:58 AM - 7:03 AM | Update On The Value Of Motor Evoked Potentials To Decrease SCI With TAAA Repairs: What Is The Difference Between Peripheral And Central SCI |
Presenter(s):Barend M.E. Mees, MD, PhD / Michael J. Jacobs, MD / Geert Willem H. Schurink, MD, PhD | |
7:04 AM - 7:09 AM | Cerebrospinal Fluid (CSF) Drainage (To Decrease SCI) Is Not A Benign Procedure: Why: When Not And When To Use It |
Presenter(s):Gustavo S. Oderich, MD, FACS | |
7:10 AM - 7:15 AM | SCI Is More Severe And Resolves Less When Routine CSF Drainage Is Used With TAAA Repairs: When Should It Be Used Selectively And With What Precautions |
Presenter(s):Adam Beck, MD | |
7:16 AM - 7:21 AM | Status Of CSF Drainage With TAAA Repairs In Europe: Evidence Is Lacking: What Is The Standard Practice |
Presenter(s):Geert Willem H. Schurink, MD, PhD | |
7:22 AM - 7:27 AM | Near Infrared Spectrometry (NIRS) Monitoring Is Helpful In Decreasing SCI With TAAA Repairs: How To Do It: Why Is There Controversy |
Presenter(s):Carlos H. Timaran, MD | |
7:28 AM - 7:33 AM | The Intraspinal Collateral Arterial Network And Its Importance In Preventing SCI And Paraplegia With Complex Aortic Repairs |
Presenter(s):Martin Czerny, MD | |
7:34 AM - 7:39 AM | Current Strategies To Minimize SCI With TAAA Repairs, Endo And Open: Status Of Intercostal Embolization As Preconditioning To Prevent Ischemia (MIS2ACE): Status Of PAPA-ARTIS RCT |
Presenter(s):Christian D. Etz, MD, PhD | |
7:40 AM - 7:45 AM | Clinical Experience With Intercostal Coil Embolization (MIS2ACE) To Prevent SCI With Endovascular TAAA Repair |
Presenter(s):Daniela Branzan, MD / Andrej Schmidt, MD / Christian D. Etz, MD, PhD | |
7:46 AM - 7:53 AM | Panel Discussion |
END OF SESSION 79 | |
SESSION 80 SCHEDULE | |
Friday
SESSION 80:
NEW DEVELOPMENTS IN THE TREATMENT OF CAROTID STENOSIS WITH MESH COVERED STENTS AND TRANSCERVICAL CAROTID ARTERY REVASCULARIZATION (TCAR)
Moderators:Frank J. Veith, MD / Klaus D. Mathias, MD
|
|
x | |
MESH COVERED STENTS | |
7:53 AM - 7:58 AM | Long-Term Results Of Micromesh Stents Show Their Value In Carotid Artery Stenting (CAS): Are There Limitations: Do The Differences In The 3 Micromesh Stents Matter |
Presenter(s):Max Amor, MD | |
7:59 AM - 8:04 AM | Advantages And Limitations Of Mesh Covered Stents In CAS: Are They Really Better |
Presenter(s):Laura Capoccia, MD | |
8:05 AM - 8:10 AM | 7-Year Experience With Micromesh Stents For CAS: Are There Downsides (Thrombosis Or ISR): Technical Tips To Optimize Their Results |
Presenter(s):Stefan Müller-Hülsbeck, MD | |
8:11 AM - 8:16 AM | Results From A Multicenter Italian Study Of The C-Guard Micromesh Stent For CAS: Advantages And Complications |
Presenter(s):Francesco Speziale, MD / Wassim Mansour, MD / Pasqualino Singnano, MD / Carlo Setacci, MD | |
TCAR RELATED TOPICS | |
8:17 AM - 8:22 AM | TCAR Versus CEA (Carotid Endarterectomy): A Propensity Matched SVS VQI Study: 1-Year Results Show Equal Stroke/Death Rates And Decreased Cranial Nerve Injuries With TCAR: Findings Also Confirmed By A Meta-Analysis |
Presenter(s):Mahmoud B. Malas, MD, MHS / Marc L. Schermerhorn, MD | |
8:23 AM - 8:28 AM | TCAR Versus Transfemoral CAS (TFCAS): A Propensity Matched SVS VQI Study Shows That TCAR Has Lower Stroke And Death Rates Than TFCAS |
Presenter(s):Marc L. Schermerhorn, MD / Mahmoud B. Malas, MD, MHS / Vikram S. Kashyap, MD | |
8:29 AM - 8:34 AM | Why I Am Uncertain That TCAR Will Have Better Outcomes Than TFCAS: What Does The CREST 2 Registry Show |
Presenter(s):Thomas G. Brott, MD / William A. Gray, MD / Giancarlo Biamino, MD, PhD | |
8:35 AM - 8:40 AM | DEBATE: For TFCAS Reversal/ Of Flow With Gore/MoMA Device Cerebral Embolic Protection Is No Better Than Filter Protection: Why Is This So |
Presenter(s):Marc L. Schermerhorn, MD | |
8:41 AM - 8:46 AM | DEBATE: Not So: In Some Specific Circumstances Reversal/Cessation Of Flow Protection During TFCAS Is Better And Safer Than Filter Protection |
Presenter(s):Giancarlo Biamino, MD, PhD / William A. Gray, MD | |
8:47 AM - 8:52 AM | Based On Data To Date When Should TCAR Replace CEA And When Should It Not: A Balanced View |
Presenter(s):Vikram S. Kashyap, MD | |
8:53 AM - 8:58 AM | TCAR Seems Better Than TFCAS And Equal To CEA: It Has A Bright Future: What Are Its Drawbacks |
Presenter(s):Wesley S. Moore, MD | |
8:59 AM - 9:07 AM | Panel |
9:07 AM - 9:17 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 80 | |
SESSION 81 SCHEDULE | |
Friday
SESSION 81:
MORE CAROTID HOT TOPICS RELATED TO TCAR, MINI-INCISION CEA, SIGNIFICANCE OF DW MRI DEFECTS AND COGNITIVE FUNCTION
|
|
x | |
9:17 AM - 9:22 AM | TCAR Is Safe In Recently Symptomatic Patients And Those With Contralateral Carotid Occlusions: Why It Should Be The Procedure Of Choice In Those Conditions |
Presenter(s):Peter A. Schneider, MD | |
9:23 AM - 9:28 AM | DEBATE: TCAR Is Not Hard To Learn: Results Are Unrelated To Operator Experience In ROADSTER 2 Trial |
Presenter(s):Vikram S. Kashyap, MD | |
9:29 AM - 9:34 AM | DEBATE: Not So: TCAR Has A Steeper Learning Curve Than Commonly Thought: Some Precautions To Prevent Adverse Events |
Presenter(s):Michael B. Silva, Jr., MD / Charles Thang, MD | |
9:35 AM - 9:40 AM | Learning And Optimizing The TCAR Procedure |
Presenter(s):Edward Y. Woo, MD | |
9:41 AM - 9:46 AM | Complications Of TCAR: How To Avoid Them And Fix Those That Occur |
Presenter(s):Thomas S. Maldonado, MD | |
9:47 AM - 9:52 AM | Adjunctive EEG Can Help With TCAR And Decrease The Stroke Rate: When And How |
Presenter(s):Todd R. Vogel, MD, MPH | |
9:53 AM - 9:58 AM | Mini-Incision CEA Is Better And Less Costly Than TCAR |
Presenter(s):Enrico Ascher, MD | |
9:59 AM - 10:04 AM | TCAR Can Be Performed Under Local Anesthesia With Outcomes Equal To TCAR Under General Anesthesia: From A VQI Study: How To Do It Safely |
Presenter(s):Dipankar Mukherjee, MD | |
SIGNIFICANCE OF SMALL DW MRI DEFECTS AFTER CEA/CAS | |
10:05 AM - 10:10 AM | DEBATE: How Size And Number Of Silent Brain Infarcts (DW MRI Defects) After CEA/CAS Affect Cognitive Changes: They Really Do Matter |
Presenter(s):Wei Zhou, MD | |
10:11 AM - 10:16 AM | DEBATE: Silent DWI MRI Brain Lesions (Small Infarcts) After CEA/CAS Don’t Matter |
Presenter(s):Thomas G. Brott, MD | |
10:17 AM - 10:22 AM | Why Asymptomatic Carotid Stenosis (ACS) Is Associated With Impaired Cognitive Function And Silent Infarcts: However, CEA And CAS For ACS Cause More Cognitive Impairment Than They Prevent |
Presenter(s):J. David Spence, MD | |
10:23 AM - 10:30 AM | Panel Discussion |
END OF SESSION 81 | |
SESSION 82 SCHEDULE | |
Friday
SESSION 82:
MORE CAROTID RELATED NEW DEVELOPMENT TOPICS RELATED TO TCAR, MESH COVERED STENTS, MINI-INCISION CEA, TIMING OF TREATMENT, MEDICAL TREATMENT AND DEALING WITH DISTAL (HIGH) CAROTID LESIONS
|
|
x | |
10:30 AM - 10:35 AM | Comparative Cost Effectiveness: TCAR Versus CEA Versus TFCAS |
Presenter(s):Mohammad H. Eslami, MD, MPH | |
10:36 AM - 10:41 AM | Transcranial Doppler (TCD) Hits During TCAR: When Do They Occur And What Is Their Significance |
Presenter(s):Cynthia K. Shortell, MD | |
10:42 AM - 10:47 AM | Value Of Lithotripsy (Shockwave) For CAS In Heavily Calcified Lesions: How To Do It Safely And Technical Tips: Limitations And Precautions |
Presenter(s):Max Amor, MD | |
10:48 AM - 10:53 AM | Value Of Mesh Covered Stents With TCAR: Is It The Best Of All Worlds: Limitations |
Presenter(s):Ralf R. Kolvenbach, MD | |
10:54 AM - 10:59 AM | OCT Proves CAS Is Rendered Safer Because Emboli Are Decreased By Mesh Covered Stents: The Evidence |
Presenter(s):Francesco Setacci, MD / Carlo Setacci, MD | |
11:00 AM - 11:05 AM | TCAR Versus Minimal Incision CEA: Cost Effectiveness, Advantages And Limitations Of Both |
Presenter(s):Robert M. Proczka, MD, PhD | |
11:06 AM - 11:12 AM | Panel Discussion |
TIMING OF CAROTID INTERVENTIONS AFTER SYMPTOM ONSET | |
11:12 AM - 11:17 AM | Optimal Timing Of Carotid Revascularization (CEA, TFCAS, TCAR) After Symptom Onset: Within 48 Hours Risk Is Increased For All Procedures; After 48 Hours Risk Is Less With CEA And TCAR Than With TFCAS: Based On Large National Database Study |
Presenter(s):Mahmoud B. Malas, MD, MHS | |
11:18 AM - 11:23 AM | DEBATE: It’s Reasonable To Perform CEA Within 48 Hours After A Stroke’s Symptoms Start: Under What Conditions And What Precautions Should Be Taken |
Presenter(s):R. Clement Darling III, MD | |
11:24 AM - 11:29 AM | DEBATE: Patients With Moderate To Severe Strokes Do Poorly With Both CEA And CAS Done Within 48 Hours Of Symptom Onset: Both Procedures Should Be Avoided During This Period: How Long Should One Wait |
Presenter(s):Hernan A. Bazan, MD, DFSVS, FACS | |
11:30 AM - 11:35 AM | When Is CEA Within 48 Hours Of Stroke Symptom Onset Necessary: What Are The Risks: How To Make It Reasonably Safe: When Is It Totally Contraindicated |
Presenter(s):Domenico Valenti, DMChir, PhD, FRCS, FRCS(Ed) ,FEBVS | |
11:36 AM - 11:41 AM | What Is The Best Medical Treatment For Patients With Carotid Stenosis (Asymptomatic And Asymptomatic): Can High Risk Plaques Be Made Low Risk And Can They Be Made Smaller: Are Some Plaques Resistant To Medical Treatment And Why |
Presenter(s):J. David Spence, MD | |
11:42 AM - 11:47 AM | Technical Tips and Maneuvers To make Treatment Of High Carotid Lesions Safe And Relatively Simple |
Presenter(s):Richard J. Powell, MD | |
11:48 AM - 11:53 AM | Getting Non-Compliant Carotid Patients To Comply With Best Medical Treatment By Showing Them Their Duplex Scans And Pictures Of Hemorrhagic And Ulcerated Plaques |
Presenter(s):J. David Spence, MD | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 82 | |
SESSION 83 SCHEDULE | |
Friday
SESSION 83:
MORE HOT CAROTID TOPICS: UPDATES ON KEY CAROTID RCTs; NEW INFORMATION ON TREATMENT OF TANDEM LESIONS, CAROTID ANEURYSMS AND STROKES DURING INTERVENTION
Moderators:Claudio J. Schonholz, MD / Christopher J. Kwolek, MD, MBA
|
|
x | |
UPDATE ON CAROTID RCTs | |
1:00 PM - 1:05 PM | Update On ACST 2: CEA Versus CAS For ACS: What Is It Telling Us And When Will We Have All The Answers |
Presenter(s):Richard Bulbulia, MA, MD, FRCS / Alison Halliday, MS, FRCS | |
1:06 PM - 1:11 PM | Update On SPACE 2: CEA Versus Best Medical Treatment (BMT); CAS Versus BMT For ACS: Updated And Interesting Findings From A Stopped RCT |
Presenter(s):Hans-Henning Eckstein, MD, PhD | |
1:12 PM - 1:17 PM | Update On CREST 2: CEA Versus BMT And CAS Versus BMT For ACS: Findings To Date And When Will We Have Final Results |
Presenter(s):Brajesh K. Lal, MD / Thomas G. Brott, MD | |
1:18 PM - 1:23 PM | Why Is BMT With Clopidogrel Different In The Arms Of CREST and CREST 2 And Why This Difference Could Invalidate The RCTs Results (Power Point Presentation With Synched Audio) |
Presenter(s):Timothy M. Sullivan, MD | |
TANDEM CAROTID LESIONS | |
1:24 PM - 1:30 PM | DEBATE: Tandem Lesions At The Carotid Bifurcation Plus The Common Carotid Or Innominate Arteries: Stroke And Mortality Risks Are Higher Than For Simple Bifurcation Lesions: How Best To Treat: Endo, Open, Staged, Hybrid |
Presenter(s):W. Darrin Clouse, MD / Mark Conrad, MD, MMSc | |
1:30 PM - 1:35 PM | DEBATE: Tandem Carotid Lesions: Treatment Risks Need Not Be Increased: Based On A Meta-Analysis: How Best To Treat To Minimize Risk |
Presenter(s):Ross Naylor, MD, FRCS | |
1:36 PM - 1:41 PM | CEA And Retrograde Stenting Of A Tandem Proximal Lesion: Technical Tips To Make It Safe And Effective |
Presenter(s):Christopher J. Smolock, MD | |
1:42 PM - 1:47 PM | Optimal Management Of Extracranial Carotid Aneurysms In 2020: When Open; When Endo: Technical Tips And Results |
Presenter(s):Samuel R. Money, MD, MBA | |
1:48 PM - 1:53 PM | How Best To Treat Strokes Apparent During Or Right After CEA, CAS Or TCAR: Best Diagnostic Modalities And Treatments: What Skills Are Needed |
Presenter(s):Gert J. de Borst, MD, PhD | |
1:54 PM - 2:02 PM | Panel Discussion |
END OF SESSION 83 | |
SESSION 84 SCHEDULE | |
Friday
SESSION 84:
MORE HOT CAROTID TOPICS: TREATMENT IN 2020 OF STRING SIGN, BIG CAROTID BODY TUMORS, AND CAROTID DISSECTIONS; OPTIMAL PLATELET AND PROTAMINE STRATEGIES; BENIGNANCY OF ACS; VALUE OF LOCAL ANESTHESIA; STROKE RISK WITH ACS PLAQUES - A WAY TO PREDICT HIGH RISK PLAQUES
Moderators:Glenn M. LaMuraglia, MD / Samuel R. Money, MD, MBA
|
|
x | |
2:02 PM - 2:07 PM | Current Optimal Treatment For Carotid Artery Dissections: When Medical Treatment (Anticoagulation And BP Control); When Open Surgery; When Stenting With Proximal Protection: Precautions |
Presenter(s):Felice Pecoraro, MD | |
2:08 PM - 2:13 PM | How Best To Diagnose And Treat Near Occlusion Of The Internal Carotid Artery (ICA) In 2020: Based On A Meta-Analysis: Is This The ICA String Sign Of Past Descriptions |
Presenter(s):Gert J. de Borst, MD, PhD | |
2:14 PM - 2:19 PM | Technical Tips For Treating Large Shamblin III Carotid Body Tumors Safely; From An Ecuadorian Team Who Treats Many |
Presenter(s):Oscar L. Ojeda, MD, FACS | |
2:20 PM - 2:25 PM | Optimal Anti-Platelet Strategy Before And After CEA |
Presenter(s):Ross Naylor, MD, FRCS | |
2:26 PM - 2:31 PM | Value Of Protamine Use During CEA: How Should It Be Used And With What Precautions |
Presenter(s):David H. Stone, MD | |
2:32 PM - 2:38 PM | Panel Discussion |
2:38 PM - 2:43 PM | Restenosis After CEA And CAS Is Benign And Should Rarely Be Treated: When Can It Cause Strokes Justifying Prophylactic Treatment |
Presenter(s):Ross Naylor, MD, FRCS | |
2:44 PM - 2:49 PM | DEBATE: Local Anesthesia And Intraoperative Control With Duplex Or Angiography Is Key To Safe CEA: How To Do Them |
Presenter(s):Hans-Henning Eckstein, MD, PhD | |
2:50 PM - 2:55 PM | DEBATE: Not So: CEA Can Be Performed Safely And Optimally Under General Anesthesia And Without Completion Duplex Or Angio Control: What Is Required To Do So And Are There Downsides To Duplex Or Angio Controls |
Presenter(s):Ali F. AbuRahma, MD | |
2:56 PM - 3:01 PM | Are Symptomatic And Asymptomatic Carotid Stenosis Really 2 Different Diseases As Some Suggest |
Presenter(s):Thomas G. Brott, MD | |
3:02 PM - 3:07 PM | What Percent Of Carotid Plaques Are Really High Stroke Risk: How To Detect Them With Ultrasound To See Neovascularization: Can High Risk Plaques Be Made Low Risk By Lipid Lowering |
Presenter(s):Henrik Sillesen, MD, DMSc | |
3:08 PM - 3:13 PM | When An Asymptomatic Carotid Stenosis (ACS) Patient Has A Stroke What Is Its Magnitude: Does It Make The Case For More Or Less Prophylactic CEAs And CASs |
Presenter(s):Gianluca Faggioli, MD | |
3:14 PM - 3:20 PM | Panel Discussion |
3:20 PM - 3:30 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 84 | |
SESSION 85 SCHEDULE | |
Friday
SESSION 85:
MORE HOT AND CONTROVERSIAL CAROTID TOPICS AND NEW OR UPDATED CONCEPTS FOR ENDOVASCULAR TREATMENTS
Moderators:Ali F. AbuRahma, MD / Sean P. Lyden, MD
|
|
x | |
HOT CAROTID TOPICS | |
3:30 PM - 3:35 PM | Risks And Causes Of Non-Ipsilateral Stroke Complicating CEA |
Presenter(s):W. Darrin Clouse, MD / Mark Conrad, MD, MMSc | |
3:36 PM - 3:41 PM | Unnecessary Redundant Testing/Imaging Prior To CEA: What Is The Reason For This Needless Addition To Health Care Costs |
Presenter(s):Reese A. Wain, MD | |
3:42 PM - 3:47 PM | Floating Clot At The Carotid Bifurcation Is A Prime Indication For Flow Reversal Technology During Treatment Of Carotid Stenosis: How Can Flow Reversal Best Be Achieved In This Setting |
Presenter(s):Juan C. Parodi, MD | |
3:48 PM - 3:53 PM | What Is Carotid Near Occlusion And How Is It Best Treated Currently: Conservatively, CEA, CAS |
Presenter(s):Weiguo Fu, MD | |
3:54 PM - 3:59 PM | DEBATE: CAS Is The Best Treatment For Young Patients With A High Grade Asymptomatic Carotid Stenosis (ACS) |
Presenter(s):Giancarlo Biamino, MD, PhD | |
4:00 PM - 4:05 PM | DEBATE: Not So: Young Patients With A High Grade ACS Should Not Be Treated By CAS Or CEA |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
4:06 PM - 4:12 PM | Panel Discussion |
NEW OR UPDATED CONCEPTS OR ENDO TREATMENTS | |
4:12 PM - 4:17 PM | Clinical Judgment Is Required In The Application Of Evidence Based Medicine: RCTs Can Have Flaws Leading To Misleading Conclusions |
Presenter(s):J. David Spence, MD | |
4:18 PM - 4:23 PM | How Should Left Subclavian Artery Stenosis Be Treated In Patients Before Coronary Artery Bypass: Stent Versus Carotid Subclavian Bypass Versus Ignore But Don’t Use The Left Internal Mammary Artery |
Presenter(s):Jennifer L. Perri, MD, MBA | |
4:24 PM - 4:29 PM | Progress In Open And Endovascular Treatment For Erectile Dysfunction: Diagnosis And Treatment Of Cavernous Leak And Other Pathology: A New Horizon |
Presenter(s):Eric Allaire, MD, PhD | |
4:30 PM - 4:35 PM | Embolic Treatment Of Hemorrhoids: How To Do It And How Well Does It Work |
Presenter(s):Gloria Salazar, MD | |
4:36 PM - 4:41 PM | Transfemoral Transcaval Liver Biopsy: A Better Way And How To Do It |
Presenter(s):Jacob Cynamon, MD, FACR, FSIR | |
4:42 PM - 4:48 PM | Panel Discussion |
END OF SESSION 85 | |
SESSION 86 SCHEDULE | |
Friday
SESSION 86:
NEW DEVELOPMENTS IN PERCUTANEOUS ACCESS CLOSURE, ENDOVASCULAR SUTURING AND WOUND CARE
Moderators:Kenneth Ouriel, MD, MBA / Zvonimir Krajcer, MD, FACC
|
|
x | |
4:48 PM - 4:53 PM | Update On Large Bore Percutaneous Access Closure Devices: Key New Devices And Developments: How To Prevent Failure And Complications |
Presenter(s):Zvonimir Krajcer, MD, FACC | |
4:54 PM - 4:59 PM | Endovascular Suturing Devices At The Tip Of An 8-9 French Catheter To Close Large Bore Sheath Access From Inside: The NovelRad Device: How Does It Work And Present Status |
Presenter(s):Elchanan Bruckheimer, MBBS | |
PROGRESS IN WOUND CARE | |
5:00 PM - 5:05 PM | Access Complications Despite Modern Closure Devices And Endovascular Suturing: Strategies And Wound Care |
Presenter(s):Martin Storck, MD, PhD / Peter Reimer, MD, PhD | |
5:06 PM - 5:11 PM | Best Treatment Strategies For Complex Infected Groin Wounds After Vascular Surgery: When To Do What: Wide Debridement, Antibiotics, Muscle Flap Reconstruction Or Graft Removal |
Presenter(s):Jan-Willem Elshof, MD | |
5:12 PM - 5:17 PM | Optimal Treatment For Groin Infection After Prosthetic Bypasses From The Common Femoral Artery: How To Save The Graft And The Leg |
Presenter(s):Hosam F. El Sayed, MD | |
5:18 PM - 5:23 PM | New Developments In The Treatment Of Mixed Arterial And Venous Wounds And Ulcers |
Presenter(s):Katherine A. Gallagher, MD | |
5:24 PM - 5:29 PM | Value Of A Wound Care Center To A Vascular Practice: Who Should Staff It And How To Make It Revenue Positive |
Presenter(s):Venita Chandra, MD | |
5:30 PM - 5:36 PM | Panel Discussion End of Program K |
END OF SESSION 86 | |
SESSION 87 SCHEDULE | |
Friday
SESSION 87:
POPLITEAL DISEASE TOPICS RELATED TO NEW GUIDELINES, ANEURYSM TREATMENT (PRIMARY AND REDO), ENTRAPMENTS AND ATHERECTOMY FOR OCCLUSIVE LESIONS
Moderators:Enrico Ascher, MD / Keith D. Calligaro, MD
|
|
x | |
POPLITEAL ANEURYSMS AND THEIR BEST CURRENT TREATMENTS | |
7:00 AM - 7:05 AM | High Points Of New SVS Guidelines For The Treatment Of Popliteal Aneurysms: Roles Of Endo And Open Repairs |
Presenter(s):Alik Farber, MD, MBA / Patrick J. Geraghty, MD | |
7:06 AM - 7:11 AM | Contemporary Treatment Of Popliteal Aneurysms In 14 Countries: There Is Great Variation In Treatment, Techniques, Complications And Outcomes: The Take Home Message Is . . . |
Presenter(s):Martin Bjorck, MD, PhD | |
7:12 AM - 7:17 AM | DEBATE: Endovascular Repair Is The Best Option For Most Popliteal Aneurysms Requiring Repair: Recent Progress In The Procedure: When Is Open Repair Indicated |
Presenter(s):Irwin V. Mohan, MBBS, MD, FRCS, FEBVS, FRACS | |
7:18 AM - 7:23 AM | DEBATE: Open Repair With Prosthetic Bypass Graft Is Better Than Endovascular Treatment For Popliteal Aneurysms Requiring Repair |
Presenter(s):Laurent Chiche, MD, FEBVS | |
7:24 AM - 7:30 AM | Update On Optimal Treatment For Popliteal Aneurysms: When Observation; When Endo Repair; When Open Repair And How |
Presenter(s):Fred A. Weaver, MD, MMM | |
7:30 AM - 7:36 AM | Panel Discussion |
7:36 AM - 7:41 AM | What Are Complex Popliteal Aneurysms And How Should They Be Fixed: When Endo; When Open |
Presenter(s):Jacques Busquet, MD | |
7:42 AM - 7:47 AM | Rescue Procedures For Failed Endovascular Repairs Of Popliteal Aneurysms: Observation May Be Enough: If Not, Hybrid Versus Open Repair: Technical Tips |
Presenter(s):Jose Fernandes e Fernandes, MD, PhD, FRCS (Eng), FACS,FESC,FEBVS | |
POPLITEAL ENTRAPMENTS | |
7:48 AM - 7:53 AM | What’s New In The Treatment Of Popliteal Entrapments |
Presenter(s):Niten Singh, MD | |
POPLITEAL ARTERY INJURY | |
7:54 AM - 7:59 AM | Surgical Approach And Graft Usage For Popliteal Artery Injury From Posterior Knee Dislocation |
Presenter(s):Charles J. Fox, MD, FACS | |
POPLITEAL ARTERY ATHERECTOMY | |
8:00 AM - 8:05 AM | Value Of Orbital Atherectomy For Popliteal Artery Occlusive Lesions: Indications, Results, Precaution |
Presenter(s):Konstantinos P. Donas, MD | |
8:06 AM - 8:12 AM | Panel Discussion |
END OF SESSION 87 | |
SESSION 88 SCHEDULE | |
Friday
SESSION 88:
NEW DEVELOPMENTS IN TREATING ARTERIAL (INCLUDING AORTIC) AND ARTERIAL GRAFT INFECTIONS
Moderators:Keith D. Calligaro, MD / Peter F. Lawrence, MD
|
|
x | |
8:12 AM - 8:17 AM | Update On Deep Vein Use For Arterial Procedures: The NAIS Operation For Infections: Recent Technical Improvements |
Presenter(s):Patrick A. Stone, MD | |
TREATMENT OF MYCOTIC ANEURYSMS | |
8:18 AM - 8:23 AM | Optimal Treatment Of Mycotic AAAs In 2020: Value Of And Precautions With EVAR: Is It Ever A Stand-Alone Treatment |
Presenter(s):Timur P. Sarac, MD | |
8:24 AM - 8:29 AM | Rifampin Soaked Endografts To Treat Mycotic AAAs: How To Prepare Them And When To Use Them: Are They Stand-Alone Treatment Or Do They Need Adjunctive Techniques |
Presenter(s):Guillermo A. Escobar, MD | |
8:30 AM - 8:35 AM | Why Open Repair Is The Best Treatment For Mycotic AAAs: Is EVAR Ever Of Value |
Presenter(s):Yamume Tshomba, MD | |
8:36 AM - 8:41 AM | Best Treatment For Mycotic Aortic Aneurysms In The Thorax And Abdomen Based On Long-Term Results |
Presenter(s):Samy S. Nitecki, MD | |
8:42 AM - 8:48 AM | Panel Discussion |
TREATMENT OF AORTIC AND ARTERIAL GRAFT AND ENDOGRAFT INFECTIONS | |
8:48 AM - 8:53 AM | Infected Endografts After EVAR: Etiological Factors, Diagnosis, Treatment, Outcomes |
Presenter(s):Mohammad H. Eslami, MD, MPH | |
8:54 AM - 8:59 AM | Optimal Techniques For Treating Aorto-Iliac Graft And Endograft Infections In 2020 |
Presenter(s):Anders Wanhainen, MD, PhD | |
9:00 AM - 9:05 AM | Update Of Surgical Treatment For Infected Aortic Grafts And Aortic-Enteric And Aortic-Bronchial Fistulas: Current Results In A Committed Center |
Presenter(s):Germano Melissano, MD / Roberto Chiesa, MD | |
9:06 AM - 9:11 AM | Update On Progress In The Optimal Treatment Of Aortic And Arterial Graft Infections: What’s New In 2020 |
Presenter(s):Jean-Paul de Vries, MD, PhD | |
9:12 AM - 9:17 AM | DEBATE: Semi-Conservative Therapy May Be Best For Some Aortic Graft Infections: What Is It And When Will Saving All Or Part Of An Infected Graft Work |
Presenter(s):Zoran Rancic, MD, PhD | |
9:18 AM - 9:23 AM | DEBATE: Not So: Aggressive Graft Removal Is Always Necessary In Treating Infections Involving Aortic Grafts |
Presenter(s):Franco Grego, Vascular Surgery | |
9:24 AM - 9:29 AM | Open Repair Of Suprarenal Aortic Graft Infections: Technical Tips And Long-Term Results |
Presenter(s):Thomas C. Bower, MD / Manju Kalra, MBBS | |
9:30 AM - 9:37 AM | Panel Discussion |
9:37 AM - 9:52 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 88 | |
SESSION 89 SCHEDULE | |
Friday
SESSION 89:
PROGRESS IN VASCULAR IMAGING AND GUIDANCE FOR ENDOVASCULAR TREATMENTS WITH LESS RADIATION EXPOSURE OR CONTRAST TOXICITY
Moderators:Barry T. Katzen, MD / Matthew J. Eagleton, MD
|
|
x | |
VASCULAR HOLOGRAPHY | |
9:52 AM - 9:57 AM | How Will The Microsoft Hololens Look Through Patients’ Bodies And Facilitate Endovascular Interventions: The ARCUS System Of Augmented Reality And Its Value In Vascular Surgery |
Presenter(s):Jan M.M. Heyligers, MD, PhD, FEBVS | |
9:58 AM - 10:03 AM | Real View Holographic Imaging: How Will It Help In Endovascular Treatments: Is It Available In The US |
Presenter(s):Elchanan Bruckheimer, MBBS | |
10:04 AM - 10:09 AM | Holographic Guidance Of Endovascular Procedures: What Is Possible And What Is Not |
Presenter(s):Claude Mialhe, MD | |
DUPLEX AND INTRAVASCULAR ULTRASOUND | |
10:10 AM - 10:15 AM | Duplex Ultrasound Guidance: How, Where And When Can It Replace Fluoroscopy For Endovascular Procedures: Advantages, Limitations, And Why Its Use Is Increasing |
Presenter(s):Enrico Ascher, MD / Natalie A. Marks, MD, RPVI, RVT, FSVM | |
10:16 AM - 10:21 AM | Intravascular Ultrasound (IVUS) Assistance In EVAR And TEVAR: Advantages And Limitations - Based On A Multicenter Study |
Presenter(s):Jean-Baptiste Ricco, MD, PhD | |
10:22 AM - 10:28 AM | Panel Discussion |
IMPROVED IMAGING | |
10:28 AM - 10:33 AM | Contrast Induced Nephropathy Is Over-Exaggerated: When Patients Need A Contrast Study, They Should Get It: How To Minimize Consequences |
Presenter(s):Lindsay Machan, MD | |
10:34 AM - 10:39 AM | CO2 As A Contrast Agent For Endo Treatment Of PAD And CLTI: How To Use It Safely And Effectively |
Presenter(s):Jim Caridi, MD, FSIR | |
10:40 AM - 10:45 AM | Dual Fluoroscopy With Live Image Digital Zooming: How Does It Work And Why Does It Decrease Radiation During Complex AAA Repairs: What Is Its Cost |
Presenter(s):Carlos H. Timaran, MD | |
10:46 AM - 10:51 AM | The Cydar System Deformation Tool For Improving Image Fusion Accuracy: How Does It Work And Why Does It Help |
Presenter(s):Cynthia K. Shortell, MD | |
10:52 AM - 10:57 AM | Cydar Medical System’s Evolution To Facilitate Fusion With All Digital Fluoroscopes: How The System Uses AI To Improve EVAR Planning, Guidance And Deployment |
Presenter(s):Jan M.M. Heyligers, MD, PhD, FEBVS | |
10:58 AM - 11:03 AM | The Cydar System’s Value In Standard And Complex EVAR |
Presenter(s):Venkatesh G. Ramaiah, MD | |
11:04 AM - 11:12 AM | Panel Discussion |
END OF SESSION 89 | |
SESSION 90 SCHEDULE | |
Friday
SESSION 90:
CHALLENGING RECORDED LIVE CASES FROM THE MAYO CLINIC AND THE UNIVERSITY OF TEXAS, HOUSTON
Moderators:Gustavo S. Oderich, MD, FACS / Bernardo C. Mendes, MD
|
|
x | |
11:12 AM - 12:00 PM | PROGRAM TBD |
12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 90 | |
SESSION 91 SCHEDULE | |
Friday
SESSION 91:
ONE PRESENTATION AND CHALLENGING RECORDED LIVE CASES FROM MÜNSTER, GERMANY
Moderators:Martin J. Austermann, MD / Giovanni B. Torsello, MD
|
|
x | |
1:00 PM - 1:44 PM | Complex Cases From Münster With Questions And Discussion |
Presenter(s):Giovanni B. Torsello, MD / Martin J. Austermann, MD | |
END OF SESSION 91 | |
SESSION 92 SCHEDULE | |
Friday
SESSION 92:
NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC OUTLET SYNDROMES (TOSs)
Moderators:Robert W. Thompson, MD / Mark A. Adelman, MD
|
|
x | |
1:44 PM - 1:49 PM | New Developments In The Treatment Of Neurogenic TOSs: What Preop Factors Correlate With Good Outcomes; With Bad Outcomes |
Presenter(s):Karl A. Illig, MD | |
1:50 PM - 1:55 PM | Supraclavicular Approach To Arterial And Neurogenic TOSs (Video Presentation) |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
VENOUS TOSs | |
1:56 PM - 2:01 PM | Venous TOSs: Lessons Learned After Treating >1000 Cases |
Presenter(s):Robert W. Thompson, MD | |
2:02 PM - 2:07 PM | Spectrum Of Treatment Options For Venous TOS: What Are The Outcomes And How Do They Differ |
Presenter(s):Jason T. Lee, MD | |
2:08 PM - 2:13 PM | Patients With Symptomatic Venous TOS With And Without Venous Thrombosis May Not Need Surgical (1st Rib Resection) Treatment: Antiplatelet Drugs And Anticoagulation May Resolve Symptoms: Which Patients Require Rib Resection |
Presenter(s):Sam S. Ahn, MD, FACS, MBA | |
2:14 PM - 2:19 PM | Technical Tips For Optimal Surgical Treatment For Venous TOS |
Presenter(s):Robert W. Thompson, MD | |
2:20 PM - 2:26 PM | Panel Discussion |
2:26 PM - 2:36 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 92 | |
SESSION 93 SCHEDULE | |
Friday
SESSION 93:
NEW DEVELOPMENTS IN MEDICAL AND DRUG TREATMENTS: BEST ANTIPLATELET REGIMENS; UPDATE ON RARE VASCULAR DISEASES
Moderators:Caron B. Rockman, MD / James H. Black, III, MD
|
|
x | |
ANTIPLATELET REGIMENS | |
2:36 PM - 2:41 PM | Optimal Antiplatelet Management With CEAs, Lower Extremity Bypasses And Open AAA Repairs |
Presenter(s):David H. Stone, MD | |
2:42 PM - 2:47 PM | Optimal Anticoagulation And Antiplatelet Treatment For High Risk Lower Extremity Bypasses – Vein And PTFE |
Presenter(s):Peter Henke, MD | |
2:48 PM - 2:53 PM | Most Effective Antiplatelet After Lower Extremity Interventional Treatments For CLTI – POBA, DCBs, Stents, Etc. |
Presenter(s):Maciej L. Dryjski , MD, PhD | |
2:54 PM - 2:59 PM | Why Clopidogrel Is Effective In <50% Of Patients At Standard Doses: How To Identify And Fix This Problem |
Presenter(s):Karthikeshwar Kasirajan, MD | |
NEW DEVELOPMENTS IN LIPID MANAGEMENT – STATINS | |
3:00 PM - 3:05 PM | Safety And Benefit Of Statins And Medical Treatment In Vascular Patients: Shockingly These Treatments Are Underutilized – Especially In Women: Why Is This So |
Presenter(s):Christian A. Behrendt, MD | |
3:06 PM - 3:11 PM | Value Of Statins In AAA Patients After Repair: Long-Term Impact On Mortality |
Presenter(s):Adam Beck, MD | |
3:12 PM - 3:17 PM | The Importance Of Lipoprotein Little a [Lp(a)] Levels In Determining Atherosclerotic Risk: When Should It Be Measured And If High, How Treated: Do PCSK-9 Inhibitors Help |
Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC | |
3:18 PM - 3:24 PM | Panel Discussion |
3:24 PM - 3:29 PM | Elevated Neutrophil To Lymphocyte Ratio Predicts Poor Outcomes And Mortality After Elective EVAR And CEA: What Is The Mechanism |
Presenter(s):Jae S. Cho, MD | |
3:30 PM - 3:35 PM | The Justification For Carotid Screening Is To Promote Medical Treatment To Decrease Stroke And MI Risks, Not To Push Patients To Have Unnecessary Invasive Procedures |
Presenter(s):Kosmas I. Paraskevas, MD | |
3:36 PM - 3:41 PM | Lowering LDL-C And Controlling Elevated Blood Pressure Can Lower Cardiovascular Risk 80%: Doing These Things Should Be A Lifetime Goal |
Presenter(s):Richard Bulbulia, MA, MD, FRCS | |
3:42 PM - 3:47 PM | Current (2020) Status Of Diagnosis And Treatment Of Buerger’s Disease: Does It Exist Or Is It Just A Variant Of Atherosclerosis |
Presenter(s):Kamphol Laohapensang, MD | |
3:48 PM - 3:53 PM | How To Make Operations For Complications Of Vascular Ehlers Danlos Syndrome Go Well |
Presenter(s):James H. Black, III, MD | |
3:54 PM - 4:00 PM | Panel Discussion |
END OF SESSION 93 | |
SESSION 94 SCHEDULE | |
Friday
SESSION 94:
ADVANCES IN THE ENDO AND OPEN TREATMENT OF VASCULAR TRAUMA
Moderators:Timur P. Sarac, MD / Todd E. Rasmussen, MD, FACS
|
|
x | |
4:00 PM - 4:05 PM | Resuscitative Endovascular Balloon Occlusion Of The Aorta (REBOA): When Is It A Valuable Procedure And When Is It Not: Limitations And Precautions |
Presenter(s):Gilbert R. Upchurch, MD | |
4:06 PM - 4:11 PM | Value Of REBOA For Pending And Actual Cardiac Arrest: What Is Partial And Intermittent REBOA And How Is It Helpful |
Presenter(s):Tal M. Hörer, MD, PhD | |
4:12 PM - 4:17 PM | Value Of Simulator Based Training For REBOA: How Does It Work: Can It Improve Results And Decrease Mishaps |
Presenter(s):Lars B. Lonn, MD, PhD | |
4:18 PM - 4:23 PM | Transexamic Acid – An Antifibrinolytic Drug: Does It Reduce Mortality With Mild To Moderate Traumatic Brain Injuries: Based On A RCT |
Presenter(s):Todd E. Rasmussen, MD, FACS | |
4:24 PM - 4:29 PM | Why One Should Have A Stock On Hand Of Balloon-Expandable And Self-Expandable Covered Stents To Deal With Emergencies From Iatrogenic And Other Traumatic Vascular Injuries: What Should Be In The Stock |
Presenter(s):Maria A. Ruffino, MD, EBIR | |
4:30 PM - 4:35 PM | Radial Access Techniques And Technology For Embolotherapy To Treat Vascular Trauma: Indications And Results |
Presenter(s):Jonathan J. Morrison, PhD, FRCS | |
4:36 PM - 4:41 PM | For Major Venous Injuries: Repair Versus Ligation – Which Is Currently Best When |
Presenter(s):Samy S. Nitecki, MD | |
4:42 PM - 4:47 PM | Update On Best Current Management Of Pediatric Vascular Injuries: When Conservative; When Open; When Endo And Precautions |
Presenter(s):Michael C. Dalsing, MD | |
4:48 PM - 4:54 PM | Panel Discussion |
BLUNT THORACIC AORTIC INJURY (BTAI) | |
4:54 PM - 4:59 PM | Endovascular Repairs Of Traumatic Aortic Injuries – Civilian And Military: Technology, Technical Tips And Results |
Presenter(s):James W. Dennis, MD | |
5:00 PM - 5:05 PM | When Can Minor BTAI Be Treated By Observation Without TEVAR: What Precautions Are Necessary |
Presenter(s):Elina Quiroga, MD, MPH | |
5:06 PM - 5:11 PM | DEBATE: Are We Overtreating BTAI – Especially Lesser Injuries |
Presenter(s):Joseph J. DuBose, MD | |
5:12 PM - 5:17 PM | DEBATE: Why Many Patients With Lesser Degrees Of BTAI Require TEVAR |
Presenter(s):Ali Azizzadeh, MD | |
5:18 PM - 5:23 PM | Why Rapid And Complete Aortic Healing After TEVAR For BTAI Should Influence The Length And Diameter Of The Endograft Used: Oversizing And Length Of Seal Zone Can Be Minimized: Technical Tips |
Presenter(s):Shang Loh, MD | |
5:24 PM - 5:29 PM | How To Manage Heparin In TEVAR For BTAI When Head Or Other Injuries Are Also Present: Some, None Or Just Sheath Flushing |
Presenter(s):Charles J. Fox, MD, FACS | |
5:30 PM - 5:35 PM | With TBAI Requiring TEVAR, When Can The Left Subclavian Artery Be Covered And When Not: Tips On Endograft Sizing |
Presenter(s):Elina Quiroga, MD, MPH | |
5:36 PM - 5:42 PM | Panel Discussion End of Program L |
END OF SESSION 94 | |
SESSION 95 SCHEDULE | |
Friday
SESSION 95:
PELVIC VENOUS DISORDERS, FEMORO-ILIOCAVAL INTERVENTIONAL STRATEGIES TO REDUCE VENOUS HYPERTENSION
|
|
x | |
7:00 AM - 7:04 AM | Introduction: Deep System |
Presenter(s):Lowell S. Kabnick, MD, RPhS, FACS, FAVLS | |
7:05 AM - 7:10 AM | Iliocaval Duplex Ultrasound With Image Optimization |
Presenter(s):Jan M. Sloves, RVT | |
7:11 AM - 7:16 AM | PTS Patients: Identifying Patients Most Likely To Fail Stenting |
Presenter(s):Andrew N. Nicolaides, MS, FRCS | |
7:17 AM - 7:22 AM | Venographic Techniques To Identify Pelvic Anatomy And Escape Points |
Presenter(s):Mark H. Meissner, MD | |
7:23 AM - 7:28 AM | Ovarian Vein Embolization: Which Patient Benefits And Reimbursement |
Presenter(s):Kathleen D. Gibson, MD | |
7:29 AM - 7:34 AM | Open Surgery For Nutcracker: Techniques And Results |
Presenter(s):Cynthia K. Shortell, MD | |
7:35 AM - 7:40 AM | We Need Dedicated Venous Stents For Nutcracker Syndrome And We Need Them Now |
Presenter(s):Peter Gloviczki, MD | |
7:41 AM - 7:46 AM | Panel Discussion |
CHRONIC VENOUS OBSTRUCTION | |
Moderator(s): Jose I. Almeida, MD, FACS, RPVI, RVT / Patrick E. Muck, MD, FACS | |
7:47 AM - 7:52 AM | Recanalizing Occluded Venous Stents |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
7:53 AM - 7:58 AM | Deep Reflux: What Happens After Concomitant Obstruction Correction |
Presenter(s):Marzia Lugli, MD | |
7:59 AM - 8:04 AM | Contralateral Limb Improvement After Unilateral Iliac Vein Stenting: Argument Against Simultaneous Bilateral Stenting |
Presenter(s):Seshadri Raju, MD | |
8:05 AM - 8:10 AM | Precise Positioning Of Venous Stents Using Anatomical Landmarks Only |
Presenter(s):Gerard J. O'Sullivan, MD | |
8:11 AM - 8:16 AM | Utilizing The Radiofrequency Power Wire To Vaporize A Channel Through Chronic Iliocaval Venous Obstructions (CICVO) |
Presenter(s):Patrick E. Muck, MD, FACS | |
8:17 AM - 8:22 AM | Panel Discussion |
END OF SESSION 95 | |
SESSION 96 SCHEDULE | |
Friday
SESSION 96:
FEMORO-ILIOCAVAL INTERVENTIONAL STRATEGIES TO REDUCE VENOUS HYPERTENSION
Moderators:Ellen D. Dillavou, MD / Rabih A. Chaer, MD
|
|
x | |
8:23 AM - 8:28 AM | Impact Of Stent Structure On Venous Flow (In Vitro Investigations With A Designed Fluid Dynamic Model) |
Presenter(s):Houman Jalaie, MD | |
8:29 AM - 8:34 AM | Does Vein Stenting Reduce Great And Small Saphenous Venous Reflux |
Presenter(s):Natalie A. Marks, MD, RPVI, RVT, FSVM | |
8:35 AM - 8:40 AM | Misconceptions Regarding Elastic Compression For Prevention Of Post-Thrombotic Changes |
Presenter(s):Armando Mansilha, MD, PhD, FEBVS | |
8:41 AM - 8:46 AM | Best Anticoagulation After Deep Venous Stenting |
Presenter(s):Ellen D. Dillavou, MD | |
8:47 AM - 8:52 AM | Appropriate Iliofemoral Venous Stent Sizing |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
8:53 AM - 8:58 AM | Outcomes And Predictors Of Failure Of Iliac Vein Stenting |
Presenter(s):Rabih A. Chaer, MD | |
8:59 AM - 9:04 AM | Reinterventions Following Vein Stent Placements – Lessons Learned From 166 Cases |
Presenter(s):Windsor Ting, MD | |
9:05 AM - 9:10 AM | Panel Discussion |
END OF SESSION 96 | |
SESSION 97 SCHEDULE | |
Friday
SESSION 97:
HYBRID TECHNIQUES, STENT PROBLEMS, POST-IMPLANTATION
Moderators:Houman Jalaie, MD / Gerard J. O'Sullivan, MD
|
|
x | |
9:11 AM - 9:16 AM | Endovascular Remote Endovenectomy For Chronic Venous Disease Using The Inari CloTriever |
Presenter(s):Steven D. Abramowitz, MD | |
9:17 AM - 9:22 AM | Neointima Formation Following Venous Placement Of Self-Expanding Nitinol Stents Of Different Porosity: Clinical And Experimental Results |
Presenter(s):Houman Jalaie, MD | |
9:23 AM - 9:28 AM | Biopsy Of Venous In-Stent Stenosis: Histopathology And Treatment |
Presenter(s):David M. Williams, MD | |
9:29 AM - 9:34 AM | Utilizing Indigo System To Extract Thrombus Prior To ISR Ballooning And Stenting: Our Institution’s Experience |
Presenter(s):Frank R. Arko, MD | |
9:35 AM - 9:40 AM | Predilating A Chronic Thrombotic Obstructive Lesion: Balloon Size And What Pressure-Nominal Or Burst Pressure |
Presenter(s):Gerard J. O'Sullivan, MD | |
9:41 AM - 9:46 AM | Endovectomy And Iliac Vein Stent Placement: How I do It (Video Technique Demonstration) |
Presenter(s):Houman Jalaie, MD | |
9:47 AM - 9:52 AM | Iatrogenic Balloon Laceration O Central Vein: Now What |
Presenter(s):Gerard J. O'Sullivan, MD | |
9:53 AM - 9:58 AM | Techniques For Endovenectomy And Concomitant Iliocaval Stenting With And Without Adjuvant Arteriovenous Fistula Creation |
Presenter(s):Steven D. Abramowitz, MD | |
9:59 AM - 10:04 AM | Panel Discussion |
END OF SESSION 97 | |
SESSION 98 SCHEDULE | |
Friday
SESSION 98:
STRATEGIES FOR CORRECTING SEVERE DEEP VENOUS REFLUX AND/OR OBSTRUCTION, WOUNDS, MEDICINES, AND NEW HORIZONS FOR VENOUS DISEASE MANAGEMENT
Moderators:Mark J. Garcia, MD / Marzia Lugli, MD
|
|
x | |
10:05 AM - 10:10 AM | What To Do When Iliac Vein Stenting As Well As Endovenous Ablation Fail To Heal The Venous Ulcer: Tips And Tricks |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
10:11 AM - 10:16 AM | When Deep Venous Reflux Repair Is Not Effective: What Next |
Presenter(s):Marzia Lugli, MD | |
10:17 AM - 10:22 AM | Evolution Of Endovenous Treatment Options For Acute DVT |
Presenter(s):Antonios P. Gasparis, MD | |
10:23 AM - 10:28 AM | Femoral-Popliteal Intervention For Post-Thrombotic Syndrome: ACCESS Trial: EKOS And TPA Overnight |
Presenter(s):Mark J. Garcia, MD | |
10:29 AM - 10:34 AM | Management Options Of Infrainguinal Disease: Indications And Options |
Presenter(s):Steve Elias, MD | |
10:35 AM - 10:40 AM | Panel Discussion |
WOUNDS AND NEW HORIZONS | |
Moderator(s): Peter F. Lawrence, MD / William A. Marston, MD | |
10:41 AM - 10:46 AM | What Is The Standard Of Care For Venous Wounds |
Presenter(s):William A. Marston, MD | |
10:47 AM - 10:52 AM | Skin Substitutes To Promote Venous Leg Ulcer Healing |
Presenter(s):Sarah Onida, MD, PhD | |
10:53 AM - 10:58 AM | Treatment Of Superficial And Perforator Reflux And Deep Venous Stenosis Improves Healing Of Chronic Venous Leg Ulcers |
Presenter(s):Peter F. Lawrence, MD | |
10:59 AM - 11:04 AM | Do The EVRA Study Results Apply For Ulcers <6 Months Chronicity |
Presenter(s):Manj S. Gohel, MD, FRCS, FEBVS | |
11:05 AM - 11:10 AM | The Economic Impact Of Infections In Venous Leg Ulcer Patients |
Presenter(s):Thomas F. O'Donnell, Jr., MD | |
11:11 AM - 11:16 AM | Panel Discussion |
END OF SESSION 98 | |
SESSION 99 SCHEDULE | |
Friday
SESSION 99:
VENOUS STENT TRIALS AND CONCEPTS
|
|
x | |
11:17 AM - 11:22 AM | Differences Between Elgiloy And Nitinol Stents |
Presenter(s):Lowell S. Kabnick, MD, RPhS, FACS, FAVLS | |
11:23 AM - 11:28 AM | Virtus Trial - 3-Year Update |
Presenter(s):William A. Marston, MD | |
11:29 AM - 11:34 AM | Vernacular Trial - 3-Year Update |
Presenter(s):Gerard J. O'Sullivan, MD | |
11:35 AM - 11:40 AM | Abre Trial Results |
Presenter(s):Stephen A. Black, MD | |
11:41 AM - 11:46 AM | Zilver Vena Stent Trial |
Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
11:47 AM - 11:52 AM | What Can The Arnsberg Registry Tell Us |
Presenter(s):Michael K.W. Lichtenberg, MD | |
11:53 AM - 11:58 AM | What Is Aspect Ratio And What Does The Clinical Data Reveal |
Presenter(s):Lowell S. Kabnick, MD, RPhS, FACS, FAVLS | |
11:59 AM - 12:04 PM | Aspect Ratio Of Iliac Stenosis: Does It Matter |
Presenter(s):Seshadri Raju, MD | |
12:05 PM - 12:10 PM | Panel Discussion |
12:10 PM - 12:40 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 99 | |
SESSION 100 SCHEDULE | |
Friday
SESSION 100:
MORE ILIOFEMORAL FLOW AND PELVIC ISSUES
Moderators:David J. Dexter, MD / Peter J. Pappas, MD
|
|
x | |
12:40 PM - 12:45 PM | Do Venous Stent Fractures Matter |
Presenter(s):David J. Dexter, MD | |
12:46 PM - 12:51 PM | Treatment Algorithm For Pelvic Venous Reflux |
Presenter(s):Antonios P. Gasparis, MD | |
12:52 PM - 12:57 PM | Which Is More Important: Pelvic Venous Insufficiency Or Iliac Vein Obstruction |
Presenter(s):Peter J. Pappas, MD | |
12:58 PM - 1:03 PM | Male Pelvic Congestion And Varicose Veins: How Much Of A Problem |
Presenter(s):Mark S. Whiteley, MS, FRCS | |
1:04 PM - 1:09 PM | Diagnosis And Treatment Of Pelvic Congestion Syndrome: UIP Consensus Document |
Presenter(s):Neil M. Khilnani, MD | |
1:10 PM - 1:15 PM | A Novel Technique And Outcomes For Iliocaval Extravascular Reconstruction (TIER) For Iliocaval Agenesis |
Presenter(s):Steven D. Abramowitz, MD | |
1:16 PM - 1:21 PM | Deep Venous Reconstruction: Is It Safe And Profitable In An OBL |
Presenter(s):Paul J. Gagne, MD | |
1:22 PM - 1:27 PM | Panel Discussion |
END OF SESSION 100 | |
SESSION 101 SCHEDULE | |
Friday
SESSION 101:
STRATEGIES FOR THROMBOEMBOLIC EVENTS IN THE VENOUS SYSTEM
Moderators:Michael K.W. Lichtenberg, MD / Stephen A. Black, MD
|
|
x | |
VTE INTERVENTIONAL | |
1:28 PM - 1:33 PM | DVT Removal Without Thrombolytics – Mechanical Thrombectomy Is Now The Standard Of Care For Both Upper And Lower Extremity DVT |
Presenter(s):Constantino Pena, MD | |
1:34 PM - 1:39 PM | P-Max Study: Mechanical Thrombectomy For Iliofemoral DVT With Aspirex |
Presenter(s):Michael K.W. Lichtenberg, MD | |
1:40 PM - 1:45 PM | Thrombolysis For Acute DVT: Utilization And Guidance From Current Clinical Trials |
Presenter(s):Brian G. DeRubertis, MD | |
1:46 PM - 1:51 PM | A Comparison Of Angiojet Versus CDT For The Treatment Of Iliofemoral DVT |
Presenter(s):Stephen A. Black, MD | |
1:52 PM - 1:57 PM | Angiovac Venous Thrombectomy: Where, When, And How |
Presenter(s):David J. Dexter, MD | |
1:58 PM - 2:03 PM | Venous Aneurysms: Should They Be Treated |
Presenter(s):Peter F. Lawrence, MD | |
2:04 PM - 2:09 PM | Renal Failure In Acute DVT Treatment: Incidence And Strategies For Prevention |
Presenter(s):Stephen A. Black, MD | |
2:10 PM - 2:15 PM | Clot Registry For The Inari CloTriever |
Presenter(s):David J. Dexter, MD | |
2:16 PM - 2:21 PM | Panel Discussion |
CENTRAL VENOUS THROMBOSIS; COVID-19 | |
Moderator(s): Ian J. Franklin, MS, FRCS(Gen Surg) / Jinsong Wang, MD | |
2:22 PM - 2:27 PM | Investigation And Treatment Of Pelvic Vein Reflux Associated With Varicose Veins: Current Views And Practice Of 100 UK Vascular Specialists |
Presenter(s):Ian J. Franklin, MS, FRCS(Gen Surg) | |
2:28 PM - 2:33 PM | Does PMT Now Lead To Over-Stenting |
Presenter(s):Stephen A. Black, MD | |
2:34 PM - 2:39 PM | Outcome Of Venous Stents In Adolescents, Teenagers, And Pregnancy |
Presenter(s):Mahmood Razavi, MD | |
2:40 PM - 2:45 PM | COVID-19: What Have We Learned – China Experience |
Presenter(s):Jinsong Wang, MD | |
2:46 PM - 2:51 PM | COVID-19 Treatment Of Venous Thrombosis In Hospitalized Patients |
Presenter(s):Mikel Sadek, MD | |
2:52 PM - 2:57 PM | COVID-19 Outpatient Experience With Anticoagulation |
Presenter(s):Steve Elias, MD | |
2:58 PM - 3:03 PM | COVID-19 And Thrombotic Or Thromboembolic Disease: Implications For Prevention, Antithrombotic Therapy, And Follow-Up |
Presenter(s):Joseph A. Caprini, MD | |
3:04 PM - 3:09 PM | Panel Discussion |
Moderator(s): Anthony J. Comerota, MD, FACS, FACC / Peter Henke, MD | |
3:10 PM - 3:15 PM | Using The Femoral Vein As A Tunneling Conduit For An Arterial Bypass: Venous Outcomes In PQ Bypass |
Presenter(s):Mark A. Adelman, MD | |
3:16 PM - 3:21 PM | Duration Of Anticoagulation |
Presenter(s):Rachel Rosovsky, MD, MPH | |
3:22 PM - 3:27 PM | Should All Patients With Acute VTE Be Treated With A Statin: When And Dose |
Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
3:28 PM - 3:33 PM | Update On Reversal Agents For The DOACs |
Presenter(s):Timothy K. Liem, MD, MBA | |
3:34 PM - 3:39 PM | Thrombus Aging Using MRI |
Presenter(s):Stephen A. Black, MD | |
3:40 PM - 3:45 PM | Role Of Thrombophilia Testing |
Presenter(s):Rachel Rosovsky, MD, MPH | |
3:46 PM - 3:51 PM | Update In Experimental DVT Pathogenesis And Resolution |
Presenter(s):Peter Henke, MD | |
3:52 PM - 3:57 PM | DOAC Revolution – Which Drug For What Disease: Review Of Ongoing Trials |
Presenter(s):Andrea T. Obi, MD | |
3:58 PM - 4:03 PM | Pediatric DVT: An Evidence Summary |
Presenter(s):Dawn M. Coleman, MD | |
4:04 PM - 4:09 PM | Inflammation And Venous Thrombosis: An Evidence Summary |
Presenter(s):Thomas W. Wakefield, MD | |
4:10 PM - 4:15 PM | Family History Of Thrombosis: The Forgotten Risk Factor |
Presenter(s):Joseph A. Caprini, MD | |
4:16 PM - 4:21 PM | Current Strategy Of VTE Prevention In China |
Presenter(s):Jinsong Wang, MD | |
4:22 PM - 4:27 PM | Mesenteric Vein Thrombosis: What Is The Best Strategy |
Presenter(s):Mark G. Davies, MD | |
4:28 PM - 4:33 PM | Thoracic Outlet Acute VTE: What To Do And When |
Presenter(s):Saum A. Rahimi, MD | |
4:34 PM - 4:39 PM | Closed Plication Is A Safe And Effective Method For Treating Popliteal Venous Aneurysm |
Presenter(s):Thomas W. Wakefield, MD | |
4:40 PM - 4:45 PM | Panel Discussion |
END OF SESSION 101 | |
SESSION 102 SCHEDULE | |
Friday
SESSION 102:
DEEP VEIN VALVE TECHNOLOGIES, CAVAL INTERRUPTION
Moderators:Mikel Sadek, MD / Jorge H. Ulloa, MD, FACS
|
|
x | |
DEEP VALVE PROGRESS | |
4:46 PM - 4:51 PM | The Need For A Deep Venous Valve For Severe CVI Patients With DVT |
Presenter(s):Mikel Sadek, MD | |
4:52 PM - 4:57 PM | Safety And Efficacy Report On The Venovalve (First In Man) IDE Feasibility Study |
Presenter(s):Jorge H. Ulloa, MD, FACS | |
4:58 PM - 5:03 PM | US Experience Of The BlueLeaf®Endovenous Valve Formation: Update |
Presenter(s):William A. Marston, MD | |
5:04 PM - 5:09 PM | Implantable Bicuspid Valve: Early Preclinical Results |
Presenter(s):Paul J. Gagne, MD | |
5:10 PM - 5:15 PM | Surgical Creation Of A Monocusp Valve |
Presenter(s):Marzia Lugli, MD | |
5:16 PM - 5:21 PM | Panel Discussion |
CAVAL INTERRUPTION | |
Moderator(s): Timothy K. Liem, MD, MBA / Constantino Pena, MD | |
5:22 PM - 5:27 PM | The Novate Sentry Trial With A Novel Bio-Convertible IVC Filter: Follow-Up At 2 Years |
Presenter(s):Michael D. Dake, MD | |
5:28 PM - 5:33 PM | Thrombosed IVC Filter: How To Recanalize The Cava And Manage The Filter |
Presenter(s):Jose I. Almeida, MD, FACS, RPVI, RVT | |
5:34 PM - 5:39 PM | IVC Management In Pregnant Patients |
Presenter(s):Joann Lohr, MD | |
5:40 PM - 5:45 PM | Surgical Removal Of IVC Filters: Perforation Or Infiltration |
Presenter(s):Timothy K. Liem, MD, MBA | |
5:46 PM - 5:51 PM | Why Temporary Filters Are Not Removed: Clinical Predictors In 1,000 Consecutive Cases |
Presenter(s):Heron E. Rodriguez, MD | |
5:52 PM - 5:57 PM | What To Do With Fractured Filters And Embolic Filter Fragments |
Presenter(s):Constantino Pena, MD | |
5:58 PM - 6:03 PM | Panel Discussion End of Program M |
END OF SESSION 102 | |
Saturday, November 20, 2021
Print Entire 2020 Program:
|
|
SESSION 103 SCHEDULE | |
Saturday
SESSION 103:
LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS)
Moderators:Keith D. Calligaro, MD / Frank J. Veith, MD
|
|
x | |
7:00 AM - 7:05 AM | Optimal Vessel Prep Is Key To Successful BTK And Tibial Angioplasty (PTA): How To Do It |
Presenter(s):Peter A. Schneider, MD | |
7:05 AM - 7:10 AM | Why Endovascular Treatments Should Be The First Choice For Common Femoral Artery (CFA) Occlusive Lesions |
Presenter(s):Koen R. Deloose, MD | |
7:10 AM - 7:15 AM | Technical Tips For Retrograde Tibial And Pedal Access Under Ultrasound (Duplex) Guidance: Contraindications When Fluoro Is Better |
Presenter(s):Steven Kum, MD | |
7:15 AM - 7:20 AM | What Is The Real Complication Rate With Retrograde Tibial And Pedal Access: How To Minimize These Complications |
Presenter(s):Michael H. Wholey, MD, MBA | |
7:20 AM - 7:25 AM | DEBATE: An Endo First Approach Is Best For Treating CLTI In All Patients: Is There Any Role For Open Bypasses |
Presenter(s):Christopher J. Abularrage, MD | |
7:30 AM - 7:35 AM | Panel Discussion |
7:35 AM - 7:40 AM | Complications Of Atherectomy: How To Prevent Some, How To Treat The Others |
Presenter(s):Theodosios Bisdas, MD | |
7:40 AM - 7:45 AM | Are Isolated Pedal Interventions For CLTI Worthwhile |
Presenter(s):Mark G. Davies, MD | |
7:45 AM - 7:50 AM | DEBATE: Multivessel Tibial Revascularization Does Not Improve Limb Salvage In CLTI Patients: From A VQI Study |
Presenter(s):Venita Chandra, MD | |
7:50 AM - 7:55 AM | DEBATE: Not So: In Some Circumstances Multivessel Tibial Revascularization Does Improve Outcomes In CLTI Patients: Which Circumstances |
Presenter(s):Brian G. DeRubertis, MD | |
7:55 AM - 8:00 AM | Panel Discussion |
8:00 AM - 8:05 AM | Indication And Technical Tips For Performing Retrograde Popliteal Artery Access |
Presenter(s):Jeffrey J. Siracuse, MD | |
8:05 AM - 8:10 AM | Prograde SFA Access Can Be Safe And Effective For Lower Extremity Endo Procedures; When And How To Do It |
Presenter(s):Todd Berland, MD | |
8:10 AM - 8:15 AM | Technical Tips For Open Tibial And Pedal Artery Exposures In Virginal And Redo Situations |
Presenter(s):William P. Robinson, MD | |
8:15 AM - 8:20 AM | When Are Oral Antibiotics Without Excision Of Infected Bone Adequate Treatment For Osteomyelitis In The Foot |
Presenter(s):Wayne J. Caputo, DPM | |
8:20 AM - 8:25 AM | Panel Discussion |
END OF SESSION 103 | |
SESSION 104 SCHEDULE | |
Saturday
SESSION 104:
MORE LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS)
Moderators:Ali F. AbuRahma, MD / Enrico Ascher, MD
|
|
x | |
8:25 AM - 8:30 AM | Technical Tips For Retrograde Access Via The SFA, Popliteal And BTK Arteries: When And How To Do It |
Presenter(s):Lorenzo Patrone, MD | |
8:30 AM - 8:35 AM | Dangers And Pitfalls Of Retrograde Lower Extremity Access Distal To The Common Femoral Artery |
Presenter(s):Venita Chandra, MD | |
8:35 AM - 8:40 AM | Impact Of A Dedicated Limb Preservation/Limb Salvage Service On Amputation Rates: Must It Include An Open Bypass Surgery Component |
Presenter(s):Niten Singh, MD | |
8:40 AM - 8:45 AM | Importance Of Functional And Ambulatory Status In Decision Making In CLTI Patients: Why Limbs Should Be Saved In Patients Who Are Not Ambulatory |
Presenter(s):Vincent L. Rowe, MD | |
8:45 AM - 8:50 AM | Endo Versus Open Reinterventions To Assist In Maintaining Patency Of Distal Vein Grafts: Both Are Needed |
Presenter(s):Francesco Spinelli, MD | |
8:50 AM - 8:55 AM | Panel Discussion |
8:55 AM - 9:00 AM | Relationship Between Zinc Deficiency And The Outcomes Of Lower Extremity Bypasses For CLTI: Should All CLTI Patients Be Given Zinc |
Presenter(s):Kimihiro Komori, MD, PhD | |
9:00 AM - 9:05 AM | Open Versus Endo Revascularizations In Dialysis Patients With CLTI: What Is The Role Of Each |
Presenter(s):Rabih A. Chaer, MD | |
9:05 AM - 9:10 AM | What Is The Best Vessel Prep For Endo Treatments Of Heavily Calcified Lesions: Technical Tips And Precautions |
Presenter(s):Theodosios Bisdas, MD | |
9:10 AM - 9:15 AM | How To Correct The “No Flow” Phenomenon After Lower Extremity Endovascular Interventions: What Is The Etiology And How To Fix |
9:15 AM - 9:20 AM | Real World Outcomes With Zilver PTX DESs For Complex Fempop Disease: Why Do They Differ From Trial Results |
Presenter(s):Ali F. AbuRahma, MD | |
9:20 AM - 9:25 AM | Panel Discussion |
9:25 AM - 9:30 AM | Value Of Duplex Gray Scale In Predicting Successful SFA CTO Crossing, Re-Entry And The Need For Distal Access |
Presenter(s):Natalie A. Marks, MD, RPVI, RVT, FSVM | |
9:30 AM - 9:35 AM | Effect Of Short-Term Complications Of Lower Extremity Revascularizations On Long-Term Outcomes And Patient Survival |
Presenter(s):Joseph L. Mills, MD | |
9:35 AM - 9:40 AM | Endovascular Diagnosis And Control f Hemorrhage After Fempop Open Operations: It Is A Better Way And How To Do It |
Presenter(s):Francesco Setacci, MD / Carlo Setacci, MD | |
9:40 AM - 9:45 AM | Longer Procedure Times Are Predictive Of Worse Outcomes With Endovascular Treatments Of Lower Extremity Occlusive Lesions |
Presenter(s):Alan M. Dietzek, MD, RPVI, FACS | |
9:45 AM - 9:50 AM | Panel Discussion |
9:50 AM - 10:00 AM | Break – Visit Exhibits And Pavilions (3rd Floors) |
END OF SESSION 104 | |
SESSION 105 SCHEDULE | |
Saturday
SESSION 105:
AORTIC TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS)
Moderators:Timur P. Sarac, MD / Kenneth Ouriel, MD, MBA
|
|
x | |
10:00 AM - 10:05 AM | Improved System For Evaluating Aortic Neck Anatomy And Suitability For EVAR And F/EVAR |
Presenter(s):David J. Minion, MD | |
10:05 AM - 10:10 AM | Top 10 Clinical Trials That Are Needed In AAA Disease |
Presenter(s):Ronald L. Dalman, MD | |
SPINE EXPOSURE SURGERY | |
10:10 AM - 10:17 AM | Technical Tips And Tools For The Vascular Surgeon To Provide Anterior Exposure For Spine Procedures (7-Minute Presentation) |
Presenter(s):Jeffrey Jim, MD, MPHS | |
10:18 AM - 10:25 AM | Vascular Complications Of Anterior Spine Exposures; How To Avoid Them And How To Treat Them If They Occur (7-Minute Presentation) |
Presenter(s):William P. Robinson, MD | |
10:25 AM - 10:30 AM | EVAR Outside The IFUs Of Commercial Devices Is Sometimes Justified And Does Not Negatively Impact On Midterm Outcomes: When Is This So |
Presenter(s):George A. Antoniou, MD, PhD, MSc, FEBVS | |
10:30 AM - 10:35 AM | The Aortyx Aortic Patch For Repairing Focal Aortic Defects: How Does It Work And Current Status |
Presenter(s):Vicente Riambau, MD, PhD | |
10:35 AM - 10:40 AM | Panel Discussion |
10:40 AM - 10:45 AM | How To Avoid Axillary Artery Complications After Large Sheath Use In Complex AAA Repairs |
Presenter(s):Michael C. Stoner, MD | |
10:45 AM - 10:50 AM | Late Complications Of F/B/EVAR In An Experience Of >1000 Cases |
Presenter(s):Athanasios Katsargyris, MD / Eric L.G. Verhoeven, MD, PhD | |
10:50 AM - 10:55 AM | With F/EVAR Intraoperative Endoleaks Do No Predict Midterm Failure |
Presenter(s):Michael J. Singh, MD | |
10:55 AM - 11:00 AM | Left Subclavian Revascularization With TEVAR: Technical Tips And Tools To Make In Situ Fenestration Easy |
Presenter(s):Wayne W. Zhang, MD | |
11:00 AM - 11:05 AM | Variable Curve Directional Sheaths Will Eliminate The Need For Upper Extremity Access With F/B/EVAR: Which Sheath Is Best And Pitfalls |
Presenter(s):James F. McKinsey, MD | |
11:05 AM - 11:10 AM | How Can Computer Modeling Help To Improve The Treatment Of TBADs |
Presenter(s):Ross Milner, MD | |
11:10 AM - 11:15 AM | Panel Discussion |
END OF SESSION 105 | |
SESSION 106 SCHEDULE | |
Saturday
SESSION 106:
AORTIC AND CAROTID TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS)
|
|
x | |
AORTIC TOPICS | |
11:15 AM - 11:20 AM | Options For Managing The Left Subclavian Artery When Performing Endovascular Treatment Of Zone 2 Lesions |
Presenter(s):Edward Y. Woo, MD | |
11:20 AM - 11:25 AM | Carotid-To-Axillary Bypass Is Better Than Carotid-Subclavian Bypass For Revascularizing Subclavian Arteries With TEVAR: Why And How To Do It |
Presenter(s):Frank J. Criado, MD | |
11:25 AM - 11:30 AM | When Is A Left Subclavian Chimney Graft Better Than A Carotid-Subclavian Bypass For Preserving Subclavian Artery Flow |
Presenter(s):R. Clement Darling III, MD | |
11:30 AM - 11:35 AM | Upper Extremity Access For Complex Endo AAA Repairs Is Associated With A High Rate Of Stroke: From A VQI Study |
Presenter(s):Marc L. Schermerhorn, MD | |
11:35 AM - 11:40 AM | DEBATE: The Vast Majority Of Failed EVARs Can Be Treated Endovascularly |
Presenter(s):Jean-Pierre Becquemin, MD, FRCS | |
11:40 AM - 11:45 AM | DEBATE: Not So: Many Failed EVARs Are Best Repaired By Open Conversion |
Presenter(s):Michel Makaroun, MD | |
11:45 AM - 11:50 AM | AAAs With Large Diameter Necks (>34 mm) Do Poorly With EVAR: How Should Such Patients Be Treated |
Presenter(s):Matt M. Thompson, MD | |
11:50 AM - 11:55 AM | Value Of 3D Flow Models To Analyze The Cause Of Failure After F/EVAR And TEVAR |
Presenter(s):Maciej L. Dryjski , MD, PhD | |
11:55 AM - 12:00 PM | Panel Discussion |
CAROTID TOPICS | |
12:00 PM - 12:05 PM | Optimal Anticoagulant And Antiplatelet Treatment For Patients With Asymptomatic Carotid Stenosis |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
12:05 PM - 12:10 PM | How To Use The Silk Road TCAR Device In The Treatment Of Tandem Carotid Lesions: Technical Tips And Results |
Presenter(s):Michael C. Stoner, MD | |
12:10 PM - 12:15 PM | Update On Isolated Carotid Webs As A Cause Of Cryptogenic Stroke: How To Diagnose And Treat |
Presenter(s):W. Charles Sternbergh III, MD / Clayton Brinster, MD | |
12:15 PM - 12:20 PM | Mini-Incision CEA With Standard Or Eversion Techniques: How To Do It Safely: It’s Better Than Transfemoral CAS Or TCAR |
Presenter(s):Alan M. Dietzek, MD, RPVI, FACS | |
12:20 PM - 12:25 PM | TCAR With Flow Reversal Versus Transcervical CAS With Distal Protection: TCAR’s Benefit Is Not Just Due To Its Avoidance Of Having To Traverse The Aortic Arch |
Presenter(s):Mahmoud B. Malas, MD, MHS | |
12:25 PM - 12:30 PM | Panel Discussion End of Program N The A-V Access Program Continues in the Grand Ballroom West. |
END OF SESSION 106 | |
SESSION 107 SCHEDULE | |
Saturday
SESSION 107:
IMPORTANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)
Moderators:Larry A. Scher, MD / Anton N. Sidawy, MD, MPH
|
|
x | |
8:00 AM - 8:05 AM | Introduction |
Presenter(s):Anton N. Sidawy, MD, MPH / Larry A. Scher, MD | |
8:06 AM - 8:13 AM | What Vascular Access Issues Are Important To Patients |
Presenter(s):Dori R. Schatell, MS | |
8:14 AM - 8:21 AM | Where Should Patients And Physicians Get Information About Hemodialysis Access |
Presenter(s):Ellen D. Dillavou, MD | |
8:22 AM - 8:29 AM | Kickstarting Your Peritoneal Dialysis Program |
Presenter(s):Sean D. Kalloo, MD | |
8:30 AM - 8:37 AM | Selecting The Right Access In The Chronically Hypotensive Patient |
Presenter(s):Aisha Shaikh, MD | |
8:38 AM - 8:45 AM | TBD |
8:46 AM - 8:53 AM | Cardiovascular Implantable Electronic Devices In Hemodialysis Patients: Prevalence And Strategies For Management |
Presenter(s):Theodore F. Saad, MD | |
8:54 AM - 9:04 AM | Panel Discussion |
9:05 AM - 9:12 AM | Body Image, Sexuality And Hemodialysis Access |
Presenter(s):Dori R. Schatell, MS | |
9:13 AM - 9:20 AM | Wearable Technology For Remote Patient Monitoring During Home Hemodialysis |
Presenter(s):Richard F. Neville, MD | |
9:21 AM - 9:28 AM | Managing The Pulsatile AV Access: How To Prolong Access Life |
Presenter(s):Surendra Shenoy, MD, PhD | |
9:29 AM - 9:36 AM | Use Of Drug Eluting Balloons And Stents: What Does The Data Tell Us |
Presenter(s):Theodore F. Saad, MD | |
9:37 AM - 9:44 AM | LIMA Steal Syndrome After Ipsilateral AV Fistula: Is It Real |
Presenter(s):Jeffrey E. Indes, MD | |
9:45 AM - 9:52 AM | Early Banding For High Flow AV Fistulas |
Presenter(s):Moro Salifu, MD | |
9:53 AM - 10:03 AM | Panel Discussion |
10:04 AM - 10:25 AM | Break – Visit Exhibits And Pavilions (3rd Floor) |
END OF SESSION 107 | |
SESSION 108 SCHEDULE | |
Saturday
SESSION 108:
MORE IMPORTANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)
|
|
x | |
10:26 AM - 10:33 AM | Performance Of Vascular Access Procedures During A Global Pandemic |
Presenter(s):Haimanot (Monnie) Wasse, MD, MPH, FASN | |
10:34 AM - 10:41 AM | Surgeon’s Perspective On Management Of Acute Kidney Injury During The COVID-19 Pandemic |
Presenter(s):Clifford M. Sales, MD, MBA, FACS | |
10:42 AM - 10:49 AM | How Has COVID-19 Impacted Medicare Reimbursement |
Presenter(s):Evan C. Lipsitz, MD, MBA | |
10:50 AM - 10:57 AM | Telemedicine For Vascular Access Patients: Preoperative Planning, Postoperative Visits, Access Maintenance |
Presenter(s):Aisha Shaikh, MD | |
10:58 AM - 11:05 AM | Accelerating Technology Development During A Pandemic To Bring More People With Kidney Failure Home |
Presenter(s):Prabir Roy-Chaudhury, MD, PhD | |
11:06 AM - 11:16 AM | Panel Discussion |
THE USE OF ULTRASOUND IN CONTEMPORARY DIALYSIS ACCESS PRACTICE | |
Moderator(s): John E. Aruny, MD / Clifford M. Sales, MD, MBA, FACS | |
11:17 AM - 11:24 AM | Preoperative Vessel Mapping: Did KDOQI Really Make This Optional |
Presenter(s):Charmaine Lok, MD | |
11:25 AM - 11:32 AM | Economic And Clinical Impact Of Changes In Reimbursement For Predialysis Duplex Planning |
Presenter(s):Jason K. Wagner, MD | |
11:33 AM - 11:40 AM | Incorporating Point Of Care Ultrasound Into The Practice Of Nephrology |
Presenter(s):Vandana D. Niyyar, MD | |
11:41 AM - 11:48 AM | Use Of IVUS For Evaluation And Sizing Of Central Vein Stenosis |
Presenter(s):John E. Aruny, MD | |
11:49 AM - 11:59 AM | Panel Discussion |
12:00 PM - 12:50 PM | Lunch – 3rd Floor Foyer Visit Exhibits And Pavilions (3rd Floor) |
END OF SESSION 108 | |
SESSION 109 SCHEDULE | |
Saturday
SESSION 109:
POLITICAL, ECONOMIC AND LEGAL ISSUES IN HEMODIALYSIS ACCESS (7- 10-MINUTE TALKS)
Moderators:Larry A. Scher, MD / Anton N. Sidawy, MD, MPH
|
|
x | |
12:50 PM - 12:57 PM | Creating AV Fistulas For Children In Guatamala |
Presenter(s):William Jennings, MD | |
12:58 PM - 1:05 PM | How Will Government Initiatives Move Patients From Dialysis Centers To Home Dialysis |
Presenter(s):Sean D. Kalloo, MD | |
1:06 PM - 1:13 PM | Implementing The Results Of A Randomized Trial Comparing Early Cannulation Grafts To Catheters Into Practice |
Presenter(s):David Kingsmore, Mr, MD, FRCS (Ed), MBChB, BMedBiol | |
1:14 PM - 1:24 PM | How Artificial Kidneys And Miniaturized Dialysis Could Save Millions Of Lives |
Presenter(s):Buddy D. Ratner, PhD | |
1:25 PM - 1:35 PM | Keynote Speaker: Health And Human Services Initiatives To Improve Management Of Kidney Disease: A $35 Billion Innovation Black Hole |
Presenter(s):Ed Simcox, JD | |
1:36 PM - 1:46 PM | Panel Discussion |
END OF SESSION 109 | |
SESSION 110 SCHEDULE | |
Saturday
SESSION 110:
NEW TECHNOLOGIES FOR AV ACCESS CREATION (7-MINUTE TALKS)
|
|
x | |
1:47 PM - 1:54 PM | Use Of External Support Devices To Improve AV Fistula Maturation |
Presenter(s):Ellen D. Dillavou, MD | |
1:55 PM - 2:02 PM | Use Of Pharmacologic Adjuncts To Improve AV Fistula Maturation |
Presenter(s):Alan Dardik, MD, PhD | |
2:03 PM - 2:10 PM | DEBATE: Will EndoAV Fistulas Ever Become The Gold Standard: EndoAV Fistula Is Better Than Surgery |
Presenter(s):Neghae Mawla, MD, FASDIN | |
2:11 PM - 2:18 PM | DEBATE: Will EndoAV Fistulas Ever Become The Gold Standard: Surgery Is Still The Gold Standard |
Presenter(s):John R. Ross, Sr., MD | |
2:19 PM - 2:26 PM | Cannulation Issues With Endovascular Fistulas |
Presenter(s):Deborah Brouwer-Maier, RN, CNN | |
2:27 PM - 2:37 PM | Panel Discussion |
END OF SESSION 110 | |
SESSION 111 SCHEDULE | |
Saturday
SESSION 111:
UPDATE ON CLINICAL CHALLENGES IN HEMODIAYLSYS (7-MINUTE TALKS)
Moderators:Larry A. Scher, MD / Surendra Shenoy, MD, PhD
|
|
x | |
2:38 PM - 2:45 PM | Options For Management Of Deep AV Fistulas |
Presenter(s):William Jennings, MD | |
2:46 PM - 2:53 PM | Surgical Management Of The Mega Fistula |
Presenter(s):John R. Ross, Sr., MD | |
2:54 PM - 3:01 PM | TBD |
3:02 PM - 3:09 PM | Why Choose A Biologic Conduit For Hemodialysis Access |
Presenter(s):Matthew J. Dougherty, MD | |
3:10 PM - 3:17 PM | What Is The Best Option For Cephalic Arch Stenosis |
Presenter(s):Mark G. Davies, MD | |
3:18 PM - 3:25 PM | Management Of The Abandoned HeRO Device |
Presenter(s):Stephen E. Hohmann, MD | |
3:26 PM - 3:33 PM | HeRO Graft With ARtegraft Attachment For Hemodialysis Access: What Are The Outcomes |
Presenter(s):Jesse Garcia, MD | |
3:34 PM - 3:41 PM | Does A High Bifurcation Brachial Artery Affect Outcomes For AV Fistulas And Grafts |
Presenter(s):John S. Futchko, MD | |
3:42 PM - 4:00 PM | Panel Discussion End of Program O |
END OF SESSION 111 | |